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Abstract of Thesis. 
The gene encoding topoisomerase II of P. falciparum (PfTopoll) was 
isolated and characterised in 1994 (Cheesman et al.,) as part of an overall 
strategy to isolate parasite genes involved in DNA replication and 
evaluate their potential as anti-malarial drug targets. As a natural 
progression, this study has focussed on heterologous expression of the 
gene to enable sufficient recombinant protein to be purified for 
biochemical analysis and drug screening. The species divergent C-
terminal region of the protein was expressed in E. coli, and used to raise 
polyclonal antiserum in rabbits, which detects a protein of 160/175 kDa in 
extracts from P. falciparum. 
The same antiserum was used to monitor expression of recombinant 
PfTopoll in baculovirus. A triplet of proteins of 160/175 kDa were detected 
by the antiserum in cell extracts derived from baculovirus-infected insect 
cells, but in very small quantities. This is close to the predicted size of 
PfTopoll. Incorporation of a C-terminal hexahistidine affinity tag into the 
protein was used as a means to purify the small amount of recombinant 
protein that was made, using nickel affinity chromatography. 
Decatenation assays, which are a specific test for type II topoisomerase 
activity, detected activity in some fractions obtained from the affinity 
purification. However, a mock purification, using an unrelated 
recombinant baculovirus gave similar results, indicating that a 
contaminating co-purifying topoisomerase II activity was present. 
Full length expression of recombinant PfTopoll was not detected in cell 
extracts prepared from E. coil. However, there is evidence that the 
recombinant protein was expressed, but may have undergone rapid 
proteolytic degradation in vivo. Expression of a functionally inactive 
version of the protein, in which the active site, tyrosine, was changed to 
phenylalanine, had no noticeable affect on protein stability. 
A modified version of the PfTopoll gene, in which the first four codons 
were replaced with the first five codons of the yeast topoisomerase II gene 
was expressed in S. cerevisiae. A control plasmid expressed the human 
topoisomerase II c homologue to high levels, but no evidence of 
expression of recombinant PfTopoll was detected. Northern analysis of 
the mRNA revealed the presence of truncated transcripts, and RT-PCR 
mapped the sites of polyadenylation to 370 and 376 nucleotides from the 
AUG. An analysis of the region upstream of these sites revealed the 
presence of specific AT-rich sequence elements which are known to cause 
transcription termination of yeast mRNAs. Site directed mutagenesis was 
used to change these sequences, and analysis of the mRNA from the 
modified construct showed that the original transcriptional block had 
been abolished, but was replaced by a new transcriptional block, which 
gave rise to a truncated transcript some 617 nt in length. 
An investigation into the developmental regulation of PfTopoll 
throughout the blood stages of parasite growth was also undertaken. 
Northern analysis indicates that three transcripts accumulate principally 
in the trophozoite stage, although interestingly, work conducted by Paul 
Horrocks indicates that the promoter is active in both ring and 
trophozoite/schizont stage parasites. Western analysis of protein extracts 
derived from synchronised populations of parasites shows that 
trophozoite and schizont stages express a triplet of proteins of 160/175 kDa 
in size, and at similar levels. Although protein extracts from trophozoite 
and schizont stage parasites are proficient at decatenation, activity was 
highest in schizonts, and could be inhibited completely after 
immunodepleting the parasite extracts. 
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Estimates suggest that between 1.5 and 2.7 million people die annually 
from the disease Malaria, and the number of infected individuals is 
currently 300 to 500 million (World Health Organisation, 1994). 
In humans, the disease is caused by a group of protozoan parasites of the 
genus Plasrnodiu;n, which fall within the phylum Apicomplexa, grouped 
together on the basis of the presence of an apical complex at some stage of 
the life cycle. Malaria is an insect-borne infection caused by the bite of an 
infected Anopheles mosquito. Only female Anopheles are able to 
transmit the malaria parasite and transmission occurs upon ingestion of a 
blood meal which is necessary for successful egg development in the 
female. 
There are four species of Plasmodium known to infect man, Plasmodium 
vivax, P.ovale, P.malariae, and P. falciparurn. Of these species, P. 
falciparurn is the most dangerous, because it can lead to the potentially 
lethal condition, cerebral Malaria. Young children, pregnant women, 
foreign travellers and military troops on active service in endemic areas 
are most at risk from the disease. 
40% of the worlds' population now live with endemic Malaria, but twenty 
years ago this percentage was significantly lower, perhaps closer to 32%. 
Several decades ago it was believed that Malaria would eventually share 
the same fate as Smallpox and be effectively controlled, if not completely 
eradicated. However, Malaria eradication has only been successful in the 
more temperate regions of the globe. 
Despite extensive mosquito eradication programmes by the WHO as far 
back as 1955 using insecticides such as DDT, malaria is present today in 102 
countries. The disease has profound economic consequences for 
developing third world countries, where the cost of disease is both 
financial and humanitarian. 
The disease is confined to tropical and sub-tropical zones including 
Central Africa, Thailand, India and South America. The native people of 
malarious regions that survive infection develop premunition which is a 
state of partial immunity where parasite multiplication is decreased but 
blood parasitaemia still exists. Repeated infection maintains an 
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equilibrium of asymtomatic infection. Thus malaria can be seen as an 
insidious problem where symptomless infected individuals contribute to 
a reservoir of infection between the mosquito vector and its host. 
The primary control strategy for Malaria is geared towards chemotherapy, 
however, many of the drugs which are commonly used for treatment, 
such as chioroquine, are now virtually obsolete due to the emergence of 
drug resistant strains. So serious is the problem in many areas of the 
world that falciparum malaria is now almost untreatable. Not only is it 
imperative that new drug treatments are developed, but if we are to gain 
effective long term control of the disease we must also strive to achieve a 
better understanding of how novel drugs operate. 
In this introduction, traditional and modern antimalarial drug treatments 
will be considered, along with novel antimalarial drugs and vaccines 
which are still under development. 
1.2 Lifecycle of the Malarial parasite in man. 
The lifecycle is shown in full in Figure 1 (Philips, 1983). It consists of two 
distinct phases. The exogenous sexual phase (sporogony) which takes 
place in certain Anopheles mosquitoes, and the endogenous asexual 
phase (schizogony) that occurs in the vertebrate host. 
1.2.1 The mosquito host. 
The cycle commences upon ingestion of a blood meal containing infected 
red blood cells harbouring male and female gametocytes from the human 
host. Male gametocytes undergo three successive rounds of DNA 
replication resulting in octoploidy prior to maturation. Eight motile male 
microgametes are produced by exflagellation and this restores the haploid 
state. 
Female gametocytes ingested in the blood meal shed the red blood cell 
and differentiate into mature macrogametes. Meiosis occurs soon after 
fertilisation by the microgametes. Approximately 18-24 hours later the 
zygote elongates, becomes motile and is known as an ookinete form 
which is able to penetrate the mid gut epithelium to the outer surface 
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Growth and repeated cell division eventually result in thousands of 
mature nucleated sporozoites which rupture the oocyst and migrate to the 
salivary glands via the body cavity, thus completing the infection process 
in the mosquito. 
1.2.2 The human host. 
Infective sporozoites from the anopheline salivary glands are released 
into the human circulation upon ingestion of a blood meal. Sporozoites 
that are not destroyed by phagocytosis enter the parachymal cells of the 
liver where they mature and undergo multiplication. This is known as 
exo-erythrocytic schizogony and it lasts for around 6-16 days. The end of 
this period is characterised by rupture of the mature schizont, releasing 
infective merozoites that invade the red blood cells. This is the start of the 
erythrocytic cycle, the first developmental stage of which is the ring form. 
Continued parasite growth and development give rise to the trophozoite 
form that consumes host cell haemoglobin for nutrition. Mature 
trophozoites then undergo asexual cell division to produce schizonts 
which rupture the red cell blood cell membrane releasing invasive 
merozoites which can reinvade uninfected erythrocytes in the circulation. 
This repetitive cycle is highly characteristic of a Malaria infection and is 
responsible for the major clinical symptoms of the disease. 
The intraerythrocytic cycle varies in length according to the species of 
Plasmodium responsible for the infection. It is, for example, completed in 
around 48 hours in P. falciparurn. Because the cycle is repeated over and 
over again, a very high blood parasitaemia eventually develops. After 
many generations, sexually differentiated forms (gametocytes) are 
produced facilitating completion of the sexual cycle in the anopheline 
vector following transmission (Bruce-Chwatt, 1985) 
1.3 Drugs used in the treatment of Malaria. 
A number of clinically important drugs are available that target the 
parasite. A description of some of the most well known and widely used 
is given below. 
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1.3.1 The chinchona alkaloids. 
Quinine and related antimalarials. 
Long before the causative agent of Malaria was positively identified, 
South American Peruvian Indians are reported to have chewed the bark 
of the Chinchona tree to relieve 'bad fevers' which were probably caused 
by Malaria. Some time later, 16th century Jesuit priests, recognising the 
medicinal properties of the bark, transported it back to Spain where it was 
used to treat Malaria that was prevalent in Europe at that time. 
Today, quinine is still used to treat cerebral Malaria, but although cheap to 
administer, it is only used as an emergency treatment due to its high 
toxicity in man. One of the most common side effects is deafness and 
tinitis, symptoms that were frequently experienced by British military 
troops engaged in active service in malarious regions during the First and 
Second World Wars. 
There are two principal pharmacological activities present in Chinchona 
bark, quinine and quinidine, both of which contain a quinoline ring 
structure that was used as the basis of the synthetic derivatives, 
chloroquine, amodiaquine, mepacrine and sontaquine manufactured 
during the 1930's and 40's. After the Second World War chioroquine came 
into widespread use and, motivated by the possibility of complete 
eradication of the disease, was used as a population prophylactic in 
Thailand and South America. It was in these countries where drug 
resistance was first reported (Foote and Cowman, 1994). 
Quinoline-containing antimalarials appear to target the asexual blood 
stages of the parasite that degrade haemoglobin as a source of nutrition. 
The parasite food vacuole is the site of degradation. Here, haemoglobin is 
broken down to its constituent amino acids and heme, in the form of 
ferriprotophorphyrin IX (FP), which is toxic to the parasite. As a result the 
parasite sequesters it as hemozoin, a non-toxic crystalline structure 
composed of insoluble haem polymers (Slater et al., 1991). Chioroquine 
becomes concentrated in the food vacuole of the parasite and microscopic 
studies have shown that it induces gross morphological changes in the 
organelle; similar results have been obtained for another quinoline 
compound, mefloquine, which was developed by the Walter Reed Army 
Research Institute in response to the large number of cases of malaria 
amongst American troops during the Vietnam conflict. 
The fact that chioroquine accumulates 100-fold more in parasitised 
erythrocytes is believed to be due to its weak basicity, which allows it to 
diffuse though membranes. Once chloroquine passes into the acidic food 
vacuole of the parasite, it becomes deprotonated and is unable to pass out 
again (De Duve et al., 1974). The precise mechanism of its action remains 
uncertain, however, and several possibilities exist, including possible 
inhibition of enzyme activity within the food vacuole (Vander, 1986). The 
most popular explanation at present is that chioroquine renders the 
parasite incapable of detoxifying haem causing the build up of FP which is 
toxic. There has been much debate about the possibility that a haem 
polymerase activity exists in the food vacuole. Evidence in favour of this 
comes from Slater and Cerami, (1992), and evidence against from Egan et 
al., (1994), who found evidence of spontaneous polymerisation. 
Chloroquine is a safe, effective antimalarial that is also extremely cost 
effective to administer (50p per person/week). However, P. falciparum 
parasites in particular have developed mechanisms to counteract its 
effects. One of these, has been shown to be an energy-dependent process 
in which chioroquine is expelled 40-50 times faster in chioroquine 
resistant parasites. Some drugs, such as verapamil, a calcium channel 
blocker, can reverse this process (Martin et al., 1987). This efflux 
phenomenon is similar to the multi-drug resistant (MDR) phenotype 
found in mammalian tumor cells which also involves the rapid efflux of 
an array of chemically distinct anti-cancer drugs mediated by an ATP-
dependent P-glycoprotein (Endicott et al., 1989). In mammalian cells these 
proteins are encoded by mdr genes which are often amplified in MDR 
tumor lines resulting in large increases in P-glycoprotein levels. P. 
falcipa rum has two P-glycoprotein homologues, Pgh-1 and Pgh-2 which 
are encoded by two genes pfmdrl and pfmdr2 (Foote et al., 1989 and 
Wilson et al., 1989). The Pgh-1 molecule is situated on the surface of the 
acid vesicle where its function appears to be related to regulation of the 
pH inside the food vacuole. Some chloroquine-resistant parasite lines are 
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found to have amplification of the pfrndr Ti gene copy number (Foote et 
al., 1990a), and there is strong correlation between amplification and 
overexpression of the Pgh-1 protein. 
1.3.2 The antifolates. 
Pyrimethamine, proguanil and suiphadoxine. 
DNA synthesis is an essential requirement of all living creatures at some 
point in their life cycle, and the malaria parasite which reproduces 
asexually in its human host is no exception. Malarial parasites scavenge 
purine bases from the host red blood cell but synthesise pyrimidine bases 
de novo. The synthesis of the amino acids serine and methionine, in 
common with pyrimidines, require folate as a co-factor. The parasite 
pathway for folate production is targeted by four groups of drugs. 
Suiphadoxine and dapsone inhibit dihydropteroate synthetase (DHPS) 
which catalyses the conversion of p-aminobenzoic acid (PABA) to 7,8, 
dihydropteroate. Pyrimethamine and proguanil both act by binding to and 
inhibiting the activity of dihydrofolate reductase (DHFR) which catalyses 
the reduction of dihydrofolate to tetrahydrofolate. 
As with choloroquine, resistance to pyrimethamine and suiphadoxine 
has developed and there is evidence that suggests that it is mediated by 
changes in the enzyme which reduce its affinity for the drug. Several 
changes have been mapped, for example, at position 108 serine is replaced 
by asparagine, giving a ten-fold increase in resistance (Cowman et al., 
1988). 
Amplification of the DHFR gene has also been shown to increase levels of 
the enzyme (Inselberg and Zhang, 1988), however, this type of change has 
never been connected with pyrimethamine resistance in the field. 
1.3.3 The sesquiterpenes. 
Quinghaosue and its derivatives. 
In Thailand, Cambodia, Vietnam and Burma the Malaria parasite is now 
resistant to chioroquine and virtually all other antimalarials including 
mefloquine (Larium) and halofantrine. Although health care is 
sufficiently well developed in Southeast Asia to keep the death rate 
relatively low, there is now considerable concern that effective 
antimalarials are so limited. 
One promising candidate, however, is the endoperoxide Quinghausue, 
(also know as artemisinin) which is extracted from the shrub Arternisia 
annua (wormwood). It been used in traditional Chinese medicine as a 
cure for fever, Malaria and haemorrhoids for many centuries. Isolation of 
the active compound Quinghausue, was achieved in 1971 by the Chinese. 
Since then various semi-synthetic derivatives have been developed 
including artemether, arteether, artesunate and artelinate. These second 
generation drugs are now widely used in Thailand, Vietnam and China. 
Literally hundreds of synthetic endoperoxides have been developed in an 
attempt to improve the inherent short half-lives and poor solubility of 
these drugs, and also to avoid the high levels of recrudescence that occur 
following treatment. 
Artemisinin and its derivatives are stage specific, targeting late ring stage 
and trophozoite stage parasites. They are also gametocidal, but do not 
affect the liver stages of the parasite and therefore cannot be used 
prophylactically. The cytotoxicity of artemisinin is mediated by a two step 
mechanism involving an endoperoxide bridge. In the first step, 
artemisinin is activated by heme or molecular iron giving rise to 
electrophilic alkylating intermediates and free radicals. In the step that 
follows, these highly reactive species react with and damage specific 
membrane associated proteins in the parasite (Meshnick, 1994). These 
drugs have been successfully used against chioroquine-resistant 
falciparum Malaria and are an effective way of treating the often fatal 
condition, cerebral malaria. 
1.3.4 9-anilinoacridines. 
Pyronaridine. 
Pyronaridine, a 9-anilinoacridine derivative based on m-AMSA (figure 2) 
is another drug developed in the Peoples's Republic of China during the 
1970's, and is the product of 30 years chemical research which began with 
the mepacrine nucleus, selected on the basis of the search for a 
chioroquine alternative. Synthesis of a large number of derivatives 
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Figure 2. (a) Chemical structures of representative compounds from the 
major classes of antimalarial drugs discussed in the main text. (b) 
Structure of 9-anilinoacridine compounds pyronaridine, an antimalarial 
and m-AMSA (amsacrine) an anticancer agent. 
10 
produced a compound containing an amodiaquine side chain to the 
mepacrine nucleus. This derivative is a highly active schizonticide with 
few reported adverse effects (Fu and Xiao, 1991). The World Health 
Organisation have shortlisted pyronaridine as a potential candidate 
antimalarial whose use should be thoroughly evaluated outside of China 
(011iaro and Trigg, 1995). To date, pyronaridine has undergone two 
successful clinical trials in Cameroon (Ringwald et al., 1996) and Thailand 
(Looareesuwan et al., 1996) with patients afflicted by acute uncomplicated 
Malaria. 
Although clinical trials are underway, the target of this drug remains 
uncertain. Kawai et al., (1996) have monitored the effects of pyronaridine 
on the P. falciparum parasitised red blood cells of a severely ill owl 
monkey, and found that it induced distinct morphological changes in the 
food vacuole of late trophozoite and schizont stage parasites, thirty 
minutes after administration. They concluded that pyronaridine must 
therefore interfere with the parasite digestive system. 
Chavalitshewinkoon et al., 1993, and Carnage et al., 1994 have tested a 
range of 9-anilinoacridine derivatives against the pyrimethamine-
chioroquine resistant KI isolate of P. falciparum. 
The ability of these drugs to inhibit parasite growth in culture and 
topoisomerase II activity were tested. In the former study, blood stage 
parasites were incubated with drugs for 24 hours, followed by the addition 
of 3H hypoxanthine for a further 24 hours. Drug activity was then 
recorded as the concentration of drug required to inhibit the 
incorporation of 3H hypoxanthine into parasites by 50% (IC 50)  compared 
to untreated controls. Human Jurkat leukemia cells were used for 
comparison, and cytotoxicity was measured in this case by assessment of 
cell growth (IC5o) and viability. The outcome of these experiments 
showed that some 9-anilinoacridine derivatives, including pyronaridine, 
appeared to exhibit selective antimalarial activity. There also appeared to 
be a relationship between antimalarial activity and enzyme inhibition 
For example, one derivative called 7n, exhibited a potent antimalarial 
activity (in the tritiated hypoxanthine assay), and inhibited partially 
purified Topoll from the parasite and human Jurkat cells at 
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concentrations of 6M and 201iM, respectively. However, it was recognised 
that inhibition of the parasite topoisomerase II enzyme may not be the 
sole mechanism of action (Gamage et al., 1994). Clearly, further 
investigation is required to corroborate the promising preliminary studies 
that have been done with pyronaridine, if it is to be used effectively in the 
field as an antimalarial. 
1.4 Vaccine development. 
1.4.1 Conventional vaccines. 
Considerable time, money and effort have been invested in attempting to 
obtain a safe and effective anti-malarial vaccine. Advances in this area 
have been discouragingly slow, however. 
Plasmodium surface proteins should provide suitable targets for vaccine 
development, but a major problem relates to the fact that the parasite 
spends much of its life cycle within the cells of its host (eg. liver stages, 
ring, trophozoite, schizont and gametocyte blood stages) and thus 
"shielded" from the immune system. This is exacerbated when red blood 
cells infected with P. falciparum parasites become sequestered in the 
capillary systems of organs (Hyde, 1990). 
The search for protective antigens has also been complicated by the 
discovery of numerous cross-reactive parasite proteins, which, it has been 
proposed, will impair the development of protective immune responses 
in the host. This may occur by absorption of antibodies to antigens that are 
not essential to parasite survival, or by induction of low affinity 
antibodies that are ineffective at directing a strong immune response. The 
latter mechanism has been termed the "smokescreen effect", and there is 
good evidence to support it. The antibody response to sporozoites, for 
example, is almost entirely directed towards the repetitive domain of the 
circumsporozoite protein, indicating that this appears to be a single 
immunodominant epitope. 
Despite these problems, recombinant circumsporozoite surface 
protein/ hepatitis B surface antigen fusions were recently found to protect 
six out of seven vaccinees in a preliminary trial (Stoute, 1997). 
Another potential vaccine candidate developed by Columbian scientist 
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Manual Patarroyo, is currently undergoing clinical trials. It is a synthetic 
peptide vaccine based on the pre-erythrocytic and asexual blood stage 
antigens of P. falciparum. (SPf-66 vaccine). 
Clinical trials of the vaccine began in 1985/1986 with monkeys and 
showed that the vaccine gave partial protection and was safe (Maurice, 
1995). Since that time a number of trials have been conducted in humans 
with varying success. The best results came from a trial conducted in 
Tanzania, an area of intense perennial transmission of P. falciparum; 
children in the age group 1-5 were the subjects of the trial. The vaccine 
was shown to be highly immunogenic with all recipients positive after 3 
doses. The efficacy was reported to be 31% (Alonso et al., 1994). 
Much criticism has been directed against the design of the early clinical 
trials for this vaccine and the most recent trial showed a disappointingly 
low level of protection (8%). Patarroyo now proposes to conduct a new 
trial in the summer of 1997 using fifty Columbian volunteers and a new 
adjuvant code named QS21 which has been shown to increase protection. 
1.4.2 Transmission blocking vaccines. 
Transmission blocking vaccines work by inhibiting development of the 
sexual stages of the parasite in the mosquito, so that transmission back to 
the human host cannot occur. The process is mediated by vaccinating the 
host with antibodies directed against specific parasite sexual stage 
antigens. In this sense, the vaccine is said to be altruistic because the 
human host gains no direct protection or immediate benefit from the 
vaccine. Various sexual stage antigens targets have come under scrutiny, 
most of which are present on the surface of the parasite, for example 
Pfs230, a gametocyte-gamete surface antigen and Pfs25, a ookinete surface 
antigen. 
The concept of transmission blocking immunity is not a new idea and 
early work using whole gametes (Carter and Chen, 1976) and a mixture of 
macrogametes and gametes (Carter et al., 1979) has shown that the 
transmission route between host to vector can be interrupted. This has 
also been tested with monoclonal antibodies using a membrane feeding 
apparatus, which mimics what might occur when mosquitoes feed on an 
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Malaria infected individual. 
No hard data is available at present on how well these vaccines might 
perform in the field, however. 
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1.5 Topoisomerases. 
The search for novel antimalarial drug targets has recently focussed on a 
group of enzymes which are better known as the cellular targets of many 
widely prescribed anticancer and antimicrobial drugs. These enzymes, the 
topoisomerases, perform many roles relating to DNA topology within the 
cell, for example, DNA replication, transcription and recombination, as 
well as chromosome structure and segregation. 
Before the biological roles that the topoisomerases play is discussed, 
however, certain features relating to the topological organisation and 
characteristics of a DNA molecule require definition. The linking number 
of a DNA molecule is defined as the number of times that the two strands 
of a DNA helix are interwound in a covalently closed DNA molecule. 
The mean helical pitch of unconstrained DNA is 10.6 base pairs per turn 
and a relaxed covalently closed circular DNA will have a linking number 
equal to an integral value close to N/10.6, where N is the number of DNA 
in base pairs (Wang 1979). It follows that underwound DNA circles which 
are negatively supercoiled will have linking numbers less than this 
value, whilst overwound DNA circles which are positively supercoiled 
will have linking numbers greater than this value. The only way to 
change the linking number of a DNA circle is by breaking one or both of 
the DNA strands so that the interwinding of the two strands is altered. 
Identical DNA molecules which differ only in their respective linking 
numbers are referred to as topological isomers. 
The interconversion of different topological isomers is accomplished by 
the transient introduction of single or double-stranded cuts into DNA; 
enzymes that catalyse the former reaction being classified as a type I DNA 
topoisomerases, the latter a type II. Some topoisomerases can supercoil 
DNA, some are able to relax positive and negative supercoils, others can 
relax positive or negative supercoils, whilst some can decatenate 
catenated rings or sister chromatids. No topoisomerase has been 
identified that is able to catalyse all of these reactions, however. Indeed, as 
more topoisomerases are discovered, the degree of specialisation that each 
of these enzymes has evolved becomes more apparent. 
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1.5.1 Type I topoisomerases. 
1.5.1.1 Eukaryotic topoisomerase I. 
Eukaryotic topoisomerase I enzymes cut one strand of a DNA duplex 
allowing rotation of the severed strand relative to the uncut strand and 
change the linking number by one. These enzymes are able to relax both 
negative and positive supercoiled DNA substrates. 
Type I topoisomerases have been isolated from many different eukaryotic 
sources including humans (D'Arpa et al., 1988), Drosophila melanogaster 
(Hsieh et al., 1992), S. cerevisiae (Goto and Wang, 1985 and Thrash et al., 
1985), P. falciparum (Tosh and Kilbey, 1995), and Caenorrhabditis elegans 
(Kim et al., 1996). All have apparent molecular masses of around 100 kDa, 
but there are exceptions. Topoisomerase I activity isolated from the 
kinetoplastid protozoan Trypanosoina cruzi (Riou et al., 1983) is 
associated with a 65 kDa monomeric protein. This is considerably smaller 
than most other eukaryotic topoisomerases I apart from Vaccinia virus, at 
32 kDa. 
There is a marked degree of sequence conservation over most of the 
protein except the N-terminal portion. A conserved seventy amino acid 
domain sited close to the the C-terminus has been implicated in catalysis, 
and mutational replacement of tyrosine 727 in S. cerevisiae results in an 
inactive enzyme suggesting that this residue is necessary for catalytic 
activity (Eng et al., 1989). 
A reaction intermediate, called the cleavable complex, can be trapped 
using a protein denaturant (SDS or strong alkali). Under these conditions, 
the enzyme becomes covalently bound to the 3' phosphoryl end of the 
severed DNA strand of the duplex via a specific phosphate/tyrosyl bond, 
leaving the 5' hydroxyl free (Champoux, 1981). This process is not 
dependent on the hydrolysis of ATP and no co-factor is required. 
In yeast, top I mutants are viable, suggesting that the protein is not 
essential (Thrash et al., 1985). However, genetic experiments with topi 
mutants have shown that the enzyme is essential for growth and 
development in D. melanogaster (Lee, 1993) and in the mouse embyo 
(Morham et al., 1996). 
Lue (1995) has crystallised a 26kDa fragment of the S. cerevisiae protein 
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(residues 135-363). Combined crystallographic and biochemical analysis of 
the fragment indicates that it corresponds to the region of the protein that 
is involved in DNA binding and catalysis. The DNA/protein interaction 
occurs on one surface of the fragment which has a strong electrostatic 
potential, implying that electrostatic forces may play a part in the 
interaction. Two separate regions of the fragment were found to be 
involved in DNA binding. It is further postulated that the residues which 
when mutated confer resistance to the Topol inhibitor camptothecin 
(Phe293 and G1y295), map to a loop that forms part of the DNA-binding 
surface. Because the drug is thought to stabilise the covalent protein-DNA 
intermediate, it is feasible that this loop may be in the vicinity of the 
active site of the enzyme. 
Recently, Topol has also been shown to exhibit functions distinct from 
DNA relaxation. Rossi et al., (1996) have reported the purification of a 
kinase activity which can be inhibited by camptothecin and specifically 
phosphorylates SR proteins involved in RNA splicing. Furthermore, 
Gobert et al., (1996) have shown that treatment of human MCF7 breast 
adenocarcinoma cells with mitomycin C, a known anticancer agent, 
results in increased Topol activity in parallel with an increase in p53 
levels. Topol was also found to co-immunoprecipitate p53 suggesting that 
the activation of Topol may be related to an interaction between these two 
proteins. Purified recombinant proteins were also tested in vitro and p53 
was again demonstrated to enhance the catalytic activity as measured by 
relaxation of supercoiled DNA, stabilisation of the covalent Topol-DNA 
complex in the presence of camptothecin, and phosphorylation of SR 
protein splicing factor ASF/SF2. p53 was also found to increase the 
thermal stability of Topol, protecting it from heat denaturation. These 
results suggest that the p53-mediated response to DNA damage may 
involve Topol activation. 
1.5.1.2 Bacterial topoisomerase I. 
E. coli topoisomerase I was the first topoisomerase to be identified (Wang, 
1971). The enzyme catalyses the relaxation of negatively supercoiled DNA. 
The enzyme is a 97 kDa protein which unlike eukaryotic topoisomerase I, 
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Topol of E. coli has a requirement for exogenous magnesium as a co-
factor. The DNA cleavage reaction occurs between the DNA 
phosphodiester bond and the active site tyrosine 319, which yields a 
covalent intermediate in which the tyrosine becomes linked to the 5' 
phosphoryl end of the cut DNA strand. Nucleophilic attack by the severed 
DNA strand on the phosphotyrosine linkage rejoins the DNA strand and 
dissociates the enzyme.The three-dimensional crystal structure of the N-
terminal 67 KDa fragment of the protein has been determined (Lima et al., 
1994). 
In E. coli, the competing activities of Topol and the type II topoisomerase 
gyrase, act to regulate the degree of intracellular DNA supercoiling. topA 
null mutants of E. coli can be tolerated, however, provided compensatory 
mutations occur at other loci that change the degree of DNA supercoiling. 
One such compensatory mutation in the gene encoding DNA gyrase 
subunit B (gyrB) leads to a ten-fold reduction in enzyme activity. 
(McEachern and Fisher 1989). 
1.5.2 Topoisomerase Ill. 
Yeast topoisomerase III is a bacterial "Topol" like enzyme with apparent 
molecular mass of 74 kDa (Wallis et al., 1989). The enzyme has 21% 
identity to the Topol of E. coli. Unlike yeast and F. coli topoisomerases I, 
yeast Topolil is somewhat inefficient at relaxing negatively supercoiled 
DNA, and positively supercoiled DNA is completely refractory to it. This 
suggests that its biological role in vivo is unlikely to be related to 
relaxation events that occur in the cell. Topolli can be converted into a 
more processive enzyme, however, and use of a 29 nucleotide long single-
stranded DNA loop within a negatively supercoiled substrate DNA has 
demonstrated this (Kim and Wang 1992). In fact, both yeast and F. coli 
Topolli activity can be enhanced by the presence of single-stranded 
regions in the DNA substrate. The minimal requirement for catalysis 
with the E. coli homologue turns out to consist of 6 bases 5' to the 
cleavage site and 1 base 3' to the site in single-stranded DNA. Nuclease P1 
protection has shown that the enzyme binds asymmetrically, protecting 12 
bases (Zhang et al., 1995). 
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Yeast and E. coli t0p3 mutants both exhibit a hyper-recombination 
phenotype suggesting that Topolil may act as a suppressor of genetic 
recombination in vivo. In line with this observation, overexpression of a 
truncated human Topolil (hTOP3 gene isolated by Hanai et al., 1996) has 
been found to partially correct multiple aspects of the autosomal recessive 
disorder Ataxia-telangiectasia (A-T) phenotype (progressive cerebellar 
degeneration, immunodeficiency, accelerated aging, increased risk of 
cancer and genetic instability). Yeast Topolil interacts with the putative 
DNA helicase SCSi in vivo and sgsl mutants can suppress the hyper-
recombination phenotype of top3 mutants. At the same time, it has also 
been observed that sgsi mutants also exhibit a hyper-recombination 
phenotype. These findings suggest that Topoill and SCSi proteins 
interact to maintain genetic stability in the cell and that imbalances in 
either protein increase the rate of mitotic recombination. Fritz et al., 
(1997), have also suggested that human Topoill may act in concert with 
other proteins to maintain chromosome stability. SGS1 shares extensive 
sequence homology with BLM, the Bloom syndrome gene and WRN, the 
Werner syndrome gene, mutations of which cause human genetic 
diseases associated with hyper-recombination. It is further speculated that 
Topolll/SGS1 complex may act in concert with BLM and/or WRN DNA 
helicases to form "reverse gyrase" like complexes in vivo. Wang, (1991) 
has also proposed that such an enzyme may be a component of a cellular 
complex involved in prevention of incorrectly paired DNA strands. 
Another interesting possibility is that Topolli may be able to reduce 
recombination by preventing the formation of Z-DNA and other 
recombinogenic structures. 
1.5.3 Reverse gyrase. 
This enzyme is found in thermophilic archaebacteria and eubacteria. In 
common with DNA gyrase, it has a novel intrinsic supercoiling activity 
but no relaxation activity, and in this respect is quite unlike any other type 
I topoisomerase discovered to date. This enzyme is able to catalyse the 
introduction of positive supercoils at high temperature, into closed 
circular DNA substrates at the expense of ATP. Confalonieri et al., (1993) 
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have proposed a model for the mechanistic action of the enzyme in 
which supercoiling is driven by a helicase plus topoisomerase. The 
Sulfolobus acidocaldarius DSM 639 gene encodes a protein of 1247 amino 
acids and sequence analysis suggests the protein consists of two domains. 
The N-terminal domain although without similarity to other 
topoisomerases, contains several helicase motifs, and an ATP binding site, 
while the C-terminal domain of 630 amino acid residues appears to be 
related to eubacterial topoisomerase I and also to the S. cerevisiae TOP3 
gene. The biological function of reverse gyrase is as yet unclear. 
1.5.4 Type II DNA topoisomerases. 
The reactions of the type II topoisomerases are summarised in figure 3. 
Type II enzymes catalyse the formation of transient double-stranded 
breaks in a DNA duplex, a process dependent on the hydrolysis of ATP 
and presence of divalent cations. A second intact DNA duplex is then 
passed through the double-stranded gap. The process occurs by means of 
nucleophilic attack on a 5' staggered pair of phosphodiester bonds four 
base pairs apart (Morrison and Cozzarelli 1979). The 5'-phosphoryl ends of 
the duplex become covalently linked to the phenolic oxygens of the 
tyrosine groups present on each subunit of the enzyme. This forms the 
basis of a DNA gate through which the second duplex can be transported 
Following transportation, a transesterification reaction occurs; this is 
mediated by the reaction of the two 3'-hydroxyl groups present on the 
severed DNA ends and the phosphotyrosine bonds to the protein. This 
reaction seals the broken duplex without damaging the DNA (Roca and 
Wang 1994). Eukaryotic topoisomerase II relaxes both negative and 
positive supercoiled DNA. 
1.5.4.1 Eukaryotic topoisomerase H 
The catalytic cycle of eukaryotic topoisomerase II has been elucidated by 
Osheroff et al., (1991) and comprises the six following steps; (Step 1) 
involves substrate recognition and binding, and is determined by 
topological structure and nucleotide sequence. In humans and chicken 







The reactions of type II topoisomerases. 
21 
+ G 
NON NGYNGTTNYNYN N 
NG NNCRNCAAN RN RN N 
C, 
Where I = pyrimidines, R = purines and N = any complementary base (G 
and C are alternative recognition sites. 
Topoll can discriminate between different topological structures and 
interacts preferentially with supercoiled substrates. This is important 
because it enables the enzyme to distinguish between the supercoiled 
substrate and the products of its own reaction. 
Step 2: Following substrate recognition, topoisomerase II establishes a 
rapid double-stranded DNA cleavage / religation equilibrium, which 
favours religation. This process requires the presence of a divalent cation, 
which is normally magnesium in vivo, but calcium can substitute in 
vitro. Transesterification from the phosphodiester DNA backbone to the 
catalytic tyrosine, results in a covalent bond between each subunit of the 
protein. The cut introduced into the DNA substrate is staggered with a 4-
base 5' overhang and evidence suggests that the cuts are introduced 
sequentially. This step is the target of several classes of antineoplastic 
drugs (eg. amsacrine and etoposide) which stabilise the topoisomerase 
11/DNA cleavage complex, by decreasing the apparent first order rate 
constant for religation. 
During the third step, following strand breakage, strand passage occurs, a 
process which depends on ATP binding and results in the relaxation of 
two negative supercoils. Whilst in the fourth step, following strand 
passage, topoisomerase II establishes another cleavage/ religation 
equilibrium. This step has not been studied in detail due to the difficulty 
involved in isolating the intermediate, however this step is also a target 
for certain classes of inhibitor which act by stabilising the post-strand 
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passage enzyme/DNA complex, inhibiting the religation event as in Step 
2 although their effects appear to be less dramatic than in the pre-strand 
passage step. 
In Step 5 bound ATP is hydrolysed to ADP and orthophosphate, whilst in 
Step 6 enzyme turnover occurs after the protein has dissociated from the 
DNA substrate. Under optimal conditions the enzyme is highly 
processive remaining bound to the DNA until all supercoiling has been 
removed. 
Berger et al.,(1996), have crystallised a 92 kDa fragment of the yeast protein 
(residues 410-1202) which comprises the central domain and part of the C-
terminal domain (shown in Fig. 4 a). The structure is heart shaped with a 
central hole. The 92 kDa fragment can cleave DNA but cannot execute 
duplex transport because it lacks the ATPase domain. Using information 
already obtained on the crystal structure of the ATPase domain from E. 
coli GyrB, Berger et al., have proposed a molecular model of the enzyme 
as an ATP-modulated clamp with two sets of jaws at opposite ends, 
connected by multiple joints (Fig. 4 b). 
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Figure 4 (a). 
Representation of the yeast DNA topoisomerase 11(410-1202) dimer. Two 
crescent-shaped monomers form a pair to make a heart shaped dimer 
with a large central hole. The A' subfragment of each monomer contains 
residues 682-1178 and the B' subfragment residues 420-633. Subfragments 
belonging to one subunit are shaded more darkly than their counterparts. 
Figure 4 M. 
The molecular model proposed for the catalytic reaction of topoisomerase 
II. The G-segment DNA (containing the DNA gate) is coloured grey and 
the transported T-segment is green. (1) enzyme binds the G-segment DNA 
which induces the conformational change shown in (2). ATP binding 
(represented by asterisks) and T-segment binding (3) induce additional 
conformational changes in which the G-segment is broken by the A' 
subfragments as they separate from each other. Concomitantly, the 
ATPase domains dimerise, and the T-segment is transported through the 
break and into the central hole (4). The B' subfragment in front is 
uncoloured in (4) to permit visualisation of the DNA behind it. For 
clarity, the DNA transport step is shown to proceed through a 
hypothetical intermediate (brackets). Following transport, the G-segment 
is resealed and the T-segment released from the enzyme through the 
opening of the dimer interface between A' subfragments (5). The interface 
between the two A' subfragments again dimerises, and ATP is hydrolysed 
and released to regenerate the starting state (2). 










The sequences encoding several topoisomerases II have been determined, 
including the yeasts S. cerevisiae (Giaever et al., 1986), S. pombe (Uemura 
et al., 1986) and Ccindida albicans (Keller et al., 1997), D. melanogaster 
(Wyckoff et al., 1989), Trypanosoma brucei (Strauss and Wang 1990) and P. 
falciparum (Cheesman et al., 1994). The apparent molecular masses of 
each subunit range in size between 155 to 170 kDa which comprise 
holoenzymes of 310-340 kDa. 
Eukaryotic topoisomerases II share extensive homology over the N-
terminal region of the protein. This is especially so for the residues that 
appear to have known functions. The N-terminal domain is homologous 
to the B subunit of the bacterial gyrase homologue. It contains a highly 
conserved glycine which is involved in ATP binding (residue 147 in 
PfTopoll). The structure of this region in the gyrase protein has been 
defined by x-ray diffraction (Wigley et al., 1991). The central region of the 
protein corresponds to the gyrase A subunit and contains the tyrosine 
residue (residue 829 in PfTopoll) that is involved in strand-breakage and 
religation. This region also contains the highly conserved motif 
LIMTDQD, which has been used as a means to isolate the gene in many 
species, including P. falciparum where the leucine residue is replaced 
with a methionine (MIMTDQD). 
Although the C-terminal domain appears not to have any known 
catalytic function and is remarkably species divergent, it is retained in 
many phylo genetically distinct eukaryotic organisms. Thus it appears 
most likely that this region performs some important function for the 
enzyme. Indeed, a nuclear localisation signal is reported to be located 
within the most distal sixty amino acids in Drosophila (Greenwood-
Crenshaw and Hsieh 1993) and a putative leucine zipper motif has also 
been identified in many species which may function in subunit 
dimerisation (Caron and Wang 1994). 
Related to this, phosphorylation of the C-terminal domain has been 
proposed as a post-translational modification governing enzyme activity. 
The D. melanogaster homologue is phosphorylated in vitro by casein 
kinase IL In this case, phosphorylation led to a 3-fold stimulation of DNA 
relaxation activity compared with the unphosphorylated form. These 
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effects could be reversed by alkaline phosphatase (Ackerman et ciL, 1985). 
Yeast topoisomerase II has also been shown to be a phosphoprotein and it 
has been proposed that the existence of casein kinase II sites in the C-
terminal domain form part of the mechanism by which control of 
enzyme activity is achieved (Cardenas et al., 1992). 
Recently, the C-terminal domain of Topoll (S. cerevisicie) has been 
assigned another role. Watt et al., (1995) used a two-hybrid cloning 
strategy to isolate a protein called Sgsl p, which is structurally related to 
the E. coli Rec Q helicase protein. Sgsl p interacts with a short region of 
the C-terminal domain of Topoll that has been implicated in dimerisation 
of the Topoll protein. Strains lacking a functional SGS1 gene show a 
reduced fidelity of both mitotic and meiotic chromosome segregation, 
which leads to a diminished capacity to undergo cell division. Based on 
these findings, Watt et al., (1995) have proposed a model in which Sgsl p 
and Topoll interact during the final stages of DNA replication to achieve 
chromosome segregation. 
Two distinct DNA topoisomerases II ( a and 13)  have been isolated from 
humans which share 72% identity. The 170 kDa a isoform (Tsai-
Pflugfelder et al., 1988) is present in proliferating cells, is localised in the 
nucleoplasm and has a dual structural/ enzymatic role. This isoform 
shares 65% sequence similarity with the P. fcilcipciruin homologue. 
The 180 kDa human isoform is encoded by a different genetic locus to the 
a isoform, and has been designated topoisomerase 13  (Jenkins et al., 1992 
and Austin et al., 1993); it is reported to be present in cells which have 
reached the plateau growth phase, and is localised to the nucleolus (Negri 
et al., 1992). There is speculation that localisation to the nucleolar 
remnant may indicate that it could represent a structural element for the 
spatial organisation and regulation of transcription of ribosomal genes 
(Zini et al., 1994). 
It has been suggested that the different isoforms may have arisen by a 
gene duplication event which occurred relatively recently. Although the 
P form is larger by around 100 amino acid residues at the carboxy 
terminus, the functional significance of this is unknown. One distinct 
difference between the P.faiciparurn protein and all other eukaryotic 
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topoisomerases II is the presence of two unique adjacent polyasparagine 
rich tracks situated distal of the N-terminal domain. No functional role 
has been assigned to these inserts. 
Topoisomerase II is a multifunctional enzyme which plays several roles 
in DNA metabolism. One of these roles relates to the segregation of 
chromosomes following DNA replication during mitosis and meiosis in 
yeast (DiNardo et al., 1984 and Holm et al., 1985). S. cerevisiae top2 
mutants have been shown to accumulate catenated dimers derived from 
newly replicated circular plasmids (DiNardo et al., 1984). Failure to 
segregate these catenated DNA intermediates ultimately results in cell 
death when the cell attempts to divide at mitosis (Holm et al., 1985). 
Similar findings have been reported with living Drosophila cells, 
following immunodepletion of Topoll, daughter chromosomes fail to 
separate at anaphase (Buchenau et cii, 1993). Thus it seems most likely that 
Topoll activity is required as a decatenase, at least for circular or large 
genomes. But which topoisomerase is responsible for providing the 
swivelase activity required for the early stages of DNA replication at the 
replication fork? Work conducted by Goto and Wang 1984, Uemura and 
Yanagida 1984 and Brill et al., 1987, has indicated that although either 
topoisomerase can provide swivelase activity during the early stages of 
DNA replication, topoisomerase I is the most likely candidate. This is 
supported by studies with SV40 where Topoll inhibitors slowed only the 
last 5% of genome replication (Snapka et cii, 1988). 
The use of topoisomerase inhibitors has yielded valuable information. In 
mammalian cells, the topoisomerase I inhibitor camptothecin has been 
shown to stop DNA replication almost immediately, lending support to 
the idea that Topol is probably the major swivelase. The relatively new 
drug ICRF-193, has also been used to gain insight into the early stages of 
DNA replication. It is likely to be more informative than some of the 
earlier inhibitor studies using drugs like VP-16 and VP-26, which work by 
stabilising the cleavable complex thereby yielding unreliable results due to 
drug induced DNA damage. This damage causes blocks in chain extension 
at an early stage in during replication. ICRF-193 causes cell death during 
the G2/M phase and thus mimics the phenotype of yeast t0p2 mutants, 
unlike VP-16 and VP-26 which on the other hand cause cell death during 
S phase. The outcome of studies using ICRF-193 further support the idea 
that Topoll is not required during the early stages of DNA replication, but 
is needed for the resolution of late replication intermediates (Ishimi et al., 
1992 and Clarke et a!, 1993). 
Several lines of evidence now exist to indicate that Topoll appears 
unlikely play a direct role in transcription. Shaak et al., (1990) have 
pointed out that levels of Topoll in terminally differentiated and 
quiescent cells are very low, even though these cells are transcriptionally 
active. In addition, VP-26 does not reduce transcription of HeLa heat 
shock genes or adenoviral genes, whilst use of camptothecin led to a 
reduction of adenovirus and HeLa cell mRNA. 
Although genetic studies with yeast have demonstrated that 
topoisomerase I is dispensable for viability, it is also known that a lack of 
this protein leads to a reduction in growth rate and a decrease in large 
RNA transcripts (Brill et a!, 1987). 
Topoll is a major non-histone protein component of the metaphase 
scaffold and acts as a scaffold protein possibly joining the A/T rich DNA 
sequences found at the base of chromosome loops, the scaffold attachment 
regions (SAR), to the nuclear scaffold (reviewed in Gasser and Laemmli 
1987). Supporting this, consensus cleavage sites for Topoll are found in 
SAR sequences (Udvardy et al., 1985). 
Apart from its known catalytic and structural roles, Topoll also plays a 
role in chromosome condensation. In cultured mammalian cells, 
treatment of G-2 phase cells with the Topoll inhibitor VM-26 prevents 
chromosome condensation and entry into mitosis (Lock and Ross 1990) 
but it is unclear whether lack of a functional Topoll prevents entry into 
mitosis or whether the block is a result of DNA damage caused by the 
drug. More convincing studies have been conducted by Adachi et al., 
(1991), who has demonstrated that adding back Topoll to 
immunodepleted cells restores their ability to condense chromosomes 
effectively. 
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1.5.5 Type II bacterial DNA topoisomerases. 
1.5.5.1 DNA gyrase and topoisomerase IV. 
DNA gyrase is a type II enzyme first identified in 1976 by Gellert et al., 
that can introduce and relax negative supercoiling in steps of two. This 
process requires ATP as an energy cofactor. The protein is encoded by the 
gyr A and gyr B genes; the active enzyme is a heterotetramer composed of 
two A and two B protein subunits (A2/B2 configuration) which bind DNA 
and wrap about 120 base pairs around the protein core. The individual 
subunits are 97 kDa for the A subunit and 90 kDa for the B subunit. The 
gyrase B protein contains the active site tyrosine residue involved in the 
strand-breakage religation reaction, (Tyr 122) whilst the gyrase A protein 
contains the ATPase domain of the protein. The crystal structure of the N-
terminal fragment of the B protein has been elucidated by Wigley et al., 
1991. 
For many years gyrase was believed to be responsible for unlinking newly 
replicated daughter chromosomes, but it is now known that 
topoisomerase IV fulfils this role in vivo . TopolV is encoded by the parC 
and parE genes. In common with other type II enzymes except gyrase, 
TopolV has no intrinsic supercoiling activity, but does possess a potent 
decatenase activity. Mutations in the genes encoding both gyrase and 
TopolV are conditionally lethal. parC and parE mutations results in a 
terminal partitioning defect whereas mutations in the gyrA and gyrB 
genes lead to an "immediate-stop" DNA replication phenotype. 
Bacterial gyrase is the target of two main classes of inhibitors, but their 
bacteriocidal action is mediated by two different mechanisms; the 
quinolones, in particular the highly potent fluoroquinolones (eg. 
ciprofloxacin) work by interfering with the rejoining of double-stranded 
breaks in the DNA, whilst the coumarins (eg. novobiocin) inhibit the 
ATPase activity of the enzyme. Quinolones also target TopolV. 
1.6 Topoisomerase inhibitors. 
DNA topoisomerases I and II are the cellular targets of a group of diverse 
drugs in clinical use as anti-tumor agents. Although the drugs are 
structurally dissimilar, their mechanism of action involves either 
30 
inhibition of the DNA strand-breakage/reunion reaction (Type I or II 
enzymes) or inhibition of ATP hydrolysis (Type II enzymes). 
1.6.1. Eukaryotic topoisomerase I poisons. 
Camptothecin and related compounds. 
Camptothecin is a plant alkaloid isolated from Cain ptotheca acuminata. 
Camptothecin does not appear to react with DNA or RNA polymerases or 
with DNA itself, nor does it react directly with topoisomerase II, but in the 
presence of topoisomerase I, large amounts of single-stranded DNA 
breaks accumulate (Hsiang et al., 1985). The cytotoxic effects are thought to 
result from the accumulation of enzyme-DNA linkages when cleavable 
complexes are stabilised and trapped by the drug. 
However, despite the potentially promising antitumor properties 
exhibited by camptothecin, early clinical trials during the 1970's showed 
not only that the drug was lacking activity, but also that it was highly 
toxic. At this stage however, the target of camptothecin was unknown. 
Chemical modifications of the basic compound have produced new 
analogues in the late 1980's which appear to be not only highly active, but 
also less toxic. Irinotecan, for example, is a semisynthetic analogue of 
camptothecin whose metabolite SN-38 is 100-fold more active. This drug 
has recently been registered in Japan, USA and most European countries, 
where its use is indicated for colorectal cancer which is unresponsive to 
most other cytotoxic treatment regimes. Topotecan is another 
semisynthetic water soluble Topol inhibitor based on camptothecin which 
has recently been registered for use against ovarian cancer. 9-
Aminocamptothecin, 9-Nitrocamptothecin, Lurtotecan (CI 147211), DX 
8951 and Ho 33342 are Topol inhibitors currently undergoing clinical 
development. 
Topol inhibitors are arguably the most important class of cytotoxic agents 
developed over the last decade. 
1.6.2 Topoisomerase II poisons and inhibitors. 
It has been established that the cellular level of topoisomerase II increases 
when quiescent cells are simulated to proliferate, and decreases when cells 
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are induced to differentiate. This may explain the sensitivity of 
proliferating and tumor cells to topoisomerase II poisons. The specificity 
of different chemical compounds for topoisomerases has enabled 
synthetic organic chemists to design novel drugs which are selective 
against the topoisomerases of pathogenic species including bacteria, fungi 
and protozoan parasites. 
Topoisomerase II poisons and inhibitors can be grouped according to 
whether they act as DNA intercalators or non-intercalators. A brief 
discussion of some of the drugs that poison or inhibit topoisomerase II 
follows. 
1.6.2.1 m-AMSA (amsacrine). 
Amsacrine is a clinically active antileukemia agent first reported in 1971 
as a potentially useful therapeutic agent. Although amsacrine is reported 
to be active against myelogenous leukaemia, toxicity problems have 
limited its clinical usefulness. 
Studies have shown that the drug binds to DNA in vitro with the 
acridine moiety responsible for the intercalation between and parallel to 
the base pairs. This causes the double helix to extend and become distorted 
while the anilino moiety projects into the minor groove where it 
interacts with the enzyme (Marshall and Ralph 1985). It has also been 
shown that the drug stimulates the formation of enzyme-DNA complexes 
(Nelson et al., 1984). 
The nature of the substituents on the anilino moiety dramatically alters 
the antitumor activity of 9-anilinoacridines, possibly by altering the 
contact with the enzyme. The structural isomer o -AMSA is known to be 
inactive, here the 3' methoxy group is in the 5' position. 
Many other intercalative drugs exist that target topoisomerase II by 
forming non-productive drug-enzyme-DNA ternary complexes eg. the 
ellipticines, actinomycin D, doxorubicin and daunomycin. 
Another DNA intercalator, ethidium bromide has also been investigated 
and was found not to stimulate topoisomerase 11-mediated DNA cleavage 
demonstrating that intercalation per se is not sufficient to elicit this 
response (Pommier et al., 1983). Other intercalative antitumor drugs 
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include daunomycin, doxorubicin, mitoxantrone, and actinomycin D. 
1.6.2.2 Non-intercalating antineoplastic drugs. 
The epipodophyllotoxirts are semisynthetic derivatives of the natural 
product podophyllotoxin. Two members of this group are etoposide (VP-
16) and teniposide (VM-26). These are clinically active against Kaposi's 
sarcoma, testicular carcinoma, leukemia and small cell lung cancer. 
Neither of the drugs bind isolated DNA but are capable of stabilising the 
eukaryotic topoisomerase 11/ DNA cleavable complex, and are reported to 
be active at late S and G2 phases of the cell cycle (Krishan et al., 1985). In 
clinical trials, teniposide has been found to be 10-fold more active than 
etoposide, but this increased activity may be a function of cellular uptake 
(Sinha, 1993). 
Human leukaemia cell lines selected for resistance to teniposide have 
been isolated (Bugg et al., 1991). The basis of resistance appears to be 
related to a single mutation in the topoisomerase II gene, where arginine 
449 has changed to glutamine. Nuclear extracts from these cell lines have 
decreased levels of topoisomerase IT catalytic activity and decreased 
capacity to form drug-stabilised covalent complexes. The ATP 
concentration required for equivalent activity in a DNA unknotting assay 
was found to be 2 to 8-fold higher in nuclear extracts derived from these 
drug-resistant cell lines compared to parental lines, indicating that the 
alteration in ATP binding observed may be related to drug resistance. 
The difficulties involved in performing genetic analysis in mammalian 
cell lines has complicated the determination of whether mutations 
occurring in the topoisomerase II gene are responsible for drug resistance. 
Nitiss et al., (1994) have attempted to address this problem by constructing 
a yeast topoisomerase II gene with an equivalent mutation to that found 
in the human leukemia cell line discussed above. In this case, mutation 
of lysine 439, the equivalent amino acid in the yeast protein to either 
glutamine or glutamic acid was found to confer resistance to both 
etoposide and amsacrine. 
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1.6.2.3 ICRF-193. 
ICFR-193 is a member of the bisdioxopiperazine class of drugs and inhibits 
topoisomerase II by a novel mechanism. In the presence of ATP the 
enzyme appears to become trapped in what is thought to be the closed 
clamp form of the enzyme and is thus unable to cleave DNA (Roca et al., 
1994). 
1.6.2.4 Dual Inhibitors. 
A small number of inhibitors exist which are known to target both Topol 
and Topoll; these include saintopin, actinomycin D and intolicine. 
Leteurtre et al., (1994), studied Topol and Topoll cleavable complexes in 
the presence of saintopin and found the same preference for a guanidine 
base located 3' to the topoisomerase-induced break at position + 1. 
Furthermore, a camp tothecin-resistant topoisomerase I with Asn 722 
mutated to Ser next to the catalytic site tyrosine (position 723) was found 
to be cross resistant to saintopin, indicating that both camptothecin and 
saintopin interact with Topol near the active site tyrosine. 
1.6.2.5 9-anilinoacridines (mechanism of action unknown). 
Widespread recognition of human topoisomerase II as the target for 
chemotherapeutic agents has highlighted the potential benefit of targeting 
the protein in other pathogenic organisms, including protozoan parasites. 
The effects of certain 9-anilinoacridine derivatives have now been 
investigated for a number of parasites including Leishmania, Trypano-
soma and Plasmodium. 
Leishmaniasis (Kala-azar) is a severe tropical disease for which relatively 
few clinically effective drugs exist that do not cause severe side effects. 
Around 12 million people are infected each year, following transmission 
by female sandflies, hence the impetus for new drug development. 
Werbovetz (1994) has tested a range of anilinoacridines using the parent 
compound m-AMSA as a standard, and has obtained encouraging results 
with some of these compounds. At cytotoxic concentrations some of these 
compounds were found to generate cleavable complex formation with 
whole cell parasite extracts, suggesting the the cellular target may be 
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Topoll. 
A range of 9-anilinoacridine compounds, have also been tested against 
the multi-drug resistant KI isolate of P. falcipcirum (Chavalitshewinkoon 
et al., 1993, and Gamage et al., 1994) and the outcome of these studies were 
discussed earlier. 
1.7 Summary and scope of this thesis. 
Malaria continues to pose a severe world health problem, with over 40% 
of the world's population now at risk from the disease. The emergence of 
multi-drug resistant parasites which are increasingly refractory to most of 
the chemotherapeutic agents commonly employed for treatment is 
serious cause for concern. Hence there is an urgent need to identify novel 
antimalarial drug targets within the parasite. One such potential target in 
the parasite is topoisomerase II, which in other organisms is the target of 
effective antineoplastic and antimicrobial drugs. 
This project arose naturally from earlier work, where the gene encoding 
PfTopoll was isolated and characterised as a preliminary step in the 
evaluation of the enzyme as a target for antimalarial drugs. Purification of 
the protein directly from the parasite was not undertaken due to the 
difficulties involved in culturing the very large number of blood stage 
parasites required to yield reasonable quantities of protein for biochemical 
analysis. As an alternative, the heterologous expression of the protein was 
attempted as a means to provide sufficient recombinant protein for drug 
screening and analysis. This thesis describes our attempts to achieve 
heterologous expression of PfTopoll, and attempts to understand why 
achieving it was so difficult. In addition, data is presented on the stage-
specific expression pattern for PfTopoll during the parasite's 
developmental stages that are most closely associated with the clinical 






High speed centrifugation was conducted with either a Sorvall RC5-B 
high speed centrifuge (DuPont Instruments) or Sorvall OTB50-B 
ultracentrifuge (DuPont Instruments). Benchtop centrifugation was 
carried out using a Heraeus Biofuge 13 (Eppendorf, Germany) or a Jouan 
CR322 (Saint-Herbain, France). PCR was carried out using a GeneE 
thermal cycler (Techne Instruments). Hybridisations were done in HB-1 
or HB-11) heated cabinets (Techne Instruments). Plasticware and cell 
culture materials were supplied by Beckton Dickinson Labware, UK. 
2.1.2 Chemicals 
Unless specified otherwise, all chemicals were supplied by Sigma 
Chemical Co. Ltd, UK. Cell culture materials were supplied by Gibco Life 
Sciences, UK. Radionucleotides were supplied by Amersham 
International, UK., or ICN Flow, UK. Solvents were supplied by FSA 
Laboratory Supplies, UK. 
2.1.3 Restriction and modifying enzymes. 
Unless otherwise stated, restriction endonucleases and buffers were 
supplied by Boehringer Mannheim UK (Diagnostics and Biochemicals) 
Ltd., UK. Modifying enzymes were supplied by Gibco-BRL, UK or 
Promega UK. 
2.1.4 Autoradiography 
KODAK X-OMAT AR and X-OMAT LS autoradiography film was 
supplied by IBI Molecular Biology Products, UK. 
2.1.5 Photography 
UV-irradiated ethidium bromide-stained gels were photographed with 




2.1.6.1 Table 1. Bacterial strains. 
Strain Genotype Reference 
DH5a F, endAl, recAl, hsd R17(rk, mk), Hanahan (1983) 
sup E44, thi -1, gyrA96, relAl, 080dlacZAM15 
A(lac ZYA-argF), U169, deoR. 
BL21 (DE3) F, hsdSB, A(lcicU169) gal(1c1857 indl Sain7 Studier and 
nin 5 1acUV5-T7 genel), (rB, MB-), Moffat (1986) 
ompT, ion. 
[pLysS] Studier (1991) 
INVcxF' F, endAl, recAl, hsdRl7 (rk, mk), Hanahan (1983) 
supE44, thi-1, gyrA96, re/Al, (Ultracompetent cells supplied 
801acZzM15 A(lacZYA- argF), by Invitrogen) 
U169, A. 
2.1.6.2 Table 2. 'Yeast strains. 
Strain Genotype Reference 
Dr. C. Austin 
(pers comm.). 
JEL 1 MA Ta, ura3-52 ,1eu2, 
trpl, prbl-1122, pep 4-3, 
Ahis3,:: GAL10-GAL4 
(a protease deficient strain) 
SD117 MA Ta, ade2, 1eu2, 
his7, t0p2-1, trpl, ura3-52 
SD119 MA Ta, topl-1, t0p2-1, 
trpl, ura3-52 
JCW26 t0p2-4, ura3-52, 1eu2, 
trpl 
JCW28 topi, t0p2-4, 
ura3,-52 1eu2, 
t rp 1 
2.1.6.3 Table 3. Insect cells and baculoviruses. 
Spodoptera frugiperda fall armyworm 
Autographa californica nuclear polyhedrosis 
virus (AcMNPV) 
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Brill et al., (1987). 
Brill et al., (1987). 
Hsiang et at., (1985). 
Hsiang et al., (1985). 
Described by O'Reilly 
et al., 1992. 
Described by O'Reilly 
et al., 1992. 


























Gowman et al., 1991. 
Yanisch-Perron et al., 1985. 
Smith & Johnson, 1988. 
Schoepfer, 1993. 
Studier, 1991. 
Gietz & Sugino, 1988. 
Gietz & Sugino, 1988. 
Gietz & Sugino, 1988. 
Wasserman et al.,1993. 
Gift - Dr. Caroline Austin. 
Gruenwald & Heitz, (1993). 
Supplied by PharMingen. 
Mead et al., 1991. 
2.2. General stock solutions and media. 
Amino Acids (yeast experiments'). 
Constituent final mg/i 






1.5M sodium chloride and 0.5M sodium hydroxide. 
Glass beads. 
Glass beads were prepared by soaking in concentrated nitric acid for 1 
hour, washing extensively in sdH20 and baking until dry. 
20 % Lactate pH 5.7 solution. 
Lactic acid 85% was obtained from Sigma Chemicals. The 85% solution 
was diluted in sdH20 in a beaker placed over ice in a fume hood to give a 
final concentration of around 30%. The solution was placed on a magnetic 
stirrer with a large stirrer bar and KOH pellets added until the solution 
reached a pH of 5.7. sdH20 was added to bring the solution to 20% and 
then autoclaved in 50 ml aliquots. 
Luria- Bertani medium (LB, supplied by ICMB media service). 
1% bacto-tryptone; 0.5% Bacto-yeast extract; 1% sodium chloride adjusted 
to pH 7.2, using 1M sodium hydroxide. 
LB agar (supplied by ICMB media service). 
LB supplemented with 1.5% agar. 
Minimal medium. 
80 ml Spitzizen salts (5 X - supplied by ICMB media service). 
10 ml glucose (20% w/v); lmg/ml vitamin Bi and 320 ml sdH20. 
Neutralising Solution. 
1M ammonium acetate; 0.02M sodium hydroxide. 
Oligonucleotide Hybridisation Buffer. 
2XSSC; 0.2% SDS; 0.1% sodium pyrophosphate and 500g/ml heparin. 
Phosphate Buffered Saline (PBS). 
137mM sodium chloride; 2.7mM potassium chloride; 4.3mM disodium 
hydrogen orthophosphate and 1.4mM potassium dihydrogen 
orthophosphate. 
Pre-Hybridisation Buffer. 
0.25M sodium phosphate, pH 7.2; 7% SDS. 
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Protein loading buffer - reducing (2 X) 
62.5mM Tris-HC1, pH 6.8; 10% glycerol; 2% SDS (w/v); 5% 13- 
Mercaptoethanol. 
Rifampicin. 
1mg/mi in dimethylformamide. 
Soc medium. 
2% tryptone; 0.5% yeast extract; 10mM sodium chloride; 2.5mM potassium 
chloride; 10mM magnesium chloride; 10mM magnesium sulphate and 
20mM glucose. 
Standard Saline citrate (SSc) 20x stock solution. 
3M sodium chloride; 100mM trisodium citrate, pH 7.0. 
Tris-Borate-EDTA (TBE) lOx stock solution. 
0.9M Tris borate; 20mM EDTA, pH 8.0. 
Tris- EDTA (TB). 
10mM Tris-HCl, pH8.0; 1mM EDTA, pH 7.5 or pH 8.0. 
Tris- EDTA-lithium acetate (10 X stock). 
100mM Tris-HCl, pH 7.5; 10mM EDTA and 1M lithium acetate, pH 7.5. 
Tris- EDTA-lithium acetate-40% PEG. 
10mM Tris-HCl, pH 7.5; 1mM EDTA; 100mM lithium acetate, pH 7.5 and 
40% (w/v) PEG 4000. 
Tris- EDTA- Saline (TES). 
20mM Tris-HCl, pH 7.5; 10mM EDTA and 100mM sodium chloride. 
Tris-Saline. 
10mM Tris-HCl, pH 7.4; 150 mM NaCl. 
Tris-Saline-NP40. 
10mM Tris-HO, pH 7.4; 150 mM NaCi and 0.05% NP40 (v/v). 
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Tris-Saline-5% Marvel. 
10mM Tris-HCl, pH 7.4; 150 mM NaCl and 5% powdered milk (w/v). 
Yeast minimal medium + agar. 
For 100 ml of medium. 
0.66g yeast nitrogen base without amino acids (DIFCO); 2% glucose; 2% 
Bacto-agar (DIFCO), and appropriate amino acid. 
Yeast minimal medium. 
For 100 ml of medium 
0.66g yeast nitrogen base without amino acids (DIFCO); 2% glucose and 
appropriate amino acid. 
Yeast minimal medium with glycerol and lactate. 
For 100 ml of medium 
0.66g yeast nitrogen base without amino acids (DIFCO); 2% glycerol; 2% 
lactate and appropriate amino acid. 
Yeast cell lysis Buffer 1. 
1 X TEE (50mM Tris-HCl, pH 7.7; 1mM EDTA; 1mM EGTA) containing 
10% glycerol, 25mM sodium fluoride, 1mM sodium bisuiphite, 1mM 
PMSF, 1mM DTT, 1mM benzamide, 10.tg/m1 leupeptin, 10g/ml pepstatin 
A. 
Unless otherwise stated the methods described in the following text were 
based on those found in either Sambrook et al. (1989), Harlow and Lane 
(1988) or O'Reilly et al.(1992). 
2.3 DNA Methods 
2.3.1 Isolation of DNA. 
Plasmid DNA was prepared from Escherichia coli using either the 
QIAGEN Plasmid Midi Kit, or the WizardTMPlus Minipreps DNA 
purification system described below. 
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2.3.1.1 Midipreparation of plasmid DNA. 
lOOmi of LB medium supplemented with 100pg/ml ampicillin was 
inoculated with a single colony and grown at 37°C overnight with 
shaking. 25m1 of the culture was centrifuged (2500g for 10 minutes). The 
supernatant was discarded and the bacterial pellet resuspended in 4 ml of 
buffer P1 (50mM Tris-HCl, pH 8.0; 10mM EDTA; 100g/ml RNase A). 4 ml 
of cell lysis buffer P2 (200 mM NaOH; 1% SDS) was added and the 
suspension incubated for 5 minutes at room temperature. The solution 
was neutralised by mixing with 4 ml of buffer P3 (3 M potassium acetate, 
pH 5.5) and incubated for 15 minutes on ice. The sample was centrifuged 
(20,000g, 4°C, 30 minutes), and the supernatant removed promptly. The 
sample was re-centrifuged for 15 minutes to remove any remaining 
particulate matter. A QIAGEN tip 100 was equilibrated with 4 ml of buffer 
QBT (750mM NaCl; 50mM MOPS, pH 7.0; 15% ethanol; 0.15% Triton X-
100) by gravity flow. The cleared supernatant was applied to the column 
by gravity flow. The column was washed twice with 10 ml of buffer QC 
(1M NaCl; 50mM MOPS, pH 7.0; 15 % ethanol). DNA was eluted with 5m1 
of buffer QF (1.25M NaCl; 50 mM Tris-HCl, pH 8.5; 15% ethanol), 
precipitated with 0.7 volumes of room temperature isopropanol, then 
centrifuged (15,000g, 4°C, 30 minutes). The pellet was washed with 2 ml of 
70% ethanol, air dried briefly, and dissolved in 200il TE (10mM Tris-HCl, 
pH 8.0; 1mM EDTA). The DNA was analysed by UV spectrophotometry. 
2.3.1.2 Isolation of small scale plasmid DNA. 
WizardTM Plus Minipreps protocol. 
5 ml of LB medium supplemented with 100pg/m1 ampicillin was 
inoculated with a single colony and grown at 37°C overnight with 
shaking. 1-3 ml of the culture was centrifuged (10,000g. for 2 minutes). 
The bacterial pellet was resuspended in 200.t1 of 50mM Tris-HCl, pH 7.5; 
10mM EDTA and 100 ig/ml RNase A. 200p1 of lysis solution (0.2M NaOH; 
1% SDS) was added and the solution mixed by inverting four times. 
Alkalinity was neutralised by addition of 1.32M potassium acetate, and the 
solution centrifuged (10,000g for 5 minutes). The cleared supernatant was 
transferred to a clean tube, imi of the purification resin was added, and 
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the solution mixed and applied to the miniprep column using a 5m1 
syringe. The column was washed with a solution containing 80mM 
potassium acetate; 8.3mM Tris-HC1, pH 7.5; 40tM EDTA and 55% ethanol. 
The column was dried by centrifugation (10,000g for 30 seconds) and the 
DNA eluted in 50.t1 of TE pH8 (10,000g for 20 seconds). The DNA was 
analysed by agarose gel electrophoresis or UV spectrophotometry. 
2.3.1.3 Isolation of plasmid DNA from Saccharomjrces cerevisiae. 
This protocol is based on the method of Hoffman and Winston (1987). A 
single colony harbouring a recombinant F. coil/yeast shuttle-plasmid was 
picked into 5 ml of selective culture medium and grown overnight at 
30°C with agitation. The cells were harvested by microcentrifugation for 5 
seconds. The supernatant was discarded and the pellet resuspended in the 
residual liquid by vortexing briefly. 0.2 ml of 2% Triton X-100; 1% SDS; 
100mM NaCl; and 10mM Tris-HC1, pH 8.0 were added along with 0.2 ml 
phenol-chloroform-isoamylalcohol (25:24:1, v/v/v). 0.3 g of 0.4mm glass 
beads were added and the solution vortexed for 2 minutes prior to 
pelleting by microcentrifugation for 5 seconds. 1-5 p.1 of the aqueous layer 
was used for transformation of E. coil cells (2.3.6.2). 
2.3.1.4 Isolation of total DNA from Spodoptera frugiperda insect cells. 
1 X 106 non-infected insect cells, and recombinant or wild type infected 
insect cells that were still attached to tissue culture dishes, were incubated 
with 5m1 of lysis buffer (30mM Tris-HCl, pH 7.5; 10mM magnesium 
acetate; 1% NP40 v/v), for 10 minutes on ice. The lysate was transferred to 
a 15m1 conical tube (Sterilin), the solution vortexed for 20 seconds, and 
centrifuged (1000g for five minutes at 4°C). The supernatant was discarded 
and the pellet gently resuspended in 5 ml of ice-cold phosphate buffered 
saline (PBS) pH 6.2, and re-centrifuged. The pellet was resuspended in 
200p.l of extraction buffer (10mM Tris-HCl, pH 8.0; 5mM EDTA; 0.5% SDS). 
Proteinase K was added to a final concentration of 1 mg/ml and the 
solution incubated at 37°C with gentle mixing for 4 hours. The sample 
was extracted by addition of 200p.l of phenol/chloroform/IAA, pH 8.0 
(prepared and used as described in sections 2.3.1.6.1 and 2.3.1.6.2) with 
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gentle mixing, before centrifugation in a benchtop centrifuge at top speed 
for 1 minute. The upper aqueous phase was collected, avoiding the 
interface between the organic and aqueous phases. This procedure was 
repeated twice. An equal volume of chloroform was added to each 
sample, and the extraction process repeated a further two times. DNA was 
precipitated as described in section 2.3.1.7. 
2.3.1.5 UV spectrophotometry. 
The concentration and purity of nucleic acids was quantified using UV 
spectrophotometry. DNA or RNA samples were diluted 1 in 200 in sterile 
water and analysed on the Perkin Elmer 115 spectrophotometer set up to 
scan the range 200-300nm. The concentration of the sample was deduced 
from the formula: 
DNA concentration = absorption at 260nm (A 260)  X 50 X dilution factor. 
RNA concentration = absorption at 260nm (A 280)  X40 X dilution factor. 
The relative purity of the sample was determined by calculating the ratio 
A260/A280, where a value of 1.8 or greater indicates that the sample is free 
of protein contamination. 
2.3.1.6 Phenol/chloroform extraction of samples. 
2.3.1.6.1 Preparation of phenol/chloroform. 
Phenol was pH buffered prior to use to make it slightly alkaline. A small 
spatula tip full of 8-hydroxyquinine was allowed to dissolve in 5m1 of 
water saturated phenol. 2m1 of 1M Tris-HC1, pH 8.0 was added and the 
solution mixed, allowed to settle, and centrifuged for 2 minutes at 1000g. 
The aqueous phase was removed and 2m1 of TE pH 8.0 was added. The 
solution was mixed, allowed to settle, then centrifuged as before. 5m1 of 
chloroform, 0.2m1 isoamyl alcohol, and 2m1 TE pH8.0 were added, and the 
solution was stored at 4°C for up to three months. 
2.3.1.6.2 Phenol chloroform extraction. 
DNA was extracted by adding an equal volume of phenol /chloroform 
solution, mixed vigorously by hand, then spun in a micro fuge at high 
speed for 1 minute. The upper aqueous phase containing the DNA was 
transferred to a clean tube and the sample was re-extracted again, up to 
three times, until the interface between the organic and aqueous phases 
was clean. The aqueous phase was then extracted against chloroform to 
remove any traces of phenol, prior to ethanol precipitation. 
2.3.1.7 Ethanol precipitation. 
0.1 volume of 3M sodium acetate, pH 5.2 and 2 volumes of ice-cold 
ethanol were added to the DNA solution. The sample was incubated at - 
700C for at least 15 minutes to promote precipitation of the nucleic acid. 
The sample was centrifuged at high speed in a microfuge for 30 minutes 
and the pellet washed with 70% ethanol, followed by one wash with 100% 
ethanol. The pellet was air dried and resuspended in TE pH 8.0. The DNA 
was analysed by agarose gel electrophoresis and UV spectrophotometry 
(2.3,1.5). 
2.3.2 Endonuclease restriction digests of DNA. 
Restriction digests of DNA were conducted for 2-3 hours at 37°C for all 
restriction endonucleases except Smal digests which were conducted at 
30°C. 3-10 units of commercial restriction endonucleases were used to 
restrict l.tg of DNA in the presence of the appropriate buffer, supplied as a 
lox stock concentration and diluted to a final concentration of 1X in a 
total volume of 20l to 50.tl. For single restriction digests, Table 5 was 
consulted for the appropriate buffer, but for multiple restriction digests 
involving enzymes that are not active together in the same buffer, "One-
Phor-All" buffer (Pharmacia) was used instead (100mM Tris-acetate; 
100mM magnesium acetate and 500mM potassium acetate) as an 
alternative to heat inactivation of enzyme and ethanol precipation 
between each individual digest. 
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Table 5. Composition of Boehringer Mannheim buffers (mM) 
Buffer Composition 
A B L M H 
33 - - - - Tris acetate 
- 10 10 10 50 Tris-HC1 
10 - - - - Magnesium acetate 
- 5 10 10 10 Magnesium chloride 
- 100 - 50 100 Potassium acetate 
- 
- 1 1 1 Dithioerythritol 
0.5 - - - - Dithiothreitol 
- 1 - - - -mercaptoethano1 
7.9 8.0 7.5 7.5 7.5 pH at 37°C 
* Kpnl restriction digests were supplemented with BSA at 100pig/ml. 
2.3.3 Agarose gel electrophoresis. 
2.3.3.1 Casting agarose gels. 
Multi-purpose agarose was supplied by Boehringer Mannheim. 
Table 3. Relationship between concentration of agarose and separation of 
linear DNA molecules. Sambrook et al., (1989). 
Percentage agarose Separation of linear DNA molecules 
0.7 0.8-10 kbp 
0.9 0.5-7 kbp 
1.2 0.4-6 kbp 
1.5 0.2-3 kbp 
Multi purpose agarose was dissolved by heating to boiling point in 0.5 or 
1X TBE buffer (2.2). The solution was cooled to approximately 55°C and 
ethidium bromide was added to a final concentration of 0.2.tg/ml. The 
molten gel was poured into the appropriate size casting tray and allowed 
to solidify at room temperature. 
2.3.3.2 Running agarose gels. 
The solidified gel was immersed in 0.5 X or 1 X TBE buffer. Linear DNA 
size standards or samples were run with 1 X sample buffer (30% glycerol; 
0.25% bromophenol blue; 0.25% xylene cyanol; 100mM EDTA, pH8.0). 
Samples were electrophoresed at 15Vcm-1 until sufficient separation of 
the DNA fragments was observed, as determined by short wave UV 
transillumination of the gel. 
2.3.3.3 Photo documentation of agarose gels. 
The image was recorded on heat sensitive film or a negative image was 
produced using FP5 film (Kodak). Gels to be Southern blotted were 
photographed with a ruler adjacent to the left hand side of the gel for 
alignment purposes. 
2.3.3.4 DNA size standards. 
The DNA markers routinely used for size determination were ? DNA 
restricted with EcoRT and Hindill (Promega). These markers produce 
DNA fragments of approximately 23,15, 9.42, 6.56, 4.38, 2.32, 2.02 and 
0.56kbp. 
2.3.3.5 Electroelution of DNA fragments from agarose gels. 
The DNA fragment of interest was excised from the agarose gel using a 
hand held short wave UV light source. Dialysis tubing was prepared by 
boiling in 2% sodium hydrogen carbonate, 1mM EDTA for 10 minutes 
with gentle intermittent stirring. The membrane was extensively washed 
with sterile distilled water, and reboiled in 1mM EDTA for a further 10 
minutes before being washed in water, immersed in 70% ethanol and 
kept at 4°C for long term storage. Prior to use, the membrane was washed 
in sterile distilled water. 
The DNA agarose slice was inserted into 2-3" of membrane that was 
clipped at one end. 40041-lml of 0.5X or lx TBE buffer was added to the 
partially sealed membrane, air was expelled and the membrane was clip 
sealed at the other end. The 'bag" was placed into a horizontal 
electrophoresis tank and a current of 100V was applied for approximately 
30 minutes. The current was reversed for the final 30 seconds to disperse 
any DNA that may have adhered to the inside of the membrane. Elution 
was checked using short wave UV transillumination. The DNA was 
precipitated with ethanol, dissolved in T.E. and its concentration 
estimated by agarose gel electrophoresis. 
2.3.4 Southern Blotting agarose gels. 
2.3.4.1 Dry Southern blotting. 
After photography, the agarose gel was immersed in denaturing solution 
(section 2.2) for 15 minutes. When large DNA fragments of greater than 
15kb were present, the gel was depurinated using several volumes of 0.2M 
HC1 for 10 minutes, prior to rinsing with distilled water. The gel was then 
neutralised (section 2.2) for 30 minutes. Hybond N (Amersham) or 
Genescreen Plus (DuPont) membrane was cut to exactly the same size as 
the gel, and the right hand corner of both the gel and membrane was 
removed to aid future orientation. The membrane was wetted with 
neutralisation solution and placed on top of the gel slowly to avoid the 
introduction of air bubbles. Three pieces of blotting paper (Whatman) 
were wetted with neutralisation solution and placed on top of the 
gel/membrane sandwich. On top of this, two dry pieces of blotting paper 
and a stack of paper hand-towels were assembled. A large lead weight was 
placed on top of the assembly, and the transfer of nucleic acid allowed to 
proceed for a minimum of 2 hours to overnight, according to the size of 
the DNA fragments. The membrane was removed and rinsed briefly in 2 
X SSC (2.2) and allowed to air dry. Short wave UV light was used to 
crosslink the DNA to the membrane (Hybond N membranes). For 
Genescreen Plus membranes crosslinking is not necessary so the 
membrane was washed in 2 X SSC then transferred into prehybridisation 
buffer (section 2.2). 
2.3.4.2 Wet Southern Blotting. 
Wet Southern transfer was used in cases where the DNA was present in 
relatively small quantities (<lOOng). Depurination, denaturation and 
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neutralisation of DNA was conducted as described previously (section 
2.3.4.1). The prepared gel was placed on a glass plate covered with a 
blotting paper "wick" underneath it, above a reservoir containing 10 X 
SSC into which the "wick" was immersed. The gel was surrounded with 
Saran wrap to prevent the 10 X SSC solution bypassing the gel and 
soaking the paper towels. The gel was covered in Genescreen Plus ( 
DuPont) cut to exact size. Five sheets of dry blotting paper and a 5" stack of 
paper towels were placed on top of the membrane. A glass plate was 
placed on top of the gel assembly, and on top of this a heavy lead weight. 
Transfer was left to proceed overnight. Next morning the blot was 
disassembled and the membrane rinsed in 2 X SSC prior to 
prehybridisation and probing (section 2.3.4.3). 
2.3.4.3 Prehybridisation and hybridisation of radiolabelled probes. 
The same solution was used for prehybridisation and hybridisation of 
membranes, but the composition of the solution varied according to 
whether the membrane was to be exposed to end-labelled 
oligonucleotides (6 X SSC, 500.tg/ml heparin; 0.1% SDS; 0.1% sodium 
pyrophosphate) or random-labelled probes (0.25M sodium phosphate; 7% 
SDS). The membrane was transferred to a glass hybridisation tube, and 
incubated overnight with 25m1 of prehybridisation solution. The 
following day the solution was replaced, the probe added and incubated 
for a minimum of 6 hours for end-labelled probes, and overnight for 
random-labelled probes. 
2.3.4.4 5' end lab elleling of oligonucleotides. 
End-labelled probes were used when the target DNA was present in 
reasonable quantity (>25ng). Prehybridisation and hybridisation were 
done at 37°C for oligonucleotides of <20 bases in length. Oligonucleotides 
of >20 bases were hybridised at temperatures compatible with their 
melting temperature. The end labelling reaction contained the following; 
80ng of oligonucleotide (without 5' phosphate), 2ji1 of 10 X Reaction buffer 
(700mM Tris-HC1, pH 7.6; 100mM magnesium chloride; 50mM DTT), 12il 
sdH20, 1p.l (y 321? ATP) [10mCiml-1] and 1.d T4 polynucleotide kinase (10 
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Units/.tl). 
The reaction was incubated at 37°C for 1-2 hours. At this stage the probe 
was added to the prehybridised membrane. 
2.3.4.5 Random labelled probes. 
Random labelled probes were made using the Prime-ItTMII Random 
Primer Labelling Kit (Stratagene). All materials were supplied in this 
commercially available kit, with the exception of the T7 DNA polymerase 
which was supplied by Promega. The reaction was prepared as follows; 
25ng of double-stranded DNA in x pi; lOj..tl of random labelled primers (9-
mers at 8ng/il) and sdH20 to 25g1. The solution was boiled for 5 minutes 
and then snapped cooled on ice. The following were then added; 10il of 5 
X random label buffer (dCTP), containing 250mM Tris-HC1, pH 8.0; 
100mM magnesium chloride; 20mM 13-mercaptoethanol; and 0.5mM each 
of dGTP, dATP, and dTTP; 3j.ti [a 32P]  dCTP (10mCiml-1) and 0.5il T7 DNA 
polymerase (8.5 units/il). The reaction was incubated at 37°C for 10 
minutes and 2tl of 0.5M EDTA was added to stop the reaction. 
Removal of unincorporated dNTPs was achieved by use of a NucTrapTM 
Probe Purification Column (Stratagene). 70g1 of TES (100mM sodium 
chloride; 20mM Tris-HC1, pH 7.5; 10mM EDTA) were pushed slowly 
through the column using a lOmi syringe. 20jil of TES were added to the 
reaction and the solution was pushed through the column. An additional 
?Otl of TES was pushed through the column and the random-labelled 
probe collected in a tube. The solution was boiled for 10 minutes to 
separate the DNA strands, prior to adding to the prehybridised 
membrane. Random-labelled probes were hybridised to membranes at 
65°C. 
2.3.4.6 Washing of membranes and signal detection. 
2.3.4.6.1 Removal of unbound 5' end labelled oligonucleotide probes. 
The probe was transferred from the hybridisation tube and stored shielded 
at -20°C to decay. The membrane was then washed with 25m1 of 6 X 
SSC/0.1% SDS, twice for 15 minutes. The membrane was monitored with 
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a 13-geiger counter to determine whether any additional washes were 
required prior to exposure to film. Up to 2 further washes in 6 X SSC 
would be done if necessary. Washed membranes were placed into a plastic 
bag and heat sealed and a fluorescent strip (Stratagene) was positioned 
next to the membrane for orientation purposes. Membranes were 
exposed to pre-flashed film and stored at -70CC in a cassette with 
intensifying screens. Variable periods of exposure were used according to 
the strength of the signal estimated from the 13-Geiger counter (cps). The 
film was developed using a X-OGRAPH Xl (IBI Ltd.) automatic X-ray film 
developer. 
2.3.4.6.2 Removal of unbound random-labelled probe. 
The probe was transferred from the tube and stored (2.3.4.6.1). To remove 
unbound probe, the membrane was washed twice with 2 X SSC/0.1% SDS 
for 15 minutes, followed by 1 X SSC/0.1% SDS twice for 15 minutes. The 
membrane was monitored with a 13-geiger counter to determine whether a 
more stringent wash with 0.2 X SSC/0.1% SDS for 15 minutes was 
required. The membrane was treated as described in 2.3.4.6.1. 
2.3.4.7 Membrane stripping. 
2.3.4.7.1 5' end-labelled oligonucleotide probes. 
The membrane was stripped by placing it in a hybridisation tube, at 65°C 
containing 0.1 X SSC, 0.1% SDS for 1 hour. The membrane was exposed to 
film overnight to ensure that no signal was detected. 
2.3.4.7.2 Random-labelled probes. 
Random-labelled probes were stripped from membranes by placing in a 
hybridisation tube at 65°C, containing 0.4M sodium hydroxide. After 30 
minutes the solution was replaced with neutralisation solution (0.1 X 
SSC; 0.1% SDS; 200mM Tris-HCl, pH 7.5) for 30 minutes at 65°C. The 
membrane was exposed overnight to ensure that no signal was detected. 
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2.3.5 Ligations. 
2.3.5.1 End filling 3' recessed termini. 
The 5' to 3' polymerase activity of Kienow (Promega) was used to generate 
blunt termini from 3' recessed termini. lj.d of 1mM dCTP, dGTP, dATP 
and dTTP were added to 0.2 to 0.5j.tg of DNA dissolved in 20jil  of sdH20. 
Magnesium chloride was added to a final concentration of 5mM, along 
with 1 unit of Kienow. The reaction was allowed to proceed for 15 
minutes at room temperature, after which the enzyme was heat 
inactivated at 75°C for 10 minutes. The mixture was cooled slowly to 
room temperature prior to ligation. 
2.3.5.2 Phosphatase treatment of restricted vector. 
The 5' phosphate of a restricted vector was removed with calf intestinal 
alkaline phosphatase (CIP) to prevent self-ligation. The restriction 
endonuclease was removed by phenol /chloroform extraction followed by 
ethanol precipitation. The DNA was resuspended in 20j.tl of 1 X CIP buffer 
(50mM Tris-HC1, pH 8.5; 1mM EDTA; 1mM magnesium chloride; 1mM 
zinc chloride). lunit of CIP was added and the was reaction incubated at 
37°C for 30 minutes. 1/10 volume of 200mM EGTA, pH 8.2 was added and 
the reaction was heat treated to inactivate the CIP at 75°C for 15 minutes. 
The reaction was phenol/ chloroform extracted and ethanol precipitated 
before ligation. 
2.3.5.3 Ligation reactions. 
The vector and insert were restricted as required and their ends were 
modified as necessary. Typically, 40ng of vector was ligated to 40ng of 
insert, at a range of different vector to insert ratios. For example, ratios of 
1:1 and 1:3 were routinely used. Both vector and insert DNA were added 
to 1 X ligation buffer (66mM Tris-HC1, pH 7.6; 6.6mM magnesium 
chloride; 10mM DTT; 66M ATP) with 1 unit of T4 DNA ligase (Gibco 
BRL). Ligations were incubated overnight at 15°C. 
2.2.5.4 Ligation of linkers to blunt-ended DNA fragments. 
Blunt-ended DNA was used as substrate for the enzymatic addition of 
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phosphorylated linkers containing a restriction endonuclease site. 0.1.tg of 
DNA and 2g  of phosphorylated Kpnl linkers (Gibco BRL) were assembled 
in an Eppendorf in a total volume of 7.il. 2i.il  of 10 X ligation buffer was 
added (2.2.5.3) and the reaction catalysed by addition of 1 unit of T4 DNA 
ligase (Gibco BRL). Ligations were incubated overnight at 15°C. 
2.3.5.5 PCR product cloning. 
PCR products were subcloned using the commercially available TATM 
Cloning Kit (Invitrogen). This kit works by exploiting the fact that Taq 
polymerase has a non-template dependent activity which adds a single 
deoxyadenosine the the 3' end of PCR products. The linear vector used in 
this kit has single 3' deoxythymidine residues. This allows the PCR 
product to ligate efficiently to the vector. 
1ptl of fresh (less than one day old) PCR product was added to 2il of TA 
vector pCRTM II (25ng/j.tl), 1d of 10 X ligation buffer (60mM Tris-HC1, pH 
7.5; 60mM magnesium chloride; 50mM NaCl; 1mg/mi bovine serum 
albumin; 70mM 13-mercaptoethanol; 1mM ATP; 20mM DTT; 10mM 
spermidine), 5jil sdH20, and 4 units of T4 DNA ligase. The reaction was 
incubated at 15°C overnight. 
2ji1 of 0.5M 13-mercaptoethanol was added to One ShotTMINVcF' 
competent cells after defrosting on ice. 21.il of the ligation mix was added 
with gentle mixing to the cells. The transformation mix was heat shocked 
at 42°C for 30 seconds and placed on ice for 2 minutes. 450.ti of room 
temperature SOC was added and the transformation mix incubated for 1 
hour at 37°C on a rotary wheel. The cells were set on ice for 2 minutes, 
prior to spreading aseptically in 50j.il and 200.il aliquots onto LB plates 
supplemented with 100jtg/ml ampicillin and 0.004% X-Gal. The plates 
were allowed to dry, inverted and incubated at 37°C for 18 hours. To 
promote full colour development, the plates were transferred to 4°C for 2 
hours. White colonies were then tested for the present of PCR inserts by 
restriction digest. 
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2.3.6 Preparation of competent Escherichia coli cells and transformation. 
2.3.6.1 Preparation of competent Escherichia coli cells. 
A single colony was inoculated into 5m1 of LB medium and incubated 
with shaking overnight at 37°C. Next morning, 2m1 of the culture was 
added to lOOmi of fresh LB medium, the cells incubated with shaking at 
37°C for 2 hours, and cooled on ice for 10 minutes. The cells were collected 
by centrifugation (1500g, 10 minutes, 4°C). The pellet was gently 
resuspended in 20m1 of 100mM calcium chloride and incubated on ice for 
a minimum of 2 hours or overnight. The cells were collected by 
centrifugation as above and resuspended in 1/20 volume of 100mM 
calcium chloride. Any unused cells were stored at -70°C in 100mM 
calcium chloride, 14% glycerol in 200jtl aliquots for periods of up to 6 
months. 
2.3.6.2 Transformation of competent E. coli cells. 
Competent cells were transferred from the -70°C freezer and allowed to 
defrost slowly on ice. Typically between 1-5il of a ligation was incubated 
with 200pi of competent cells on ice for 30 minutes. The solution was 
mixed very gently with the end of a pipette tip to avoid mechanical 
damage to the cells. The transformation mix was then transferred to a 
42°C waterbath to heat shock the cells (45 seconds for DH5a, or 1 minute 
for BL21 cells). The mixture was immediately returned to ice for 2 
minutes before adding SOC or LB medium and incubating with agitation 
at 37°C for 60 minutes. The transformed cells were plated out in 200pJ 
aliquots onto selective medium and incubated in an inverted position at 
37°C overnight. 
2.3.6.3 Preparation of competent Saccharomyces cerevisiae cells. 
This method is based on the protocol of Gietz et al., (1992). A single yeast 
colony was inoculated into liquid YDPA medium and grown on a shaking 
incubator overnight at 30°C to 1-2 X 107 cells/ml. The culture was then 
diluted ten-fold into fresh YDPA and regrown to 1 X 107 cells/ml. Cells 
were harvested (1500g for 5 minutes) and washed in 1 ml of sterile 
distilled water before transferring to a 1.5 ml tube and pelleting at top 
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speed for 1 minute in a bench top microfuge. The cells were washed in 1 
ml of TE/lithium acetate made fresh from 10 X stocks of TE, pH 7.5, and 
lithium acetate (2.2), resuspended at 2 X 109 cells/ml in 1 X TE/lithium 
acetate. At this stage the cells were determined competent and were 
transformed immediately. 
2.3.6.4 Transformation of competent Saccharomyces cerevisiae cells. 
501.d of the competent cell suspension was mixed with 1pg  of transforming 
DNA and 50p1 of single-stranded salmon sperm carrier DNA and 300.tl of 
sterile 40% PEG 4000/lithium acetate/TE solution (2.2). The mixture was 
incubated at 30°C with agitation for 30 minutes. The cells were heat 
shocked for 15 minutes in a water bath at 42°C, then harvested in a bench 
top microfuge at top speed for 5 seconds. The pellet was resuspended in 1 
ml of 1 X TE pH 7.5 and spread onto selective medium plates which were 
inverted once dry and transferred to a 30°C incubator. The plates were 
kept at 30°C until colonies were visible, a process which took up to 5 days. 
2.3.6.5 Preparation of selective medium plates. 
2.3.6.5.1 Ampicillin supplemented LB plates. 
100 mg/ml stock solution of ampicillin was prepared in sdH20 and used 
at a final concentration of 100ig/m1 in LB medium. This was used as 
selective medium for all experiments with DH5a or BL21 cells. 
2.3.6.5.2 Yeast minimal plates. 
Yeast minimal selective medium containing 2% glucose, glycerol/ lactate, 
or galactose was prepared according to section 2.2 but omitting the amino 
acid required for selection. 
2.3.6.5.3 Chioramphenicol/ampicillin supplemented plates. 
20mg/mi stock solution of chioramphenicol was prepared in 100% 
ethanol and used at a final concentration of 20p.tg/ml, with ampicillin at a 
final concentration of 100 jig/mi in LB medium. This was used as selective 
media for all experiments using BL21 (DE3) [pLysS] cells. 
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2.3.7 Colony screening. 
2.3.7.1 Blue/white colour selection. 
The insertion of a DNA fragment into the multiple cloning site of a 
vector containing the lacZ gene which facilitates blue/white colour 
selection was tested by plating onto medium containing 200mM IPTG and 
0.004% X-GAL in DMF. Following incubation overnight at 37°C, plates 
were transferred to 4°C to allow full colour development to occur. White 
and light blue colonies were picked for further analysis. 
2.3.7.2 Patching white colonies. 
This method was used to test white colonies identified by blue/white 
selection for the presence of inserts. Individual white colonies were 
picked using a sterile toothpick and scratched onto a Hybond N 
(Amersham) membrane which had been stamped with a 100 square 
matrix and placed onto a selective media plate. The same colony was also 
scratched onto a selective media plate without a membrane, but with a 
similar matrix placed underneath the plate to enable identical colonies to 
be identified. Both plates were incubated overnight at 37°C. The colonies 
which had grown on the membrane were lysed by treating with 2 X SSC/ 
5% SDS for 2 minutes, and the DNA fixed to the membrane by 
microwaving on full power for 1 minute. The membrane was then ready 
for prehybridisation. 
2.3.7.3 Colony lifts. 
This protocol is based on the method of Buluwela et at. (1989). Hybond N 
membranes were cut to the same size as the petri plate and placed onto 
the surface. The membrane was marked for orientation purposes by 
puncturing with a needle through to the medium underneath. The 
membrane was carefully removed and soaked colony side up in 2 X 
SSC/5% SDS as described in section 2.3.7.2. 
2.3.8 Polymerase chain reaction (PCR). 
2.3.8.1 Standard PCR reaction. 
PCR reactions were based on the methods of (Saiki et al., 1988 and Innis et 
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al., 1990) but were modified to take into account the relatively high A+T 
content of the parasite template DNA. PCR reactions were assembled on 
ice and care was taken to ensure that cross contamination of tubes did not 
occur. 
bOng template DNA X .t1 
10 X PCR buffer (500 mM KC1; 100 mM Tris-HC1, 10 , 0..i1 
pH 9.0; 1% Triton X-100) 
25mM Magnesium chloride 6 . 0t1 
Forward oligonucleotide (20 ng/i1) 10 .  Ogl 
Reverse oligonucleotide (20 ng/ t1) 10 . 0 1 
100mM dNTP's (25 mM each of dATP, 0 . 711 
dTfP, dCTP, dGTP) 
Taq (Thermus aquaticus) DNA polymerase (5U/t1) 0 . 5i1 
sdH20toatota1of 100.01.11 
Taq DNA polymerase and reaction buffer were supplied by Promega UK. 
The PCR reactions were overlaid with 50j.tl of mineral oil before being 
placed onto the thermocycler. A typical programme for the thermocycler 
for a pair of 17-mer oligonucleotide primers using a genomic or plasmid 
DNA template to amplify a kilobase pair product is described below. 
Modifications were made to this standard protocol for the amplification of 
longer DNA fragments or for the amplification of DNA fragments that 
were to be used for expression. 
Denaturation Annealing Polymerisation 
950C for 5 minutes 370C for 1 minute 700C for 2 minutes 
930C for 3 minutes 370C for 1 minute 700C for 2 minutes 
930C for 3 minutes 400C for 1 minute 700C for 2 minutes 
700C for 5 minutes 
(1) and (2) were set up to run for 1 cycle each, (3) was set up for between 10 
to 28 cycles and (4) was set up for 1 cycle only. 
The maximum ramp rate (1° C sec') between each step was used in all 
PCR reactions. 1/10 volume of the PCR product was analysed by agarose 
gel electrophoresis. 
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2.3.8.2 Reverse-transcriptase PCR (RT-PCR). 
Following completion of the first strand cDNA synthesis (2.4.4) a PCR was 
used to amplify the cDNA samples according to the First Strand cDNA 
Synthesis Kit protocol (Pharmicia Biotech). The primers that were used 
for this reaction were a sense strand PfTOP2 gene specific primer (719S) 
and the Notl-d(T)18 primer that was used to prime the reverse 
transcriptase reaction. 
The entire reverse transcription reaction was used in the PCR which 
contained the following components; 45mM Tris-HC1, pH 8.3; 68mM KC1; 
15mM DTT; 9mM magnesium chloride; 0.08mg/mi BSA and 1.8 mM each 
of dATP, dTTP, dCTP and dGTP. 0.21g of 719S and Notl-d(T)18 primers 
were added, together with 2.5 units of Taq polymerase. The standard PCR 
parameters described in section 2.3.8.1 were used with 30 cycles of 
amplification. 
lj.il of total DNase I treated RNA was used in a separate PCR, with same 
primers. This PCR provided a control for non-specific binding of the 
primers, in the event that DNase I treatment of the RNA samples used 
for RT-PCR had not worked. 
2.3.9 DNA sequencing and analysis. 
2.3.9.1 Manual sequencing of double-stranded DNA templates. 
DNA sequencing was carried using the dideoxy-chain termination 
method described by Sanger et al., (1977). The commercially available 
SequenaseRVil kit (USB) was used throughout. Oligonucleotide primers 
were supplied by the OSWEL DNA Service, Southampton, UK. 
To 4tg of double-stranded DNA, 200 mM NaOH; 2 mM EDTA, pH 8.0, and 
SdH20 to a total of 30i.il were added. The DNA solution was allowed to 
denature at 37°C for 30 minutes, before ethanol precipitation. The pellet 
was resuspended in 7d of sdH20 and kept on ice ready for the annealing 
reaction. 1i1 of the appropriate oligonucleotide (20ng/d) and 2p1 of 
reaction buffer (200mM Tris-HC1, pH 7.5; 100mM magnesium chloride; 
250mM sodium chloride) was added to the DNA. The reaction was placed 
in a large beaker containing water at 65°C and allowed to cool slowly to 
30°C over a period of about 1 hour, at which point the annealing reaction 
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was complete. 
The labelling reaction was carried out as follows; lOjil of the annealed 
DNA, 2tl of dGTP labelling mix (1.5iM of dGTP; dTTP; and dCTP) 11 of 
DTT, 0.51.d of [tx35S} dATP (lOmCiml-l) and 2ji1 of SequenaseRDNA 
polymerase (1.6 U/.d) were assembled and incubated at room temperature 
for 5 minutes before 3.5.tl aliquots were removed and added to 2.5tl 
aliquots of the termination mixes (ddG, ddC, ddA and ddT) prewarmed to 
37°C. Each termination mix consisted of the following; 801iM dGTP, dCTP, 
dATP and dTTP, 50mM sodium chloride and 8j.M of the appropriate 
dideoxynucleoside triphosphate (ddGTP, ddCTP, ddATP and ddTTP). The 
termination mixes were incubated at 37°C for 5 minutes and the reactions 
stopped by the addition of loading buffer (95% formamide; 20mM EDTA; 
0.05% bromophenol blue; 0.05% xylene cyanol) prior to freezing at -20°C. 
Reaction mixes were stable for up to three days. 
2.3.9.2 Sequencing gel electrophoresis. 
Sequencing reactions were run on 6% polyacrylamide gels (20:1 
acrylamide:bisacrylamide) containing 7M urea in 1 X TBE available 
commercially from Scotlab, Scotland. 40m1 of polyacrylamide mix was 
polymerised by the addition of 2401.d of a 10% ammonium persuiphate 
solution prepared in water, and 241 of TEMED (BRL). The gel was cast 
between a pair of plates 380mm by 170mm separated by plastic spacers 
(0.3mm). A" sharks tooth" comb was used to prepare wells at the top of 
the gel to facilitate loading of the samples. 
Up to 5il of the sequencing reaction was boiled for 2 minutes, snap cooled 
on ice for 2 minutes, and loaded onto the gel. Electrophoresis was carried 
out at 50 W and monitored by the downward movement of the two blue 
tracking dyes. After an appropriate period of time the electrophoresis was 
stopped and the plates were carefully separated. The gel was fixed by 
placing the plate with the gel on it into a solution of 10% glacial acetic 
acid, 12% methanol for up to 30 minutes. The gel was then gently lifted 
out of the solution and laid onto Whatman 3MM paper before drying 
under vacuum at 80°C. Sequencing gels were usually exposed to film 
overnight at room temperature. 
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2.3.9.3 Sequence analysis. 
Storage, manipulation and comparisons of sequencing data were made 
using the University of Wisconsin Genetics Computer Group Sequence 
Analysis Software Package, versions, 6,7,8 and 9 (Devereux et al., 1984). 
2.3.9.4 Automatic sequencing of double-stranded DNA templates. 
The ABI PrismTM Dye Terminator Cycle Sequencing Ready Reaction Kit 
(Perkin Elmer) was used for sequencing reactions that were to be run and 
analysed by the ABI 377 automated sequencer (Perkin Elmer Applied 
Biosystems). Oligonucleotide primers were supplied by the OSWEL DNA 
Service, Southampton, UK. 
0.5.tg of double stranded plasmid DNA, 3.2 pmole of primer, 8l of 
Terminator Ready Reaction Mix (supplied in the Kit) and SdH20 to a final 
volume of 20jil were added to a 0.5m1 tube. The reaction was overlaid 
with 40i1 of mineral oil before being placed onto the thermal cycler. 
Thermal cycling was conducted as follows; 
Step 1) 960C for 30 sec, 500C for 15 seconds, 600C for 4 minutes. 
Step 2) repeat step 1 for 25 cycles. The maximum ramp rate (10C sec 1) 
between each step was used in all reactions. 
Mineral oil was removed and the completed reaction products purified by 
addition of 2il of 3M sodium acetate, pH 4.6 and 50iil of 95% ethanol to 
precipatate the DNA. Reactions were incubated on ice for 10 minutes 
before centrifugation to pellet the DNA, using a benchtop microfuge at 
top speed for 30 minutes. The pellet was washed once with 70% ethanol, 
and once with 100% ethanol before air drying. Reactions were stored at - 
20°C for up to two days before being run on the automated sequencing 
machine by Nicola Preston. 
2.3.9.5 Analysis of DNA sequences prepared by the automatic sequencer. 
Sequencing data were downloaded onto a floppy disc and the files 
analysed using the ABI Prism SequenceTMNavigator Programme version 
1.0.1 (Perkin Elmer). 
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2.3.10 Generation of recombinant baculoviruses by co-transfection. 
2.3.10.1 BaculoGoldTMTransfection Kit (PharMingen). 
The method of Gruenwald and Heitz (1993) was used for co-transfection. 
2ig of recombinant plasmid DNA prepared by the QIAGEN Plasmid Midi 
Kit was used for each co-transfection. Spodoptera frugiperda (Sf9 cells) 
were seeded at 2 X 106 onto 60 mm round tissue culture plates. The cells 
were left to attach for 30 minutes at room temperature whilst the co-
transfection reagents were assembled. 0.54g of linearised BaculoGoldTM 
DNA and 2j.tg of recombinant baculovirus transfer vector were mixed in 
an Eppendorf and allowed to sit for 5 minutes at room temperature before 
adding Buffer B (lml of 125mM Hepes, pH 7.1; 125mM CaC12; 140mM 
NaCl). The medium was removed and replaced with Buffer A (Graces's 
Medium supplemented with 10% fetal bovine serum). The DNA and 
transfection solution were added dropwise to the plate and rocked gently 
back and forth to mix the solutions. 
50tl of wild type virus Autographa californica nuclear polyhedrosis virus 
(AcNPV) were added to an Sf9 plate seeded at 2 X 106 to act as a control. A 
third plate was also seeded at 2 X 106 cells, but no viruses were added. All 
three plates were incubated at 27°C for 4 hours before removing the 
medium and replacing with fresh TC-100 (insect cell medium) 
supplemented with 10% fetal calf serum (Gibco). The plates were returned 
to the 27°C incubator for approximately 4 days, at which stage signs of 
viral infection should be apparent. The supernatant was collected from 
the co-transfection plate by centrifugation (1000g, for 5 minutes) and 
stored at 4°C in the dark until required. 
2.3.10.2 Generation of pure viral stocks. 
60mm cell culture dishes were seeded with 2 X 106 Sf9 cells which were 
incubated at room temperature for 30 minutes to allow the cells to attach 
to the plate. Recombinant viruses or wild type virus were serially diluted 
to 10-5 -10-8 in insect cell medium. Following attachment of the Sf9 cells 
to each dish, the medium was aspirated and replaced with 0.5m1 of the 
serially diluted viruses. Dishes were incubated with gentle rocking for 1 
hour at room temperature. 4m1 of a solution containing 25m1 Graces 
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Insect cell medium supplemented with 20% FBS (Gibco), 12.5m1 of 
ssdH20, and 4% agarose gel (Gibco) maintained at 37°C was quickly added 
to each dish. The solution was allowed to solidify at room temperature 
before incubating at 27°C for 4-6 days. At this stage the plaquing overlay 
was stained with 0.5m1 of Neutral Red dye (Gibco) for 30 minutes 
followed by three 30 minute washes with TC-100 insect medium, to 
visualise the plaques. Isolated plaques were picked with a sterile Pasteur 
pipette into imi of TC-100 and stored at 4°C. 
2.3.10.3 Amplification of virus stocks. 
A 35mm tissue culture dish was seeded with 1 X 106 Sf9 cells in a final 
volume of 2m1. Following attachment of the cells to the plate, the 
medium was removed and replaced with 0.5m1 of the viral inoculum 
prepared as described in section 2.3.10.2. The dish was incubated with 
gentle rocking for 1 hour at room temperature before adding 1.5m1 of 
fresh medium to the dish and incubating at 27°C for 4 days. The medium 
containing numerous floating cells was centrifuged (1000g for 5 minutes) 
and the supernatant diluted with 3m1 of medium stored at 4°C. This was 
designated the passage one viral stock. 
Four 100mm tissue culture dishes were seeded with 5 X 106 Sf9 cells in a 
final volume of lOmi. The medium was removed and replaced with imi 
of the passage one stock and incubated with gentle rocking for 1 hour. 9m1 
of medium was added and the dishes transferred to 27°C for 4 days. The 
supernatant was collected as before and stored at 4°C in the dark. This was 
designated passage two stock. 
2.3.10.4 Titration of virus stocks. 
To determine the titre of the passage two virus obtained in section 2.3.10.3 
virus was serially diluted and used to infect Sf9 cells according to the 
protocol described in section 2.3.10.2. Following staining of the plaquing 
overlay with Neutral Red, the plaques were counted and their numbers 
determined and expressed as plaque forming units per ml (pfu/ml). 
2.4 RNA methods. 
2.4.1 Isolation of total RNA from P. falciparum. 
This method is based on the acidified guanidinium-phenol-chloroform 
protocol of Chomczynski and Sacchi (1987). P. falciparum cultures were 
grown to approximately 5 X 109 parasites, at which stage they were 
harvested by centrifugation (2500g. 10 minutes, 4°C). The red blood cell 
pellet was resuspended in ice cold 1 X SSC, 0.15% saponin and left to lyse 
on ice for 5 minutes. Parasites were washed in 1 X SSC and collected by 
centrifugation. The parasite pellet was resuspended in 7m1 of solution D 
(4M guanidinium isothiocyanate; 25mM sodium citrate; 0.5% sodium 
lauryl sarosine; 100mM 2-mercaptoethanol), and repeatedly passed 
through a hypodermic needle to disrupt the pellet. 0,7m1 of 2M sodium 
acetate pH 4.0, 7m1 of water saturated phenol pH 5.0, and 1.4m1 
chloroform-isoamylalcohol (24:1 v/v) were added and mixed thoroughly. 
The solution was incubated on ice for 15 minutes before centrifugation 
(10,000g, 20 minutes, 4°C). The upper aqueous phase was quickly 
transferred to a clean tube and an equal volume of isopropanol was added 
before storing at -20°C for at least 2 hours to precipitate the RNA. The 
RNA was collected by centrifugation as above, and resuspended in 0.5m1 
of TE/0.1% SDS. The RNA was ethanol precipitated and resuspended in 
0.2m1 of TE/0.1% SDS, before storage at -70°C. 
The RNA was analysed by UV spectrophotometry. 
2.4.2 Isolation of yeast RNA. 
This method is based on the protocol described by Higgins and Hames 
(1994) and involves the disruption of vegetative cells with hot phenol in 
the presence of SDS, which releases RNA effectively, but retains DNA 
within the cell wall. 
200m1 yeast cultures were grown to 0D600 0.4-0.9 at which stage they were 
harvested by centrifugation for 5 minutes at 2000g. The cell pellet was 
resuspended in 2m1 of sodium acetate-EDTA buffer (50mM sodium 
acetate, pH 5.3; 10mM EDTA), 0.25m1 of 10% SDS w/v, and 2.5m1 phenol 
equilibrated against sodium acetate-EDTA buffer. The solution was 
vortexed at maximum speed for 10 seconds then incubated at 65°C for 1 
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minute. The vortexing/heat treatment was repeated over a period of 5 
minutes, then the solution was placed on ice for 10 minutes. The organic 
and aqueous phases were separated by centrifugation (2000g. 5 minutes) 
and the upper aqueous phase was quickly transferred to a clean tube. 
2.5m1 of phenol: chloroform (1:1 v/v) containing 0.5% 8-hydroxyquinoline 
and equilibrated against 10mM sodium acetate pH 6.0, 0.1M NaCl, and 
1mM EDTA were added and the solution was mixed vigorously by hand 
shaking for 10 minutes. The phases were separated by centrifugation as 
before and the aqueous phase transferred to a clean tube. 2m1 of 
chloroform:isoamylalcohol (24:1, v/v) were added and the phases mixed 
before centrifugation as before. The upper phase was transferred to a fresh 
tube and 0.1 volume of 3M sodium acetate pH 5.3 and 2.5 volumes of 
absolute ethanol were added to precipitate the RNA. The contents of the 
tube were mixed and stored for at least 1 hour at -20°C. The RNA was 
recovered by centrifugation (12,000g. 10 minutes at 4°C) and resuspended 
in 0.2m1 of TE/0.1% SDS. The RNA was analysed by UV 
spectrophotometry. A further phenol chloroform extraction followed by 
ethanol precipitation was performed prior to reverse transcription 
reactions. 
2.4.3 Isolation of insect cell RNA. 
Two 100mm tissue culture dishes were seeded with 5 X 106 Sf9 insect cells. 
The cells were left to attach for 1 hour and the medium removed. Wild 
type AcNPV, or recombinant baculoviruses were added to the insect cells 
to give a multiplicity of infection of 20 (eg. 1 X 108 plaque forming units). 
The insect cells were incubated with virus for one hour with gentle 
rocking, before the viruses were removed by aspiration. Fresh medium 
was added and the dishes incubated at 27°C for 24 or 48 hours. Insect cells 
were harvested by scraping the cells off of the plates using a cell lifter. 
Cells were resuspended in fresh medium and pelleted by centrifugation 
(2000g. 5 minutes, 4°C). 
The method used for isolation of RNA was the acidified guanidinium-
phenol-chloroform protocol of Chomczynski and Sacchi (1987) described 
in section 2.4.1. 
2.4.4 Reverse transcription. 
Reverse transcription catalysed from an oligonucleotide annealed to a 
specific mRNA was used to generate a first-strand cDNA which could be 
used for a subsequent PCR reaction. 
RNA samples were removed from -70°C and slowly defrosted on ice. 
Storage buffer TE/0.1 % SDS was removed from the sample by ethanol 
precipitation. RNA samples were treated with DNase I prior to all reverse 
transcription experiments as such; the RNA pellet was resuspended in 
10mM Tris-HCl, pH 7.5 with 10mM magnesium chloride. 1 unit of DNase 
I was added and the sample incubated for 10 minutes at 15°C. A sample of 
plasmid DNA was treated similarly to ensure that the DNase I reaction 
had worked. 
The commercially available Pharmacia First-Strand cDNA synthesis Kit 
was used throughout. 5tg of total RNA was resuspended in 8.d of RNase 
free water, placed in a 1.5m1 Eppendorf and heated to 65°C for 10 minutes 
before cooling on ice. 5j.tl of Bulk First-Strand reaction mix was added (45 
mM Tris-HC1, pH 8.3; 68mM KCl; 15mM DTT; 9mM magnesium chloride;  
FPL CpureR Murine Reverse Transcriptase; RNAguard; 0.08g/m1 
RNase/DNase-Free BSA; 1.8 mM dATP; dCTP; dGTP and dTTP), along 
with 0.2.ig of Notl-d(T)18 primer. 
The solution was mixed and incubated at 37°C for 1 hour at which stage 
the first-strand cDNA reaction was complete and could be used for 
subsequent PCR amplification. 
2.4.5 Northern blots. 
Total RNA was size fractionated on a 1%  agarose/0.185% formaldehyde 
gel prepared and run in MOPS buffer (25mM MOPS; 5mM sodium acetate; 
1mM EDTA, pH 7.0). Between 10-15ig of total RNA and 8.tg of markers 
(0.24-9.4 kb RNA marker, GIBCO-BRL) were added to 0.15m1 of loading 
buffer (2 X MOPS, 50% deionised formamide, 25% formaldehyde, 0.25% 
bromophenol blue and 0.25% xylene cyanol) and the sample was heated at 
75°C for 10 minutes. The sample was snap cooled on ice for 2 minutes and 
O.l.tl of 1g/ml ethidium bromide was added before loading to visualise 
the RNA with UV light. The samples were run at 100 V for around 3 
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hours with continuous buffer exchange by means of a peristaltic pump 
(Pharmacia LKB Pump P-i). 
After photographing, the gel was washed once in 1 X SSC for 10 minutes 
to remove the formaldehyde, and washed again in 1 X SSC, 50mM 
sodium hydroxide to slightly denature the RNA. 
The northern blot was set up as described in section 2.3.4.2 for Southern 
blotting. Following transfer of the RNA to the membrane, the membrane 
was prehybridised and hybridised to probe. 
2.5 Protein methods. 
2.5.1 SDS-polyacrylamide gel electrophoresis (SDS-PAGE). 
2.5.1.1 Preparation and running of SDS-gels. 
Proteins were size fractionated under denaturing conditions using SDS-
PAGE, with a discontinuous buffer system. Atto gel rigs (GRI 
Instruments) were used in conjunction with plates of 150mm X 150mm X 
1mm size, and Bio-Rad Protean II rigs with plates of 250mm X 200mm. 
Mighty Small rigs (Hoefer) were used with plates of 80mm X 70mm X 
0.75mm. 
Table 3: vrotein ael mix for resolving SDS-PAGE 
(quantities specified are in millilitres) 
Percentage Gel 6% 7% 8% 10% 
1.5M Tris-HC1, p1-I 8.8 15 15 15 15 
Acrylamide/bisacrylamide 30:2,67 12 15 16 20 
20% SDS 0.3 0.3 0.3 0.3 
sdH20 32.7 29.7 28.7 24.7 
The protein solution was degassed for 15 minutes to remove bubbles 
before adding 300il of Temed and 30il of 10% ammonium persuiphate. 
The solution was cast to a level corresponding to approximately of 80% 
the length of the plate. 100tl of water saturated butanol was added to 
generate a level interface between the resolving and stacking gels. The gel 
was allowed to set for 1 hour prior to use. 
Table 4: protein gel mix for stacking SDS-PAGE 
(quantities specified in millilitres) 
0.5M Tris-HCI, pH 6.8 5.0 
Acrylamide /bisacrylamide 30:2.67 2.6 
20% SDS 0.1 
sdH2O 12.3 
The solution was degassed for 15 minutes to remove bubbles before 
adding 901 of Temed and 18jji of 10% ammonium persuiphate. The 
stacking gel was cast to the top of the plate and the comb was positioned 
before leaving the gel to polymerise for 1 hour before use. 
Protein samples were added to an equal volume of 2 X SDS loading buffer 
(125 mM Tris-HC1, pH 6.8; 4% SDS; 20% glycerol; 10% 2-mercaptoethanol 
and 0.25% bromophenol blue) and were boiled for 2-5 minutes before 
loading onto the gel. Gels were electrophoresed in running buffer (25mM 
Tris; 192mM glycine; 1% SDS) at 20 mA per gel and approximately 100 V, 
at constant current. Small gels were run for about 1 hour and large gels 
around 3 hours, until the blue tracking dye reached the bottom of the gel. 
2.5.1.2 Protein size standards. 
Three types of protein markers were used. For Coomassie blue stained 
gels, SDS-6H markers (Sigma), and for western blotting of gels pre-stained 
broad range markers (New England Biolabs) or pre-stained broad range 
Rainbow markers (Amersham). 
2.5.1.3 Staining protein gels using fixing Coomassie blue stain. 
Coomassie blue stain (0.25% w/v Coomassie brilliant blue R-250 prepared 
in water: methanol: glacial acetic acid, 5:1:1, v/v/v), was routinely used to 
visualise size fractionated proteins on SDS-polyacrylamide gels. Gels were 
incubated at 37°C in 200m1 of Coomassie solution for 30 minutes before 
fixing/destaining the gel (water:methanol:glacial acetic acid, 5:1:1, v/v/v). 
The destain solution was replaced every 30 minutes until prominent 
protein bands became visible. The gels were dried under vacuum, against 
Whatman 3MM blotting paper at 80°C. 
2.5.1.4 Staining protein gels using non-fixing Coomassie blue stain. 
After electrophoresis, the gel was rinsed in several changes of distilled 
water, and incubated in 5 volumes of 0.05% Coomassie blue R-250 
prepared in distilled water for 10 minutes. The gel was rinsed in several 
changes of distilled water until the proteins were visualised. 
2.5.1.5 Isolation of proteins from SDS-polyacrylamide gels. 
Proteins isolated this way were subsequently used for immunisation of 
rabbits to raise polyclonal antiserum. 
Bacterial cells containing the recombinant protein were size fractionated 
by SDS-PAGE. The correct protein band was excised from the gel with the 
aid of non-fixing Coomassie blue stain to visualise the proteins (2.6.14). 
The protein gel slice was transferred to a clean tube and completely 
immersed in a solution of PBS/0.1% SDS and set at 4°C for 1-2 days. 
When all of the protein had leached from the gel, the solution was 
concentrated using a Microsept Filtron 10K microconcentrator which also 
removes SDS from the sample. The quantity and purity of the sample was 
assessed by SDS-PAGE. 
2.5.2 Western blotting of SDS gels. 
Proteins were separated by SDS-PAGE before western blotting by the 
method of Towbin et al. (1979) using HybondC (Amersham) 
nitrocellulose membranes. The SDS-polyacrylamide gel was removed 
from the glass plates and placed onto the nitrocellulose membrane and 
sandwiched between 2 sheets of blotting paper and 2 Scotchbrite pads each 
side. The gel sandwich was then submerged in transfer buffer (25mM Tris; 
150mM glycine; 20% methanol and 0.1% SDS) in a transfer chamber 
TransBlotTMCell (BioRad) and blotted at 30mA/50V for 4 hours until the 
protein markers were completely transferred. The membrane was 
carefully incubated in blocking solution 1 X Tris/saline-5% fat-free milk 
powder w/v (2.2) for 1 hour. The primary antibody was added at the 
appropriate dilution in the same blocking solution and the membrane 
was rocked gently for 2 hours at room temperature. The membrane was 
given three washes to remove unbound antibody as such; 1 X Tris/saline 
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for 10 minutes (2.2); 1 X Tris/saline, 0.05% NP40; (2.2) twice for 10 minutes 
and 1 X Tris/saline for 10 minutes. 
Goat anti-rabbit IgG-alkaline phosphatase conjugate or anti-mouse IgG-
alkaline phosphatase conjugate (Promega) was added to the blocking 
solution at a dilution of 1:7500. 
2.5.3 Isolation of cellular proteins. 
2.5.3.1 Isolation of total protein from P. falciparuin. for analysis by SDS-
PAGE. 
Approximately 5 X 109 parasites harvested from synchronised or 
unsynchronised stage cultures were released from infected erythrocytes by 
saponin lysis (2.7.4) The parasites were collected by centrifugation (2000g, 
10 minutes, 4°C) and washed in ice cold PBS to remove the red blood cell 
debris. The washed parasites were centrifuged (2500g, 5 minutes, 4°C) and 
lysed by resuspending the pellet in an equal volume of sdH20 to which 
had been added 100jtg/ml PMSF, 2jig/ml leupeptin, and 1ig/ml pepstatin 
A. An equal volume of 2 X SDS loading buffer was added to the sample. 
The lysate was passed repeatedly through a hypodermic needle to reduce 
the viscosity of the sample before boiling for 2 minutes prior to loading 
onto a large (Atto rig) SDS-polyacrylamide gel. 
2.5.3.2 Isolation of total protein from P. falciparurn for Topoll assays. 
5 X 108 ring, trophozoite or schizont infected erythrocytes were saponin 
lysed on ice (2.7.4) then frozen at -70°C. Parasites were lysed on ice by the 
addition of 12tl of 50mM Tris-HC1 pH 8, 120mM KC1, 10mM magnesium 
chloride, and 0.5mM each of ATP and DTT, to which 30jig/ml BSA, 
1p.g/ml pepstatin A, and 2itg/ml  leupeptin had been added. The lysate was 
centrifuged (12000g. 10 minutes, 4°C) to remove insoluble cell debris. 
2.5.4 Expression and isolation of recombinant proteins. 
2.5.4.1 Expression and isolation of recombinant glutathione-S-transferase 
fusion proteins from E. coli. 
Escherichia coli strain BL21 were transformed with recombinant PfTOP2 
or parent pGEX2-T plasmids (2.3.6.2). A single colony harbouring either 
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the recombinant or parent plasmid was picked into 5m1 of LB medium 
supplemented with 100g/m1 ampicillin (LB-Amp) and grown overnight 
at 37°C with shaking. The following day the culture was diluted 1:10 into 
fresh LB-Amp and grown at 37°C with shaking for 1 hour after which the 
culture was split into lml aliquots. The cells were induced with 0.1mM 
IPTG and grown for 1 to 4 hours. IPTG was omitted from one sample to 
allow comparisons to be made between uninduced and induced samples. 
500i1 of culture was collected using a benchtop microfuge and the 
supernatant discarded. lOOpi of 1 X SDS loading buffer was added to the 
pellet before shearing the nucleic acids with a hypodermic needle to 
reduce the viscosity of the sample. The samples were then fractionated by 
SDS-PAGE. 
2.5.4.2 Expression and isolation of recombinant hexahistidine fusion 
proteins from E. coli. 
Escherichia coli strain BL21 (DE3) pLysS were transformed with PfTOP2 
recombinant plasmid and the parent plasmid (2.3.6.2). A single colony was 
picked into 5m1 of minimal medium supplemented with 100.tg/ml 
amp icillin-20g/chloramphenicol (minimal-Amp-CMP) and grown 
overnight at 37°C with shaking. The culture was collected by 
centrifugation (2000g, 10 minutes) and the supernatant discarded. The 
pellet was washed in minimal medium and resuspended in fresh 
minimal-Amp-CMP in a fifth of the original volume. Half of the diluted 
culture was diluted 1: 50 in the same medium and grown at 37°C with 
shaking until an 0D600 of 0.7-0.8 was reached. An uninduced sample was 
removed and to the remaining culture 100mM ITPG was added to a final 
concentration of 0.5mM. The cells were incubated for an additional 1-4 
hours before being collected by centrifugation using a benchtop microfuge. 
Pellets were either frozen at -20°C or analysed by SDS-PAGE. 
2.5.4.3 Isolation of total protein from insect cells and baculovirus infected 
insect cells. 
35mm tissue culture dishes were seeded with 1 X 106 insect cells. The cells 
were allowed to attach to the dishes for 30 minutes before removing the 
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medium (TC-100 medium supplemented with 10% fetal bovine serum), 
and replacing it with recombinant, or wild type virus diluted to give 2 X 
107 plaque forming units (pfu) in a total volume of 250-500i1. Viruses 
diluted in this way give a multiplicity of infection (MOI) of 20 pfu/cell. 
One plate was left without virus to use as a mock infected control. The 
viruses were incubated with the insect cells for 1 hour at room 
temperature with gentle rocking, before being aspirated from the dishes. 
Fresh medium was overlaid before incubating at 27°C for 18 to 72 hours. 
The medium containing 'floating' infected insect cells was removed from 
the dish and the cells were collected by centrifugation (2000g, five 
minutes, 4°C). The pellet was then resuspended in 50j.tl of 1 X SDS loading 
buffer. The dishes containing infected cells that were still attached to the 
dish were placed on ice and 50il of 1 X SDS loading buffer was added and 
the lysate was scraped off using a cell lifter. Both lysates were used 
separately or combined together, and were stored at -20°C. The samples 
were then fractionated by SDS-PAGE. 
2.5.4.4 Isolation of total protein from S. cerevisiae cells. 
Six colonies were inoculated into yeast minimal medium containing 2% 
glucose/ 2%glycerol/2%lactate containing the appropriate amino acids 
(2.2) and grown for 24 hours at 30°C. Under these conditions the GAM 
promoter is repressed. 0.5 ml of this culture was added to two flasks each 
containing 9.5 ml of yeast minimal medium (2%glycerol/2%lactate and 
appropriate amino acid), and grown for an additional 24 hours at 30°C to 
deplete endogenous pools of glucose. When the 0D600 of the culture 
reached 0.4-0.9, one sample was induced with 2% galactose, and the other 
sample was allowed to continue to grow without galactose. This 
represented the non-induced control. Galactose induction was allowed to 
proceed for 2-6 hours. 
Cells were harvested by centrifugation at 1500g for 5 minutes. The cell 
pellet was resuspended in 0.5 ml of water and centrifuged at top speed in a 
benchtop microfuge for 1 minute. An equal volume of acid-washed 400-
600 micron glass beads was added to the pellet and cells were lysed by 
addition of 1 ml of Buffer 1 (2,2) per milligram of cells (wet weight) using 
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the following procedure. The mixture was vortexed for 20 seconds, placed 
in an ice water bath for 40 seconds. This was repeated ten times. Complete 
cell lysis was verified by microscopic analysis of the supernatant. The 
mixture was centrifuged for 1 minute at top speed in a benchtop 
microfuge, at 4°C and the supernatant removed. An equal volume of 2 X 
SIDS loading buffer was added to each 100.t1 sample, before analysis by 
SDS-PAGE. 
2.5.5 Metabolic labelling of proteins expressed in BL21 (DE3) pLysS. 
Cells were grown as described in section 2.5.4.2 before removing 0.5m1 
aliquots into tubes 1-4. To tubes 3 and 4, 0.5mM IPTG was added and 
incubation at 37°C maintained for 30 minutes, 200mg/ml of rifampicin 
was added to tubes 2 and 4 and incubation continued for 45 minutes. Each 
of the samples were then pulse-labelled with 5Ci of 35S methionine 
(1000Ci/mmol Tran35S-label ICN) for 5 minutes at room temperature. 
The cells were collected using a benchtop microfuge and the pellets lysed 
by addition of 200j.tl of 1 X SDS-PAGE loading buffer. The samples were 
analysed by SDS-PAGE, the gels were fixed, soaked in ddH20 for 15 
minutes followed by soaking with 1M sodium salicylate for 15 minutes. 
The gels were then rinsed with water before vacuum drying and exposing 
to unflashed film in cassettes without intensifying screens until a clear 
signal was obtained. 
2.5.6 Purification of hexahistidine-tagged proteins from baculovirus 
infected cells. 
The commercially available HisTrapTMKit (Pharmacia) was used for 
purification of recombinant hexahistidine-tagged proteins. 
2.5.6.1 Nickel column preparation. 
A luer adaptor was connected to the syringe and filled with distilled 
water. The top cap from the column was unscrewed and a few drops of 
distilled water were applied to the top of the column to prevent air 
bubbles getting into the column. The twist-off end of the column was 
removed and 5m1 of distilled water was forced through the column to 
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remove the stabilising agent. The column was activated with nickel ions 
by forcing imi of 0.1M nickel sulphate through the column. Excess nickel 
was removed by washing the column with 5m1 of distilled water. The 
column was pre-equilibrated with 10m1 of start buffer A (20mM 
disodium hydrogen phosphate-2H20; sodium dihydrogen-H20 and 0.5M 
sodium chloride, pH 7.5; 20% glycerol and 10mM imidazole). 
2.5.6.2 Sample preparation. 
Between 250m1 to 1.5 litre of recombinant infected baculovirus cells were 
harvested from spinner culture flasks. Cells were collected by 
centrifugation (500g, 5 minutes, 4°C) and the supernatant discarded. The 
pellet was resuspended in 5m1 of ice-cold start buffer A to which protease 
inhibitors were added (2mg/mi leupeptin, 1mg/mi pepstatin and 
iOomg/ml PMSF). 
Baculovirus cells were lysed by sonication using a 5mm diameter probe 
for 10-15 second bursts alternating with 30 seconds on ice. Cell lysis was 
checked by light microscopy. The viscosity of the sample was reduced by 
repeatedly passing through a hypodermic needle to shear the nucleic 
acids. The crude lysate was centrifuged (15000g. 30 minutes, 4°C) to 
remove insoluble material that could block the nickel column. 
2.5.6.3 Affinity column purification. 
All steps were carried out at 4°C. The nickel column was pre-equilibrated 
with lOmi of start buffer A before loading the sample by means of a 
peristaltic pump (Pharmacia LKB Pump P-i) at a flow rate of imi/minute. 
Fractions were collected in 0.5m1 aliquots. The column flow through was 
retained and a small quantity combined with an equal volume of 1 X SDS 
sample buffer to be analysed by SDS-PAGE. The column was washed 
using 50m1 of start buffer. Hexahistidine tagged proteins were eluted by 
the addition of 5m1 of start buffer containing 0.5M imidazole, or eluted 
using a linear gradient of 10-500mM imidazole. Samples to be used for 
assays were stored on ice until required and were desalted by drop dialysis 
using a 0.1M VC filter (Millipore) against Topoll assay buffer (2.9.1). 
Dialysed samples were analysed before and after dialysis using SDS-PAGE 
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to ensure that there was no loss of protein. Samples that were used for 
analysis by SDS-PAGE were added to an equal volume of SDS-loading 
buffer and stored at -200C until required. 
2.5.7 Indirect immunofluorescence assay (IFA). 
Thin blood smears of infected erythrocytes from unsynchronised cultures 
at 6-10% parasitaemia were made on glass microscope slides. The slides 
were air dried for 1 hour before fixing with acetone for 5 minutes. After 
drying, a grid was drawn onto the slide with nail varnish. Onto each 
section of the grid 40g1 of the appropriate antibody diluted in PBS was 
spotted and the slide and incubated in a moist chamber for 1 hour at room 
temperature. The slide was washed by immersion in PBS for 5 minutes 
twice, followed by one wash in distilled water. The slide was air dried and 
40i1 of a 1:80 dilution of a rhodamine isothiocyanate conjugate of 
immunosorbant-purified anti-rabbit immunoglobulin (RITC-anti-rabbit 
IgG, Sigma) containing 5Rg/ml  of DAPI in PBS was added to each grid 
section. The slide was incubated, washed and dried as described for the 
primary antibody. The slide was mounted in Citifluor (City University 
London) and examined by fluorescence microscopy using RITC filter set 
(Leitz). 
2.5.8 Immunoprecipitation 
2.5.8.1 Metabolic labelling of insect cells using 35S methionine. 
This method is based on O'Reilly et al (1992). 35mm culture dishes were 
seeded and infected with viruses as described in section 2.12. Two hours 
before harvesting the cells, 0.5m1 of methionine-deficient TC100 medium 
supplemented with 10 fetal bovine serum (Gibco), was added to the cells 
to deplete the endogenous pools of methionine within the cells, after 
which they were transferred to 27°C for 1 hour. One hour before 
harvesting the cells, 0.5m1 of the same medium containing 25jtCi of 
1000Ci/mmol Tran35S-label (ICN) was added. After 1 hour, the 
radiolabelled culture medium was carefully removed and disposed of 
appropriately. The cells were washed gently three times in PBS pH 6.2, 
drained and 50ji1 of NP40 lysis buffer was added (1% NP40; 150mM NaCl; 
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50 mM Tris-HC1, pH 8.0) containing 2mg/mi leupeptin, 1mg/mi pepstatin 
and 100mg/mi PMSF). The lysate was scraped from each dish using a cell 
lifter. 
2.5.8.2 Metabolic labelling of P. falcipiirum infected erythrocytes. 
Prior to labelling the parasites, an enrichment procedure was used to 
facilitate selection of infected erythrocytes only to enhance metabolic 
labelling. The 3D7 isolate was used for this purpose because it exhibits a 
"surface knob phenotype "which alters the behaviour of the infected cells 
promoting their selection. 
5 ml of infected erythrocytes at approximately 5-10% parasitaemia were 
collected by centrifugation (850g. at 20°C, for 10 minutes, with no brake). 
The medium was discarded, a blood smear taken and 2m1 of complete 
RPMI medium was added. The volume of the cell pellet was determined 
and 2.4 volumes of plasmagel (Scottish Blood Transfusion Service), and 
1.4 volume of RPMI were added (adjusting for the 2m1 of RPMI already 
added prior to determination of the pellet volume). The sample was 
mixed and incubated at 37°C for 30 minutes. The supernatant containing 
the infected erythrocytes was transferred to a fresh tube and the number of 
infected cells determined using a counting chamber. The infected cells 
were collected by centrifugation as above, and a blood smear taken to 
determine the percentage of infected cells in the population. The cell 
pellet was washed twice in RPMI without methionine and cysteine 
(Sigma). 2 X 108  infected erythrocytes in a total of 2m1 methionine-and 
cysteine-free RPMI were incubated with 100tCi of 1000Ci/mmol Tran35S-
label (ICN), at 37°C for 1.5 hours, after being gassed. The cells were 
collected by centrifugation as above and the cell pellet washed with 10ml 
of PBS. The pellet was resuspended in 0.5m1 of RPMI, the pellet volume 
determined, and the solution transferred to an eppendorff. At this stage 
the parasites were saponin lysed and the parasite pellet quick frozen and 
stored at -70°C. 
2.5.8.3 Immunoprecipitation from insect cells. 
Preparation of Protein A-Se pharose. 
77 
Protein A-Sepharose powder was swollen for one hour in swelling buffer 
(100mM Tris-HC1, pH 7.5), centrifuged (1000g, 2 minutes) before being 
washed twice in the same buffer. 
Preclearing the sample. 
291 of pre-immune rabbit serum was added to 5i1 of lysate and the sample 
incubated at 4°C for 1 hour. lOj.tl of Protein A-Sepharose CL-4B was added 
and the sample incubated at 4°C as before. The sample was spun in a 
microfuge for 2 minutes at 4°C and the pellet discarded. An additional 
lOpi of Protein A-Sepharose was added to the supernatant and incubated 
4°C for 30 minutes. This procedure was repeated once more and the pellet 
discarded. The supernatant was considered now to be precleared. 
Formation of the antigen-antibody complex. 
2pJ of the appropriate polyclonal antiserum was added to the precleared 
supernatant and incubated at 4°C for 3 hours. 
Precipitation of antigen-antibody complexes. 
50j.tl of pretreated Protein A-Sepharose was added to the complex and 
incubated at 4°C for 1 hour. The complexes were collected by 
centrifugation in a microfuge for 2 minutes and the supernatant 
discarded. The pellet was washed with 0.5m1 of NET buffer (140mM NaCl; 
50mM Tris-HC1, pH 8.0; 5mM EDTA; 0.05% v/v NP40) and vortexed 
briefly to resuspend the pellet before centrifugation as described above. 
This procedure was repeated twice. The washed antigen-antibody 
complexes were disrupted by resuspending the pellet in 1 X SDS loading 
buffer. Samples were size fractionated using SDS-PAGE. The radiolabelled 
gel was treated as described in section 2.5.5 prior to autoradiography. 
2.5.8.4 Immunoprecipitation from P. falciparum. 
Preparation of Protein A-sepharose. 
Protein A-Sepharose beads were swollen (2.5.8.3.) then equilibrated with 
washing buffer A (10mM Tris-HC1, pH 7.5; 150mM NaCl; 1% v/v NP40 
and 2mM EDTA) three times (1000g for 2 minutes). 
Preclearing the sample. 
A 1:1 ratio of sepharose beads to washing buffer was used throughout. 
One volume of solubilising buffer (50mM Tris-HC1, pH 7.5; 150mM NaCl; 
1% NP40 and 4i.ig/ml PMSF) was added to 2 X 107  parasites, and the 
volume adjusted to 50.tl. 4t1 of pre-immune serum, and 35il of sepharose 
beads (prepared as described above) were added and the slurry incubated at 
4°C for 30 minutes. The slurry was spun in a benchtop microfuge at top 
speed for 1 minute and the supernatant collected. An additional 35j.l of 
sepharose beads were added and the incubation and centrifugation steps 
repeated. 
Formation of the antigen-antibody complex. 
The supernatant was collected and 51.d of immune serum added and the 
solution incubated at 4°C for 1 hour on a rotating wheel. Following 
centrifugation in a benchtop microfuge, the supernatant containing the 
antigen-antibody complex was collected. 
Precipitation of antigen-antibody complexes. 
35p1 of Protein A sepharose beads were added to the antigen-antibody 
complex and incubation continued for an additional 1 hour at 4°C on a 
rotating wheel. The Protein A sepharose complexes were collected by 
centrifugation in a microfuge as above prior to being washed 3 times in 
washing buffer A, twice in washing buffer B (10mM Tris-HC1, pH 7.5; 
500mM NaCl; 1% NP40 v/v and 2mM EDTA) and once in washing buffer 
C (10mM Tris-HC1, pH 7.5). 251.d of 2 X SDS loading buffer was added and 
the samples analysed by SDS-PAGE, using a 10% polyacrylamide gel. Size 
fractionated proteins present in the gel were fixed using an aqueous 
solution containing 10% methanol v/v and 10% glacial acetic acid v/v, 
for 15 minutes, The gel was soaked in ddH20 for 15 minutes, then soaked 
in a solution containing 1M sodium salicylate prepared in ddH20 for 15 
minutes. After rinsing in several changes of ddH20, the gel was dried 
under vacuum and exposed to film. 
2.5.9 Complementation analysis in S. cerevisiae. 
Temperature sensitive t0p2-1 or top2-4 yeast strains (2.1.6.2) were 
transformed as described in section 2.3.17.1 with recombinant or control 
plasmids. A single colony was inoculated into 100ml of yeast synthetic 
minimal medium with 2% glucose and appropriate amino acid 
supplements (2.2). Overnight cultures were grown at permissive 
79 
temperatures and cell numbers counted using a haemocyometer (Weber). 
Equivalent cell dilutions were spotted onto selective media (containing 
either, glucose, glycerol/ lactate or galactose carbon sources at 2%) for each 
strain and the plates were transferred to permissive (25°C) or restrictive 
(34°C) temperatures. 
2.6 Polyclonal antibody production in rabbits. 
2.6.1. Raising polyclonal antisera against recombinant Pftopoll 
hexahistidine- tagged protein. 
2.6.1.1 Analysis of pre-immune sera. 
New Zealand White rabbits were used for all antibody work conducted in 
this study. Animal work was conducted by the University of Edinburgh 
Medical Faculty Animal Area. To ensure that no cross-reactive antibodies 
were present in the rabbit serum prior to immunisation, a small (1.5m1) 
blood sample was taken from several animals for individual screening. 
Blood samples were placed at 37°C for 1 hour then transferred to 4°C 
overnight. Clear serum was remove from the blood clot and screened by 
IFA . Only animals with an acceptably low background of cross-reactive 
proteins were selected for subsequent immunisations. 
2.6.1.2 Immunisation regime. 
An additional 5m1 of pre-immune blood was taken prior to the first 
immunisation. Protein for the first immunisation was prepared as 
described in section 2.11. Between 50-100itg of recombinant protein was 
added to 0.5m1 PBS/0.5m1 Freund's Complete Adjuvant. The emulsion 
was injected subcutaneously into each hind-quarter. Three weeks later the 
animal was boosted with 50-60g of the same protein, but this time 
prepared in 0.5m1 PBS/0.5m1 Freunds Incomplete Adjuvant. Rabbits 
received three boosts in total. 10-14 days after each boost, a 9m1 blood 
sample was taken from the ear. Blood samples were prepared as in section 
2.6.1.1 and the immune response monitored by IFA and western blotting. 
2.7 Parasite culture. 
The KI isolate (Thiathong and Beale, 1981) and 3D7 isolate (Walliker et at., 
1987) of P. falciparum were used during the course of this work. Stocks 
were obtained from imi samples of ring stage infected erythrocytes stored 
in liquid nitrogen. 
2.7.1 Human blood and serum. 
Blood and serum used for this work were obtained from the Southeast 
Scotland Blood Transfusion Service. Whole blood packs containing group 
0 rhesus-positive blood were aliquoted into 50m1 tubes (Falcon) and 
washed 3 times in 5 volumes of sterile RPMI 1640 (Gibco), with 
centrifugation between washes (1500g. 10 minutes, 4°C). The white blood 
cell layer on top of the erythrocytes was carefully removed following each 
spin. The erythrocytes were resuspended in RPMI 1640 to give a 66% 
haematocrit, and were stable up to 4 weeks stored at 4°C. Human serum 
packs were pooled and centrifuged (2000g, 10 minutes, 4°C). The serum 
was collected and heat treated at 56°C for 1 hour. 50m1 aliquots were 
stored at -20°C and were stable for at least 1 year. 
2.7.2 Culturing of the blood stages of P.falciparum. 
The method used in this study was originally described by Trager and 
Jenson in 1976 and was later modified by Zoig et al., 1982. Parasites were 
cultured in 75cm3 tissue culture flasks (Falcon 3024) in 50m1 of complete 
medium (RPMI 1640 supplemented with 10% human serum, 50g/ml 
gentamycin and hypoxanthine). The percentage parasitaemia was 
obtained by taking thin blood smears and fixing briefly in microscopy 
grade methanol (BDS) prior to staining with a 10% solution of Giemsa 
(BDH) prepared in distilled water. Cultures were maintained at 1-2% 
except when building up for RNA or protein preparations when up to 
10% parasitaemia was acceptable. The medium was changed on a daily 
basis by aspiration, the percentage parasitaemia determined, fresh blood 
and medium added and the parasites gassed (3% oxygen; 2% carbon 
dioxide and 95% nitrogen) and incubated at 37°C. 4m1 of infected blood 
per flask was not exceeded. 
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2.7.3 Synchronisation of blood stage parasites. 
Parasite cultures containing at least 5% ring stage parasites were 
synchronised by sorbitol treatment as described by Lambros and 
Vandenberg (1979). 
Medium was aspirated from the parasites and infected blood collected by 
centrifugation (850g. 10 minutes, 4°C). The blood pellet was washed once 
in fresh RPMI 1640 and centrifuged as before. The infected blood was 
incubated for 5 minutes at room temperature in a solution of 5% sorbitol 
and the blood collected as before. The pellet was washed twice in 5 
volumes of RPMI 1640 and resuspended in complete medium at 5% 
haematocrit. The synchronised culture was gassed and returned to a 37°C 
incubator (2.7.2). The culture was examined 48 hours later to determined 
the degree of synchrony and if necessary, the process was repeated again to 
achieve tighter synchronisation. 
2.7.4 Saponin lysis of blood stage parasites. 
P. falciparuin cultures were harvested by centrifugation (2500g, 10 
minutes, 4°C). The red blood cell pellet was resuspended in ice cold 1 X 
SSC, 0.15% saponin and incubated on ice for 5 minutes. Red blood cell 
lysis was confirmed by detection of a colour change from red to a dark 
reddish black. Parasites were washed in 1 X SSC or PBS and collected by 
centrifugation. Pellets were used immediately or stored frozen at -70°C 
until required. 
2.8 Culture of Spodopterafrugiperda (Sf9 cells). 
S. frugiperda insect cells were cultured in 50m1 tissue culture flasks 
(Falcon) which permit attachment of cells to the plate. Routinely, insect 
cells were sub-cultured 1:2-1:8 when they reached 80-90% confluency, in 
50m1 fresh TC100 medium supplemented with 10% FBS and 50tg/ml 
gentamycin. Insect cells were also grown in suspension culture in 1 litre 
glass bottles containing a hanging bar in-built magnetic stirrer (Techne) at 
60rpm (MCS-104S Biological Stirrer -Techne). Insect cells were maintained 
at 27°C. 
2.9 Enzyme assays. 
2.9.1 Decatenation assays (Parasite extract). 
Parasite extract was prepared from synchronised cultures containing ring, 
trophozoite and schizont parasites as described in section 2.7.3. 5 X 108 
parasites were harvested by saponin lysis as described in section 2.7.4. 
Parasite pellets were stored frozen and lysed on ice by addition of ice-cold 
Topoll assay buffer supplemented with lug/ml pepstatin A, 100ug/ml 
PMSF and 2,tg/ml leupeptin. Insoluble cell debris was removed by 
centrifugation (12,000g 4°C, 5 minutes). 
Typically, 0.2.tg of kinetoplast DNA (KDNA) was used per 20d assay. 
Reactions containing Topoll assay buffer (50mM Tris-HC1, pH 8.0; 120mM 
KC1; 10mM magnesium chloride; 0.5mM each of DTT, ATP, and 30u.1g/ml 
of BSA) were initiated by variable amounts of enzyme or parasite extract 
(typically 1 X 106 parasites gave good results) and were incubated for 30 
minutes at 37°C. Reactions were terminated with 0.1 volume of 2 X 
loading buffer, loaded onto 1% agarose gels containing 0.5i.ig/ml ethidium 
bromide and electrophoresed for variable periods of time. Reaction 
products were visualised by UV irradiation. One unit of topoisomerase II 
is defined as the amount required to completely decatenate 0.2j.ig of 
KDNA in 15 minutes at 37°C. 
2.9.2 Immunodepletion of PfTopoll activity. 
Parasite extract was prepared from unsynchronised cultures as described 
in section 2.7.4. Parasite pellets were lysed on ice as described in section 
2.9.1. Pre-immune or immune sera were incubated with parasite extract 
prepared from 1 X 108 parasites at dilutions in the range of 1:5- 1:2000 for 
30 minutes on ice. Decatenation assays were conducted and the reaction 
products analysed as detailed in section 2.9.1. 
2.9.3 Decatenation assay (recombinant PfTopoll). 
Fractions obtained from imidazole gradient purifications of recombinant 
PfTopoll were dialysed against Topoll assay buffer to remove imidazole 
and salt (2.5.6.3). 0.2u.tg of kinetoplast DNA (KDNA) was used per 20ul 
assay. Reactions containing Topoll assay buffer (50mM Tris-HCl, pH 8.0; 
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120mM KC1; 10mM magnesium chloride; 0.5mM each of DTT, ATP, and 
30g/m1 of BSA) were initiated by variable amounts of partially purified 
protein and incubated for 30 minutes at 37°C. Reactions were terminated 
using 0.1 volumes of 2 X loading buffer, loaded onto 1% agarose gels 
containing 0.5g/m1 ethidium bromide and electrophoresed for variable 
periods of time. 
Chapter 3 
M. 
Heterologous expression of P. falciparum topoisomerase II in E. coli. 
3.1 Introduction. 
There were two main objectives of the work described in this chapter. 
To express a fragment of the PJTOP2 gene in E. coli to use to make 
polyclonal antiserum in rabbits. 
Figure 1 shows a schematic alignment of the predicted domain structure 
of type II topoisomerases from both prokaryotic and eukaryotic species. In 
S. cerevisiae, V8 proteinase sensitive sites occur after glutamate residues 
410, and 680, the latter of which is conditional upon ATP binding. In 
addition, the region around residue 1200 is also sensitive to V8 digestion; 
this maps the beginning of the C-terminal domain, which is reported to 
be species divergent. A comparison of the predicted amino acid sequence 
of S. cerevisiae and P. falciparum topoisomerases H reveals an identity of 
44.4% between the two homogues. The degree of conservation is generally 
greater in the amino terminal two-thirds of the proteins and falls off 
markedly towards the carboxy termini. For this reason, it was decided to 
express the last 404 amino acids of PfTopoll for use as an antigen, in the 
expectation that antibodies raised against this region would be less likely 
to cross-react with topoisomerase II present in the cells of any organism 
that was subsequently used for heterologous expression of PfTopoll. The 
expression vector to be used was pRSETB. 
To express the entire PJITOP2 gene in E. coli. 
The full length PfTOP2 gene was simultaneously prepared for expression 
in pRSETB. A different expression vector, pGEX-2T was also used for full 
length expression of the gene. Both vectors are commonly used for 
heterologous expression of foreign proteins in E.coli. 
Figure 1. 
Domain structure of topoisomerase II homologues from different species. 
A diagrammatic comparison of the domain structures of E. coli DNA 
gyrase and five eukaryotic toposiomerases II. Gyrase is composed of two 
polypeptides, A and B, which in the functional enzyme are in the A2B2 
configuration. All eukaryotic homologues are composed of single 
polypeptides which associate to form a homodimeric enzyme. 
The ATP binding domain is shown in dark blue, the central DNA binding 
and strand breakage /reunion domain is shown in red, the species 
divergent carboxyterminal domain is shown in pale blue, and N-terminal 
extensions are shown in black. Each protein is aligned by the active site 
tyrosine (residue 829 in the P. falciparum homologue). Domain 
boundaries have been denoted by reference to protease-sensitive sites 
within the E. coli or S. cerevisiae proteins. 
Figure 1 is adapted from a review article by Watt and Hickson (1994). 
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Figure 1. Domain structure of topoisomerase II homologues from different species. 
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Background to the pRSET system. 
The pRSET vector system (Figure 2) uses a strong phage T7 promoter to 
drive expression of the target fragment cloned in-frame downstream of 
the vector encoded ATG. Six histidines immediately downstream of the 
ATG encode an N-terminal metal binding domain which can be cleaved 
from the recombinant protein by means of an adjacent enterokinase site. 
Stop codons are present in all three frames within 70 nucleotides of the 
polylinker. The nickel binding domain can be used to affinity purify the 
recombinant protein using nickel column chromatography. 
Background to the pGEX system. 
pGEX vectors express a fragment of foreign DNA as a fusion partner to 
glutathione S-transferase (GST) of Schistosoma japonicum (Figure 3). The 
lac repressor binds to the Ptac promoter, repressing expression of the 
fusion protein, which can be reversed by the inducer IPTG. The gene of 
interest is cloned in frame into the polylinker downstream of the end of 
the GST gene. Termination codons are present in all three frames at the 
end of the polylinker. pGEX-2T contains a thrombin cleavage site to 
enable the GST moiety to be cleaved from the fusion protein. 
3.2 Expression of the C-terminal region of PfTopoll in pRSETB. 
A 3' 1.2 kb (2979-4191 nt) fragment of the PfTOP2 gene, previously cloned 
into pUBS1 was released by restriction with BamHI and BglII. The 
fragment was gel purified and ligated in frame into the BamHI site of 
pRSETB. BglII and BamHI have compatible sticky ends making it possible 
to clone the fragment into the BamHI site. 
The ligation was transformed into competent DH5cx cells a n d 
recombinant colonies were detected by hybridisation to the 32P  random 
labelled PfTOP2 fragment (2979-4191 nt) described above. Because cloning 
into the BamHI site of pRSETB could result in ligation of the fragment in 
two different possible orientations, the cloning boundaries were checked 
by sequencing to ensure that the fragment was in-frame with the vector- 
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Figure 2. Map of the pRSET series of expression vectors. 
The elements for the control of transcription consist of a ribosome 
binding site downstream of a strong phage T7 promoter. The vector 
encoded ATG is followed by a few vector encoded amino acids plus a 
hexahistidine nickel binding domain. Stop codons in all three frames are 
present within 70 nucleotides of the multiple cloning site (MCS) which is 
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GU CCG CGT GGA TCC CCG GGA ATT CAT CGT GAG IGA CTG 
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Figure 3. Map of the pGEX-2T expression vector. 
The plasmid contains a mutant LacI gene (Laclq) which produces high 
levels of the lac repressor which binds to the Ptac promoter repressing 
expression of the GST gene. The foreign gene is inserted into the multiple 
cloning site at the 3' end of the GST gene. Stop codons are present in all 
three frames downstream of the distal EcoRI cloning site. Expression of 
the GST fusion protein is induced with IPTG. A thrombin cleavage site 
facilitates removal of the GST moiety following expression. 
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encoded ATG. Suitable recombinants were transformed into BL21 (DE3) 
[pLysS] for expression. 
BL21 cells were chosen because they lack the ion protease and the o m p  
outer membrane protease that can degrade proteins during purification. 
DE3 is a . phage derivative that carries the gene for T7 RNA polymerase 
(gene 1) under the control of the lacUV5 promoter (Studier and Moffat 
1986). Addition of JPTG induces the lacUV5 promoter to produce T7 RNA 
polymerase, which in turn transcribes any DNA under the control of a 17 
promoter. Transcription by the basal level of T7 RNA polymerase present 
in the non-induced cell can be reduced by the presence of plasmid pLysS 
(Studier, 1991). This plasmid provides the cell with T7 lysozyme which is 
a natural inhibitor of T7 RNA polymerase. 
3.2.1 Evidence of expression of the 54.5 kDa recombinant C-terminal 
region of PfTopoll. 
In order to test for expression of the fragment, individual transformants 
harbouring the recombinant plasmid, or the parent plasmid alone, were 
inoculated into minimal medium and grown to an 0D600 of 0.7-0.8. 
Cultures were grown in the presence or absence of IPTG for periods of 1 to 
4 hours (2.5.4.2). Small samples were removed and tested by SDS-PAGE 
fractionation for the presence of a novel band of around 54.5 kDa, the size 
predicted from the composition of the amino acids encoded by the DNA 
fragment. A faint band in the size range expected was observed in 
recombinant preparations only (Figure 4). 
3.2.2 Confirmation of expression of the C-terminal region of PfTopoll. 
To verify that the protein was derived from expression from the 17 
promoter, a pulse labelling experiment was conducted. This involved 
adding 35S methionine to cells grown in minimal medium without 
amino acids for 5 minute periods. This enables efficient labelling of all 
newly synthesised proteins containing methionine residues. If the 
experiment is performed in the presence of rifampicin (which inhibits E. 
coli RNA polymerase), then only proteins that are transcribed from the 17 
promoter by 17 RNA polymerase will be labelled. 
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Figure 4. 
Coomassie blue stained SDS-polyacrylamide gel of size fractionated 
proteins from E. coli cells harboring the 3' 1.2 kb fragment of the PfTOP2 
gene (2979-4191 nt) in pRSETB (pRSETB/3' PfTOP2). 
Lanes 1 and 2 contain proteins derived from expression of the parent 
plasmid pRSETB without the PfTOP2 gene fragment. Lane 3 contains 
pRSETB/3' PfTOP2 in non-induced cells. Lanes 4-7 contain pRSETB/3' 
PfTOP2 in cells induced with IIFTG for 1-4 hours, respectively. 
The position of the protein size standards are indicated in kilodaltons and 
the position of the recombinant protein is arrowed. 
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Small scale cultures containing the recombinant plasmid having reached 
an 0D600 of 0.8, were pulse labelled using 35S methionine in the presence 
or absence of IPTG or rifampicin, or in the presence of both (2.5.5.). 
Figure 5 (a) shows the results of this experiment. In the absence of both 
rifampicin and IPTG, radiolabelled host cell proteins can be clearly seen 
(lane 1). In the presence of rifampicin only, the appearance of a faint band 
of the expected size is observed, which may be attributed to leaky 
expression (lane 2). Following addition of both IPTG and rifampicin to the 
culture, however, a major protein of approximately 50-60 kDa together 
with several other smaller proteins are observed (lane 4). These small 
polypeptides could represent degradation products and /or truncated 
versions of the major protein. 
3.2.3 Purification of the C-terminal region of PfTopoll. 
In order to obtain enough pure protein to immunise rabbits, the 
recombinant protein was isolated directly from SDS-polyacrylamide gels. 
Total cell protein from a large scale induced culture, was size fractionated 
using SDS-PAGE on two 7% gels. The gels were stained with non-fixing 
Coomassie blue in aqueous solution and the appropriate band was 
excised. Protein was eluted from the gel in PBS/0.1% SDS. The 
recombinant protein was concentrated and the SDS removed with a 
microconcentrator, and the purity of the sample confirmed by SDS-PAGE. 
Two New Zealand White rabbits designated 989 and 992 were each 
immunised with 100itg of recombinant purified protein emulsified in 
0.5m1 Freund's complete adjuvant and 0.5m1 of PBS. Pre-immune serum 
was taken prior to the first immunisation. The immunisation regime 
described in section 2.6.1.2 was followed and immunisations were 
performed by qualified individuals under Home Office Regulations. 
3.3 Primary screening of antisera 
Serum obtained following second and subsequent immunisations were 
tested for the presence of PfTopoll specific antibodies. This was done by 
screening western blots of the antigenic hexahistidine fusion protein 
immobilised on nitrocellulose with appropriate dilutions of the immune 
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Figure 5 (a). Autoradiograph of metabolically labelled cells. 
Equal numbers of E. coli BL21 (DE3) [pLysS] cells harboring the 3' 1.2 kb 
BarnHI/B g/ll fragment of the PfTOP2 gene in pRSETB were treated with 
IPTG, rifampicin, or a combination of both prior to analysis by SDS-PAGE 
(10% gel). 
Lane 1. 35S methionine labelled culture. Lane 2. 35S methionine labelled 
culture previously treated with rifampicin. Lane 3. 35S methionine 
labelled culture previously treated with IPTG. Lane 4. 35S methionine 
labelled culture previously treated with rifampicin + IPTG. 
The positions of the protein size standards are indicated and the position 
of the 50-60 kDa protein of interest is arrowed. 
Figure 5 (b) Western blot of antigenic fusion protein. 
Western blot analysis of whole cell lysate following size fractionation by 
SDS-PAGE (10% gel). Lanes 1 and 2 contain BL21 (DE3) [pLysS] cells 
expressing recombinant C-terminal PfTopoll that was used as the antigen. 
The blot was probed with immune serum obtained following the second 
immunisation. Cross reactive proteins were detected using anti-rabbit IgG 
alkaline phosphatase conjugate. 
Lane 1. Strip from western blot probed with serum from rabbit 989 at a 
dilution of 1:1000. 
Lane 2. Strip from the same western blot probed with serum from rabbit 
992 at a dilution of 1:1000. 
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Figure 5 (b) shows the result of one of these experiments. Lane 1 and 2 are 
strips taken from the same western blot and probed with immune serum 
from rabbit 989 (lane 1) and rabbit 992 (lane 2). Each rabbit serum appears 
to detect a similar panel of proteins, the largest of which is estimated to be 
approximately 55-60 kDa. A comparison with Figure 5 (a) shows that the 
proteins recognised by each rabbit on the western blot are very similar to 
the pattern of expression from the T7 promoter (Figure 5 a). Taken 
together, these results indicate that both rabbits have produced polyclonal 
antiserum against the recombinant C-terminus of PfTopoll. 
3.3.1 Western blot analysis of parasite extract identifies a protein of around 
160/175kDa. 
A protein with an apparent mobility of around 160/175 kD was detected by 
each antiserum at a dilution of 1:1000 on western blots of size fractionated 
parasite proteins (10% SDS-PAGE) obtained from unsynchronised blood-
stage cultures (Figure 6). The pre-immune serum failed to recognise 
parasite protein(s) on western blots. 
3.3.2 PfTopoll localises to the parasite nucleus. 
Figure 7 (1) shows a thin smear of parasitised blood displaying the 
intraerythrocytic stages of P. falciparum (ring, trophozoite and schizont) 
taken from a culture containing human red blood cells. The parasites 
were stained with Giemsa (2.7.2). 
Antisera (from rabbits 989 and 992) were used at a dilution of 1:80 in PBS 
to screen thin blood smears of parasitised human erythrocytes in an 
immunofluorescence assay (IFA, 2.5.7) that were fixed to glass slides 
(Figure 7, panels 2 and 3). Pre-immune serum, diluted similarly, was also 
tested and PfPCNA antiserum (Horrocks et al., 1996) was used as a 
comparison as it is known to localise to the parasite nucleus and therefore 
acted as a positive control (shown in Chapter 4, page 130 b). IFAs showed 
that the pre-immune serum from each rabbit failed to cross-react with 
intraerythrocytic parasites, in contrast with the signals from each of the C-
terminal PfTopoll antisera which co-localise with the nuclear stain DAPI 
Figure 6. 
Western blot of size fractionated proteins prepared from unsynchronised 
parasites separated by SDS-PAGE on a 10% gel. Lane 1. Strip from western 
blot probed with pooled pre-immune serum from rabbits 989 and 992 at a 
dilution of 1:1000. Lane 2. Strip from from the same western blot probed 
with immune serum from rabbit 989 at a dilution of 1:1000. Lane 3. 
Adjacent strip from western blot probed with immune serum from rabbit 
992 at the same dilution as in lanes 1 and 2. 
The positions of the protein size standards are indicated in kilodaltons 









Thin blood smear of methanol-fixed and Giemsa-stained P. falciparum 
parasites in human red blood cells. A. Ring stage parasite. B. Trophozoite 
stage parasite. C. Schizont stage parasite. 
2 and 3. 
Indirect immunofluorescence assay of a trophozoite stage parasite. 
Acetone fixed thin blood smears from unsynchronised parasite 
populations were probed with polyclonal antiserum from rabbit 989 
(panel 3). Cross-reactive parasites were detected using anti-rabbit IgG RITC 
conjugated second antibody. Parasite nuclei were counter-stained with 
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in trophozoites and schizont stages. Ring stage parasites gave a weaker 
level of fluorescence (result shown in Chapter 4, page 130 b). 
3.3.3 A triplet of proteins of around 160/175 kDa can be 
immunoprecipitated from parasite extracts. 
Immunoprecipi'cation was used to determine whether PfTopoll interacts 
with other parasite protein(s). A set of pilot experiments were performed 
using the parasite isolate 3D7. This isolate exhibits a "knob phenotype" 
which affects the behaviour of infected red blood cells when immersed in 
a solution of plasmagel. 
Infected erythrocytes were separated from uninfected cells using 
plasmagel which causes uninfected erythrocytes and ring stage infected 
erythrocytes to settle at the bottom of the plasmagel solution, leaving 
trophozoite and schizont infected erythrocytes in suspension. 80% 
enrichment of the culture for these stages was achieved, enabling 
metabolic labelling of parasite proteins to be performed in a small volume 
thus promoting efficient incorporation of label. 
Enriched cultures were incubated in methionine/cysteine deficient RPMI 
medium in the presence of 35S methionine/cysteine for 1.5 hours, after 
which the parasites were harvested by saponin lysis (2.5.8.2). PfTopoll was 
immunoprecipitated using the PfTopoll antiserum from rabbits 989 and 
992. This technique exploits the specific binding of antibody with its 
cognate antigen; antigen binds to the antibody via two antigen binding 
sites present on the two Fab regions of the antibody. Addition of Protein A 
sepharose beads, which bind to the Fc portion of antibody, enable the 
complex to be precipitated. SDS-PAGE fractionation, of the precipitated 
complex in the presence of 13-mercaptoethanol disrupts the protein 
complexes and separates them according to their size and subunit 
composition. 
Figure 8 shows that a triplet of bands (the broad band arrowed in figure 8) 
is present in the immunoprecipitated complex with an apparent mobility 
of —160/175 kDa. This size is in agreement with previous results obtained 
from western blots of size fractionated parasite proteins (figure 6). Several 
other bands are also present in addition to the triplet. Their identities 
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Figure 8. Immunoprecipitation of PfTopoll from crude parasite extract. 
10% SDS-polyacrylamide gel fractionated immunoprecipitated complexes. 
Unsynchronised blood stage parasites were metabolically labelled using 
35S methionine prior to immunoprecipitation using immune serum 
from rabbits 989 and 992. 
Lane 1. Immunoprecipitation using immune serum from rabbit 989. Lane 
2. Immunoprecipitation using immune serum from rabbit 992. The 
positions of the protein size standards are indicated in kilodaltons. The 












have not yet been investigated further, but they may represent proteolytic 
degradation products of the full length protein. 
3.4 Expression of the entire PfTOP2 gene in pRSETB. 
The BglII DNA fragment comprising the complete coding sequence of the 
PfTOP2 gene (1-4191 nt) that was originally prepared for expression in 
baculovirus (described in Chapter 5) was subcloned in frame into the 
BainHl site of pRSETB. 
The ligation was transformed into E. coli DH5a competent cells and 
recombinant colonies were detected by hybridisation to the 32P  random 
labelled PfTOP2 fragment (2979-4191 nt) described above. Because cloning 
into the BamHI site of pRSETB could result in ligation of the fragment in 
both possible orientations, the cloning boundaries were sequenced to 
ensure that the fragment was correctly orientated in-frame with the 
vector encoded ATG. Suitable recombinants were transformed into BL21 
(DE3) [pLysS] for expression. 
3.4.1 Initial characterisation of protein expression. 
BL21 (DE3) [pLysS] harbouring the PfTOP2 gene in pRSETB were grown to 
an 0D600 of 0.8, prior to induction with IPTG for periods of 1-4 hours. 
Cells were harvested by centrifugation, lysed, and analysed by SDS-PAGE 
to monitor expression. Uninduced cultures containing the PfTOP2 gene, 
together with cultures containing the parent plasmid alone were used as 
controls. 
The PfTOP2 gene encodes a protein of 160 kDa/subunit. No evidence of a 
product of this size was observed after Coomassie blue staining of SDS 
protein gels (data not shown). At this time the commercially available 
monoclonal antibody against the hexahistidine tag of fusion proteins was 
not available, nor was antiserum against the recombinant C-terminus of 
PfTopoll. In an effort to establish whether the full length protein was 
being expressed, therefore, a metabolic labelling experiment was 
performed. 
Small scale cultures containing the recombinant plasmid having reached 
an 0D600 of 0.8 were pulse labelled using 35S methionine in the presence 
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of IPTG or rifampicin alone, or in the presence or absence of both. 
Figure 9 (a) shows the results of this experiment. Lanes 1-4 are derived 
from cultures containing the parent pRSETB plasmid without the PfTOP2 
gene. Lane 5-8 are derived from cultures containing the PfTOP2 gene in 
pRSETB. In the presence of rifampicin and IPTG there is little evidence of 
expression of a protein of the expected size of recombinant PfTopoll (Lane 
8). There are some very faint bands that are not observed in the culture 
derived from the parent plasmid (without the PfTOP2 gene) that was also 
treated with rifampicin and IPTG (lane 4). The presence of these proteins 
of approximately 90, 50 25 and 20 kDa may indicate that (1) the protein is 
undergoing premature transcriptional and/or translational termination 
in vivo or (ii) the full length protein is made in small amounts but is 
rapidly degraded in vivo. 
3.5 Expression of the PfTOP2 gene in pGEX-2T. 
In view of the fact that full length expression of the PfTOP2 gene was not 
observed in pRSETB, it was decided to see if changing the expression 
system could achieve better results. pGEX was considered worth trying for 
two reasons. Firstly, this system expresses foreign proteins as C-terminal 
fusions to GST. Because GST is expressed at a high level and appears to be 
very stable, it was hoped that this would improve the stability of 
recombinant PfTopoH expressed as a fusion protein. Secondly, a rabbit 
polyclonal antiserum against GST was commercially available which 
would simplify detection of GST fusion proteins. GST fusion proteins can 
also be readily purified using glutathione Sepharose columns. 
pGEX-2T does not contain a BglII site so the Bg1II fragment of the PfTOP2 
gene (1-4191 nt) was cloned in frame into the BarnHI site; this was possible 
because both enzymes generate compatible sticky ends. Ligations were 
transformed into competent DH5z cells and colonies screened for the 
presence of the PfTOP2 gene by colony hybridisation. Cloning boundaries 
were sequenced to ensure that the gene was in the correct orientation and 
in frame with the vector-encoded ATG. 
Small cultures grown at 37°C containing the recombinant PfTOP2 gene in 
pGEX-2T or the parent vector alone were induced with IPTG (2.5.4.1). 
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Figure 9 Autoradiograph of metabolically labelled cells. 
 
Equal numbers of E. coli BL21 (DE3) [pLysS] cells metabolically labelled 
with 35S methionine and harboring the PfTOP2 gene in pRSETB were 
treated with IPTG, rifampicin, or a combination of both prior to analysis 
by SDS-PAGE (10% gel). 
Lanes 1 and 5. 35S methionine labelled culture with no supplements. 
Lanes 2 and 6. 35S methionine labelled culture previously treated with 
rifampicin. Lanes 3 and 7. 35S methionine labelled culture previously 
treated with IPTG. Lanes 4 and 8. 355 methionine labelled culture 
previously treated with rifampicin + IPTG. 
The positions of the protein size standards are indicated. The positions of 
the faint bands which may represent proteolytic fragments of recombinant 
PfTopoll are arrowed. 
Figure 9. Western blot. 
 
Western blot of size fractionated proteins (8% gel) from E. coli BL21 cells 
harboring the wild type PfTOP2 gene and a mutated version of the gene in 
pGEX2T. In the mutated gene tyrosine 829 has been changed to 
phenylalanine by PCR mutagenesis. The blot was probed with the 
commercially available polyclonal antiserum against GST at a dilution of 
1:1000. 
Lanes 1 and 2. Proteins from BL21 cells containing parental pGEX2-T 
vector alone. Lanes 3-5. Proteins from BL21 cells containing the wild type 
PfTOP2 gene in pGEX2T. Lanes 6-8. Proteins from BL21 cells containing 
the mutated version of the PfTOP2 gene. Lanes 1, 3 and 6 are non-induced 
cultures. Samples run in lanes 2, 4 and 7 were induced for 2 hours, whilst 
samples run in lanes 5 and 8 were induced for 4 hours. 
The positions of the protein size standards are indicated, and the position 
of GST is arrowed. 
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Samples were taken prior to induction to act as controls. Cultures were 
grown for 1-4 hours in the presence or absence of IPTG before being 
analysed by SDS-PAGE (8% gel) using Coomassie blue to stain the gels or 
by western blotting. 
Figure 9 (b) shows a western blot analysis of this experiment. Immobilised 
proteins were probed with anti-GST polyclonal serum at a dilution of 
1:1000; cross reactive proteins were detected using anti-rabbit IgG alkaline 
phosphatase conjugate at 1:7500. Lanes 1, and 2 contain protein derived 
from the culture containing pGEX-2T without the PfTOP2 gene. Lanes 3, 4 
and 5 contain protein derived from a culture containing pGEX-2T with 
the PfTOP2 gene. In lanes 1-3 the presence of a predominant protein of 
around 27 kDa is detected by the anti-GST serum. This protein is most 
likely to be GST on the basis of the expected size of 27.5 kDa and reactivity 
with anti-GST serum. Addition of IPTG to the culture containing the 
PfTOP2 gene construct results in the appearance of numerous GST-cross 
reacting proteins of 100 kDa or less. These are present after 2 hours 
induction and are still present 2 hours later (lanes 4 and 5 respectively). 
Several possible explanations may account for this result. The fact that so 
many discrete protein bands appear to be cross reacting with the anti-GST 
serum suggests that full length PfTopoll is probably made, but that is 
undergoing C-terminal degradation. Alternatively truncated versions of 
the protein may have been expressed. It is possible that expression of the 
recombinant protein may be deleterious or toxic to the cell, a situation 
which might lead to in vivo proteolytic degradation. 
3.5.1 Mutational replacement of the PfTOP2 active site tyrosine 829 with 
phenylalanine. 
The possibility that the activity of this protein is toxic to E. coli in its own 
right, was investigated by introducing a mutation in the triplet encoding 
the tyrosine residue implicated in the DNA/protein linkages. The TAT 
triplet encoding tyrosine in the wild type enzyme was converted to TTT 
(phenylalanine) using overlapping primer extension (figures 10 and 11) 
PCR using primers G3718/T1728 amplified a product of approximately 1 
kb, which is close to the size expected. 
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Figure 10. 
Structure of the oligonucleo tides that were used to change the active site tyrosine codon to phenyalanine in the 
wild type PfTOP2 gene by PCR mutagenesis. 
(1) sense top strand 5' GAT GCA TCT GCA GCA AGA TTT ATA TTT ACA AAA TTG GCT AGC 3' 
oligonucleotide 
T1729 
D A S A A R F I F T K L A S 1 
antisense 
bottom strand 5' GCT AGC CAA TTT TGT AAA TAT AAA TCT TGC TGC AGA TGC ATC 3' 
oligonucleotide 
T1728 
wild type 5' GAT GCA TCT GCA GCA AGA TAT ATA TTT ACA AAA TTG GCT AGC 3' 
coding sequence 
D A S A A R Y I F T K L A S 
G3718 --pi, T1729_...Y\..*. 
T1728 -1— 221Y 
"Left" PCR with G3718/T1728 
"Right" PCR with 221Y/T1729 





7 3' Taq extension 
7 PCR with G3718/221y 
PfTOP2 gene with wild type TAT nucleotides 
encoding tyrosine mutagenised to TTT to 
encode phenylaanine. 
Figure 11. 
Strategy used to replace the PfTopoll tyrosine 829 with 
phenylalanine by PCR mutagenesis. 
This involved combining two separate PCR products with 
overlapping sequence into one longer product. Two overlapping 
primers T1728 and T1729 are shown containing three mismatched 
bases to the PfTOP2 gene. 
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PCR using primers 221Y/T1729 amplified a product also of the expected 
size (600 bp). 
The two PCR products were gel purified, denatured at 95°C for 5 minutes, 
cooled to 37°C for 3 minutes, prior to 3' extension using Taq and dNTPs at 
72°C for 10 minutes. A 1.6 kb 3' amplification product was subcloned into 
the pCRTMII vector and the ligation transformed into INVaF' competent 
cells (2.3.15.4). 
Hindlil F BarnHI 
I I I 
G3718 I I 221Y 
Diagrammatic representation of the PCR fragment 
cloned into the pCRTMII vector. 
Recombinant clones were sequenced to verify that the tyrosine codon had 
changed to phenylalanine and to ensure that no other mutations were 
present in the sequence. Part of the sequence containing the TAT to TTT 
(shown underlined) codon change obtained from the ABI 377 automatic 
sequencer (Perkin Elmer) is shown below. 
110 120 130 140 150 
I I 
25• Sondie I GATGCATCTG CAGCAAGATT TATATTTACA AAATTGGCTA GCTC-_kCCAG 
iSO 170 190 190 200 
26. Sandie j A?GTATATTT ?.ATG?TACG ACGATCCTAT TTThAAATAT TTA?TGAAG 
The Hindlll/BamHI fragment containing the mutation was restricted, gel 
purified and used to replace the wild type Hindlll/BamHI fragment of the 
gene. The mutated PfTOP2 gene was cloned into pGEX-2T in frame as 
described previously in section 3.8. Small scale cultures were analysed for 
expression of the PfTOP2 gene as also described previously. 
Figure 9 (b) shows the results of this experiment. Lanes 6-8 are derived 
from a culture containing the mutated PfTOP2 construct in pGEX-2T. 
Lane 6 shows that in the absence of IPTG there is little evidence of 
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expression of the gene. IPTG induction of an aliquot of cells taken from 
the same culture however, results in a similar profile as that observed in 
cultures expressing the unmutated PfTOP2 gene (figure 9 b, lanes 7 and 8). 
This indicates that expression of a functional topoisomerase II is not in 
itself responsible for the result observed when attempts were made to 
express the wild type gene. However, it is possible that expression of the 
PfTopoll itself is detrimental to cell growth and viability. 
3.6 Expression of the N-terminal region of the PfTOP2 gene in pRSETB 
Figure 12 shows the amino acid structure of PfTopoll predicted from the 
coding sequence of the gene. The position of the C-terminal fragment (404 
amino acids) that was expressed in the vector pRSETB is indicated. As part 
of a separate study, we were able to overexpress an N-terminal fragment 
of PfTopoll which comprised amino acids 6-144. This construct terminates 
before the polyasparagine tracts (not shown in figure 12). In view of the 
fact that both the N-terminal and C-terminal regions of the protein can be 
expressed, but the full length wild type and mutant forms of the protein 
appear to have a very short half-life in vivo, lead us to question whether 
the presence of the polyasparagine tracts might be detrimental to 
expression in E. coli. In addition, we were also interested to know which 
fragments of the protein could be expressed in E. coli. To investigate this 
we decided to express the Bglll to Hindffl restriction fragment (nucleotides 
1-1797) of the PfTOP2 gene which encodes amino acids 1-599 of the 
protein. 
The expression vector pRSETB was restricted with BglII and Hindill and 
the cut vector gel purified to increase the efficiency of ligation. The vector 
and gene fragments were ligated, and transformed into E. coli strain 
DH5a. Suitable recombinant plasmids were isolated and transformed into 
E. coli strain BL21 (DE3) [pLysS] for expression. 
3.6.1 Characterisation of expression. 
BL21 (DE3) [pLysS] harbouring the 5 ' end of the PfTOP2 gene (nucleotides 
1-1797) in pRSETB were grown to an 0D600 of 0.8, prior to induction with 
IPTG for periods of 1-4 hours. Cells were harvested by centrifugation, 
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lysed, and analysed by SDS-PAGE to monitor expression. Proteins were 
visualised by staining with Coomassie blue. Uninduced cultures 
containing the 5' end of the PfTOP2 gene, together with cultures 
containing the parent plasmid alone were used as controls. 
Figure 13 shows the result of a typical experiment. The recombinant 
hexahistidine fusion protein was expressed at levels detectable by 
Coomassie blue staining. Its apparent mobility was estimated to be 68-72 
kDa, a size which is consistent with the amino acid composition of the 
protein. Although expression of the recombinant protein was observed 
after 1 hours induction, expression was maximal after 4 hours induction. 
This result demonstrates that the presence of polyasparagine tracts in the 
PfTopoll protein does not appear to affect protein expression. 
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I MkKNKTIEER YQKKSQIEHI ILRPDTYIGS VEMHTQLLWV WNKEKI'RNVQ 
51 KNITYVPGLY KIFDEIIVNA ADVKAREKEK SENPMTCIKI EINKENKRIS 
101 VYNDGEGIPV DIHKEIYV PHMIFGELLT SDNYDDAEDR ITQGRNGFGA 
151 KLTNIFSKEF IVQCGDSSRK KEFKNTWSDN MSKFSEPHIK NYNGKDYVKV 
201 TFKPDLNKFC MTEMDDDIES LLFKRVYDLA QTCSVRVYLN GQRLAVKDFK 
251 SYVDLYLKDN SNDNKNNKGQ NDNNNNNNNN NDENANQNND NLDVSLSNEP 
301 ADGTPTKNNN NNNNNNDEDE IVKIHEKQHR WEIVVSKSDQ SQFQQVSFVN 
351 SICTTKCGSH VNYIVEQLLS SLSKXANAKN KGGMEIKSGH IRNHLWVFVN 
401 CLIVNPTFDS QTKETLTTKP VKFGSKCILS DKTINNVLKS PILSNIL1LWA 
451 QAKAQVELKK KMKAGSSKAR ERIIGIPKLE DANDAGSKYS QECTLILTEG 
501 DSAKTSCLAG LSIVGRDKYG VFPLKGKLLN VRDASFKQLM DNKEIQNIFR 
551 IMGLDITDKN KDDIKGLRYG SLMIMTIJQDY DGSHIKGLLI NNIHKFWPSL 
601 LKHKGFLSEF VTPIVKVQKG SQEYSFFTIA EYEQWKENTN LLGWKIKYYK 
651 GLGTSTDREF KQYFSDIKNH KIMFLWTGDR DGDSIDMAFS KKRIEDRKLW 
701 LQNFILGSYV DHKEKDLSYY DFVNKELIYY SRYDTERSIP NIMIJGWKPGQ 
751 RKVLYGCFKR NLRNECKVAQ LVGYIAEHSA YHHGESSLQQ TIINWQTFV 
801 GSNNINFLEP CGQFGSRKEG GKDASAARYI FTKLASSTRS IFNEYDDPIL 
851 KYLNEEGQKI EPQYYIPVIP TILVNGCEGI GTGYSSFIPN YNYKDIIDNI 
901 KRYINKEPLI PMVPWYKDFK GRIESNGKTG YETIGIINKI DNDTLEITEL 
951 PIKKWTQDYK EFLEELLJTDE KHQLJILDYID NSSHEDICFT IKNDPAKLQK 
1001 AEEEGLEKVF KLKSTLTTTN MTLFDPNLKL QRYSTELDIL KEFCYQRLKA 
'ta 
1051 YENRKSYLIS KLEKEKRIIS NKTKFILAIV NNELIVNKKK KKVLVEELYR 
1101 KGYDPYKDIN KIKKEEIFEQ ELLDAADNPE DNEEIIAGIT VKDYDYLLSM 
1151 PIFSLTLEKV EDLLTQLKEK ERELEILRNI WETMWLKDI EKVEEAIEFQ 
1201 RNVELSNREE SNKFKVARKQ GPSSMKKKKK KKKLSSDEES EGGDTSDSSE 
1251 FLVNTLNIKK NTNKKTTTSS NNVNNSKKRL RKADDLNSNE LDNTLSVSKT 
1301 FDDNMThTDN TPLINRLNDE NNEFSSNNVD NKSTNKNSRK KKPKIADSTN 
1351 DNNSELNSSI QINDNVNDDI NITISPNKTI NVNEFSSIKN KLLELGI* 
Figure 12. The amino acid structure of PfTopoll predicted from the coding 
sequence of the gene. 
The N-terminal fragment that was expressed in pRSETB (pRSETB/5' 
PfTOP2) as part of this study, is shown in red. The polyasparagine rich 
regions which have been demonstrated to be present in the mRNA are 
indicated in blue. 
The C-terminal fragment which was expressed in pRSETB (pRSETB/3' 
PFTOP2) is shown in purple. 
The glycine residue (147) implicated in ATP binding is shown in green, as 
is the active site tyrosine residue (829). 
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Figure 13. 
Coomassie blue stained SDS-polyacrylamide gel of size fractionated 
proteins from E. coli cells harboring the 5' fragment of the PfTOP2 gene 
(nucleotides 1-1797) in pRSETB (pRSETB/5' PfTOP2). 
The position of the protein size standards, indicated in kilodaltons are 
shown in lane 1. Lane 2 contains proteins derived from expression of the 
parent vector pRSETB without the PfTOP2 gene fragment. Lane 3 contains 
the pRSETB/5' PfTOP2 construct in non-induced cells. Lanes 4 and 5 
contain the pRSETB/5' PfTOP2 construct in cells that had been induced 
for 1 and 4 hours respectively. 
The position of the recombinant protein is arrowed. 
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Antiserum raised against the C-terminal domain of PfTopoll in two 
rabbits (989 and 992) both recognise a protein of approximately 160 kDa on 
western blots of total parasite protein. Both antisera were also able to 
immunoprecipitate a triplet of proteins of similar size from parasite 
extracts. Strong patterns of immuno fluorescence with trophozoites and 
schizonts were also obtained with each antiserum, but weaker 
fluorescence was evident with ring stage parasites. The region of 
fluorescence produced by the antibodies co-localised with the nuclear 
stain DAPI, corroborating earlier work which suggested that PfTopoll is a 
nuclear protein (Cheesman et al., 1994). Both antisera also cross-react with 
the antigenic fusion protein that was used to immunise the rabbits. 
Although both the N-terminal and C-terminal fragments of PfTopoll 
could be made in E. coil, full length expression of the gene was 
unsuccessful. No evidence of full length recombinant protein was 
observed when the gene was co-expressed with T7 RNA polymerase in 
PRSETB from a T7 promoter. When induced cultures were metabolically 
labelled in the absence of E. coil RNA polymerase activity (rifampicin 
inhibited), some very faint proteins were detected (approximate sizes 90, 
50, 25 and 20 kDa), but their nature, whether degradation products, or 
truncated versions of the full length protein has not been determined. 
Full length expression of the gene was also attempted using the pGEX-2T 
plasmid. The advantage of using this system is that PfTopoll could be 
expressed as a fusion partner with GST which is reported to increase the 
stability of some foreign proteins. When protein expression was 
monitored using a commercially available antiserum against GST, 
numerous cross-reactive bands of approximately 100 kDa or less were 
detected following induction. The possibility that expression of a 
functional topoisomerase II may have had a deleterious effect on cell 
viability, which in turn may have given rise to proteolytic degradation of 
the recombinant protein was investigated. This involved the use of PCR 
mutagenesis to change the active site tyrosine to phenylalanine, so that an 
inactive Topoll could be expressed. When this construct was expressed, 
however, a similar pattern of protein expression was observed. 
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The fact that other P.falciparum genes (eg. DNA polymerase 5 and PCNA-
pers comm.) have been successfully expressed in E. coli suggests that the 
high A+T content of falciparum genes in general does not present a 
barrier to expression. It seems more likely that recombinant PfTopoll is 
expressed in E. coli, but that it is rapidly degraded in vivo. Time 




Expression of PfTopoll throughout the blood stages of parasite growth. 
Introduction 4.1. 
Several of the genes encoding parasite proteins involved in DNA 
replication have been isolated and characterised in this laboratory in an 
endeavour to provide new potential drug targets for development. 
These include PfPCNA, PfPo1, PfPolc and topoisomerase I (Kilbey et al., 
1993, Ridley et al., 1991, White et al., 1993, Tosh and Kilbey 1995), the first 
three of which are homologues of proteins which in the SV40 system are 
known to act directly at the replication fork. Polymerase 5 is responsible 
for achieving continuous leading strand synthesis in conjunction with its 
processivity factor PCNA. Synthesis of Okazaki fragments is initiated by 
the polymerase a/primase complex, but polymerase 6/PCNA complete 
the elongation phase after complex switching (Stillman, 1994). 
As part of this work, the stage specific expression of three of these genes 
has been examined and some interesting observations have been made. 
For example, DNA PfPol5 and PfPCNA both show similar accumulation 
patterns of protein and mRNA but appear to have distinct mechanisms 
regulating their temporal expression. 
Horrocks et al., (1996) have found that both of these proteins accumulate 
principally during the trophozoite and schizont stages, but their 
transcripts are confined to the trophozoite stage. An assessment of 
promoter activity however, shows that the PfPCNA promoter is active 
throughout all of the intraerythrocytic stages, whereas PfPo16 promoter 
activity is confined to the trophozoite/schizont stages. These findings 
suggest that in the case of PfPCNA, transcript levels are regulated post-
transcriptionally, in contrast with PfPol8 where transcript levels and 
promoter activity are interrelated. 
Similar data have also been obtained for PfTopoisomerase I where 
promoter activity, transcript accumulation and protein expression all 
follow a similar pattern to PfPolö. The relationship between protein 
accumulation and enzyme activity was also investigated, and although 
levels of PfTopol were found to be similar in trophozoite and schizont 
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stage parasites, enzyme activity was found to increase markedly in 
schizonts. These findings could indicate that the protein undergoes post-
translational modification(s) as the parasite progresses from trophozoite 
to schizont stages (Dr. K. Tosh -in preparation). 
DNA replication in the malaria parasite takes place at five distinct points 
during its complex life cycle in the human host and mosquito vector 
(White and Kilbey 1996). Discussion will be limited to DNA replication in 
the parasite that occurs during the blood stages within the human host. 
Here, DNA replication first starts in the trophozoite and continues into 
the schizont stage. Up to four rounds of nuclear division result in a 
schizont with up to sixteen nuclei (Tilney and Tilney 1996). Cytokinesis 
then gives rise to merozoites which are able to invade more erythrocytes 
after the schizont bursts. Thus it seems likely that the temporal regulation 
of PfPCNA and PfPolö in particular, and possibly PfTopol as well, during 
the trophozoite and schizont stages may be intimately linked to the onset 
of DNA replication and nuclear division. 
The relationship between DNA replication in the parasite and the pattern 
of expression of PfTopoisomerase II has been investigated and the results 
of this study will be presented here. Part of the work (measurement of 
promoter activity) was done in collaboration with Dr. Paul Horrocks. 
The gene encoding PfTopoll from the parasite was isolated and 
characterised in 1994. The 4191 bp open reading frame (revised from 4194 
bp, Cheesman et al., 1994) contains no introns. Sequences conserved in 
topoisomerase II from other species are present in the falciparum 
sequence, but two unique tracks encoding asparagine repeats are predicted 
to fall towards the N-terminal domain of the protein. PfTOP2 is a single-
copy gene encoding a protein of 1397 amino acids (160 kDa/subunit). The 
gene shares 47% sequence identity with the human Topoll a homologue. 
Northern analysis reveals a transcript of approximately 5.8kb and the gene 
has been localised to chromosome 14. Preliminary qualitative data 
indicates that the protein is detectable at all stages of intraerythrocytic 
development. 
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4.2 The PfTOP2 message is temporally regulated and peaks in 
trophozoites. 
Intraerythrocytic stage parasite cultures were synchronised using sorbitol 
treatment and harvested at the ring, trophozoite or schizont stage as 
described in section (2.7.3). The degree of synchrony was checked by 
microscopic analysis of Giemsa stained parasites (2.7.2). 10!.tg of RNA from 
each stage prepared by method (2.4.1) was size fractionated on a 
formaldehyde gel alongside RNA size standards (Gibco). The gel was 
blotted to Genescreen Plus membrane and probed with gene-specific DNA 
sequences (figure 1). Three bands appear when the blot is probed with the 
random-labelled 1.8kb 5' Kpnl/Hindlll fragment of the PfTOP2 gene, 
corresponding to nucleotides 1-1795. The most prominent of these is at 
about 6.0 kb. However, two other bands at approximately 7.0 and 8.0 kb are 
also recognised by this probe. These are DNasel resistant. The bands 
appear in trophozoites, but they are absent from schizont preparations. 
Small amounts of the smallest of the three transcripts appear in rings. 
Microscopic examination of the samples revealed around 7% 
contamination of the ring stage RNA by trophozoites and schizonts, 
whilst the trophozoite sample contained about 16% contamination with 
rings. Therefore, in order to confirm the pattern of transcript 
accumulation, a series of probes derived from genes with well known 
stage-specific patterns of expression were used to probe the same northern 
blot. The 3.8 gene probe (Lanzer et al., 1992), which is specific for rings and 
trophozoites only, behaves in the expected manner. Whilst GBP 130, a 
trophozoite-specific probe (Lanzer et al., 1992) was found to hybridise 
predominantly to trophozoite stage RNA as expected, although prolonged 
exposure reveals a faint signal in the ring-stage sample. The actin I probe 
(Wesseling et al., 1989) gave rise to signals of almost equal intensity in 
rings, trophozoites and schizont stage RNA, in line with its known 
specificity. This result also helps to confirm that almost equal amounts of 
RNA were loaded in the lanes. Taken together, these data suggest that the 
PfTOP2 messages accumulate principally in trophozoites but are absent 
from schizonts and possibly present at low levels in rings. 
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Figure 1. 
Northern blot analysis of total RNA extracted from parasites synchronised 
in intraerythrocytic stages. The proportion of rings (R), trophozoites (T) 
and schizonts (S) in each sample was as follows; Ring sample (93R:4T:3S); 
trophozoites (16R:841:OS); schizonts (OR:OT: 100S). The positions and sizes 
of the three PfTOP2 transcripts are indicated. Panel (a) shows the 18S and 
28S ribosomal RNA bands present in the RNA stained with ethidium 
bromide. 
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4.3 PfTopoll levels are highest in trophozoite and schizont stage parasites. 
The antiserum raised against the C-terminal of PfTopoll (chapter 3) was 
used to probe western blots (8% SDS-PAGE) of equivalent numbers of size 
fractionated parasites synchronised in ring, trophozoite or schizont blood 
stages (figure 2). Three major bands of approximately 160/175 kDa in size 
were recognised in trophozoite and schizont samples only. It is not 
known whether the lower two bands seen on these westerns are 
proteolytic fragments of the larger protein, or alternatively, the products 
of differential processing events occurring in vivo; for example different 
phosphorylation states of the protein. 
Figure 2 also shows that similar levels of protein are detected by the 
antisera in trophozoite and schizont stage parasites. Far less recognisable 
protein is present in rings however, and interestingly only a single band, 
the largest of the three, is present in detectable amounts. 
4.4 PfTopoll activity is highest during schizogony. 
Crithidia fasciculata kinetoplast DNA (KDNA) consists of a network of 
mini and maxicircles. The minicircies are highly concatenated, a feature 
which can be exploited as a means of testing for the decatenation activity 
of a type II topoisomerase. Decatenation results in the formation of both 
open circular (OC) and covalently closed circular (CCC) DNA species 
which can be separated from each other by gel electrophoresis and from 
the unresolved catenated material which remains in the well. 
Parasites were harvested as described in section 2.7.4. The degree of 
synchrony was determined by Giemsa staining and microscopic analysis 
(2.7.2). Parasite pellets were quick frozen and lysed by the addition of 
topoll assay buffer (2.9.1). 
The decatenation activity of protein extracts from equal numbers of 
parasites at each intraerythrocytic developmental stage was tested (2.9.1) 
and the results of a typical experiment are shown in figure 3. There is 
little evidence of decatenation in rings. Virtually all of the input KDNA is 
retained in the well and there are only traces of OC and CCC DNA. In 
contrast, decatenation is readily detected in the extracts from trophozoites 
and schizonts, with higher activity in the latter as evidenced by the greatly 
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Figure 2. 
Western blot analysis of protein prepared from parasites synchronised in 
intraerythrocytic stages. The proportion of rings (R), trophozoites (T) and 
schizonts (S) in each sample was as follows; Ring sample (88R:12T:OS); 
trophozoites (5R:87T:8S); schizonts (3R:26T:715). M. represents the 
positions of the prestained protein markers (NEB). Sizes indicated are in 
kilodaltons. 
Figure 3. 
Decatenation activity assay using KDNA as substrate with parasite extract 
from asexual parasites synchronised in ring, trophozoite and schizont 
stages. The proportion of rings (R), trophozoites (T) and schizonts (S) in 
each sample was as follows; Ring sample (82R:10T:85); trophozoites 
(18R:75T:75); schizonts (36R:5T:60S); C. negative control sample without 
parasite extract. The positions of open circular DNA (OC) and covalently 
closed circular DNA (CCC) reaction products are indicated. 
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Figure 4. Indirect immunofluorescence assay of P. falciparurn blood stage parasites. 
(R) Ring stage parasite. (T) Trophozoite stage parasite. (S) Schizont stage parasite. 
Thin blood smears from unsynchronised populations of parasites were acetone fixed and 
PfTopoll cross-reactive parasites were detected using anti-rabbit IgG RITC conjugated 
second antibody. Parasite nuclei were counter-stained with DAPI (panels b, d and f) 
and rhodamine (panels a, c and e). 
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reduced amounts of unresolved KDNA in this sample. 
4.5. PfTopoll protein can be detected in all blood-stage parasites. 
Figure 4 shows an immunofluorescence assay conducted on 
unsynchronised populations of intraerythrocytic parasites. Pre-immune 
and immune sera obtained from rabbit 989 was used to probe the parasites 
which were counter-stained with DAPI (2.5.7). Figure 4 shows that 
trophozoite and schizont stage parasites cross-react most strongly with the 
immune sera. Ring stage parasites also cross-react with the immune sera, 
but to a lesser extent. The pre-immune sera failed to cross-react with any 
intraerythrocytic parasite stage. This result corroborates the western blot 
analysis data shown in Figure 2 that indicated that PfTopoll levels are far 
lower in ring stage parasites. 
4.6 PfTopoll activity can be immunodepleted. 
The same antiserum was also tested for its ability to inhibit the 
decatenation activity of parasite extracts. As can be seen in figure 5, the 
decatenation activity derived from unsynchronised populations of 
parasites was completely inhibited following exposure to antiserum at 
dilutions of 1:100 and 1:500; with activity reappearing at 1:2000. Pre-
immune serum from the same rabbit had no inhibitory effect at the same 
dilutions. The same antiserum however, failed to inhibit the 




Decatenation activity assay of immunodepleted parasite extract from 
unsynchronised parasites using KDNA as substrate. Lane 1, negative 
control; KDNA without parasite extract. Lane 2, positive control KDNA 
with parasite extract. Lanes 3-5, parasite extract with pre-immune serum 
diluted at 1:100, 1:500 and 1:2000 respectively. Lanes 6-8, parasite extract 
with immune serum diluted at 1:100, 1:500 and 1:2000 respectively. The 
lower arrow indicates the position of the covalently closed circular 
reaction product (CCC) and the upper arrow indicates the position of the 
open circular reaction product (OC). 
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4.7 Discussion. 
An analysis of the stage-specific expression of the gene encoding 
topoisomerase II of the human malarial parasite, P. falcipa rum, during 
the intraerythrocytic developmental stages has been conducted. Nuclear 
run-on analysis (conducted by Dr. Paul Horrocks) indicates that the 
PfTOP2 promoter is active at low levels in the stages which follow upon 
invasion of the red blood cell, but that activity increases markedly as the 
parasite progresses into the latter stages of development (trophozoites and 
schizonts). In this respect its pattern of activity is intermediate between 
the promoters of PfDNAPol5 and PfTopol which are both inactive in rings 
but active in trophozoites/schizonts stages. This is in contrast to PfPCNA, 
the promoter activity of which is similar in rings and 
trophozoites/schizont stage parasites (Horrocks et al., 1996). 
The steady state accumulation of PfTOP2 transcripts reflects the pattern of 
promoter activity, but the picture is complicated by the presence of three 
distinct transcripts at approximately 6, 7 and 8kb. The major 6kb PfTOP2 
transcript alone, is detectable in ring stage parasites at very low levels. All 
three transcripts are present in trophozoites, but all are completely absent 
from schizont-derived RNA. This absence is not attributable to a failure of 
the RNA to transfer to the membrane from the gel: the behaviour of the 
Actin I probe suggests that approximately equal amounts of RNA have 
been loaded for each lane and successfully transferred. Multiple 
transcripts of P. falciparuni are not unknown, indeed the PfPCNA gene 
encodes two transcripts of 1.85 and 2.2 kb (Horrocks et al., 1996). The 3.8 
gene also expresses two polymorphic messages (Lanzer et al.,1992). 
This raises interesting questions concerning where transcription initiates 
and terminates in the PfTOP2 gene. Time constraints have precluded a 
study of the untranslated flanking regions of this gene, however. 
DNA synthesis in the asexual parasite starts at the trophozoite stage, the 
same stage at which we have shown that peak accumulation of PfTOP2 
transcripts also occur. Similar findings have been reported for Drosophila, 
where, during early embryogenesis and pupation, stages which have a 
high mitotic index, Topoll transcript production also increases (Fairman 
and Brutlag 1988). 
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The relative quantities of enzyme have also been determined immuno-
logically, and again, low levels of protein (on a per parasite basis) are 
present in rings, but increasing amounts appear in trophozoites and 
schizonts. A triplet of bands (160/175 kDa) was detected by the antiserum 
on western blots of size fractionated trophozoite and schizont extracts, but 
only the largest of the bands is unambiguously detectable in the ring stage 
parasite extracts. Triplets of bands have also been reported in 
topoisomerase II westerns derived from other species. In Drosophila, for 
example, bands of 132, 145 and 166 kDa were reported to coincide with the 
onset of early embryogenesis and pupation (Heller et al.,1985). In addition, 
Sander and Hsieh (1983) reported that all three of these polypeptides were 
active. It is possible that the two smaller bands represent partially 
degraded forms of the full length protein or may be the products of 
differential post-translation modification. What is possibly surprising is 
that the levels of immunologically detectable PfTopoll persist into 
schizogony after the mRNA has ceased to be detectable. A similar 
situation pertains to the major DNA polymerase, PfDNA Po18. It appears 
that several of the replication proteins are produced in sufficient 
quantities at the trophozoite stage, and are stable enough, to satisfy the 
requirements of DNA replication during schizogony without being 
renewed. 
Decatenation assays, which are a definitive test for type II topoisomerase 
activity, have shown that activity increases as the parasite progresses from 
the trophozoite into the schizont developmental stage, although there 
appears to be very little difference in protein levels. Post-translational 
modifications are known to play a role in the control of topoisomerase II 
activity and phosphorylation by casein kinase II specifically targets the 
species-divergent carboxyterminal domain of the enzyme in yeast 
(Cardenas et al., 1992). Phosphorylation acts as a regulator of many 
eukaryotic gene functions and it has also been shown to enhance the 
topoisomerase relaxation activity in Drosophila (Ackerman et al., 1985). 
In contrast, poly-ADP-ribosylation appears to be an inhibitor of 
topoisomerase II in a number of species (Darby et aL,1985 and Scovassi et 
al., 1993). Further study of PfTopoll will be required to determine whether 
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the enzyme is subjected to similar post-translational modifications. 
The same polyclonal antiserum was also found to be proficient at 
inhibiting the decatenation activity of parasite extracts; a property not 
shared by pre-immune serum derived from the same rabbit. In contrast, 
the decatenation activity of human Topoll a, following treatment with 
the same antiserum, was completely unaffected (data not shown). This 
result corroborates previous evidence (western blot and IFA data) 




Expression of PfTopoisomerase II in baculovirus-infected insect cells. 
5.1 Introduction. 
There are several potential advantages to choosing baculovirus as a 
means to express foreign proteins. Firstly, the baculovirus expression 
system is tailored for high level expression of eukaryotic genes and large 
open reading frames are easily accommodated. Because gene expression 
occurs within an insect cell environment, most of the common post-
translational modifications to proteins that are known to occur in 
eukaryotes appear to be carried out in this system (eg. phosphorylation, 
signal peptide cleavage and glycosylation). This is an advantage over 
prokaryotic expression systems which may not make the appropriate 
modifications to eukaryotic gene products (O'Reilly 1992). 
The circumsporozoite protein (amino acids 1-412) of P. falcipa rum and the 
major ookinete surface protein of Plasmodium berghei (Pbs21) have both 
been expressed in baculovirus (Jacobs et at., 1991 and Matsuoka et al., 1996) 
and more recently, falcipain, a cysteine protease involved in haemoglobin 
degradation, has also been functionally expressed (Salas et al., 1995) 
demonstrating the utility of the system in the case of P. falciparum 
proteins. Full length PfPCNA has also been successfully expressed in our 
laboratory (White, J.W.-unpublished results). In addition, expression of 
human topoisomerase I in baculovirus gave rise to a 100-fold increase in 
expression compared to human cell lines, and the recombinant protein 
was found to be biochemically indistinguishible from the native enzyme 
(Zhelkovsky and Moore 1994) indicating that the system may be useful for 
the functional expression of topoisomerases. 
Background to the baculovirus expression system 
Baculoviruses (family Baculoviridae) belong to a diverse group of DNA 
viruses that infect many different species of insect. They are however, 
highly species specific and can only infect their natural host. Autographica 
cat ifonica nuclear polyhedrin virus (Ac.NPV) infects Spodoptera 
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frugiperda (fall army worm) insect cells. 
Progress of the infection in cell culture. 
The infection cycle follows three distinct phases: (1) early, (2) late and, (3) 
the very late phases. Briefly these correspond to (1) reprogramming the 
cell for virus replication, (2) production of budded virus particles and, (3) 
production of occluded viruses. 
In phase 1 (0-6 hours) the budded form of the virus enters the insect cell 
by adsorptive endocytosis and migrates into the nucleus. Once inside the 
nucleus, the viral core appears to be released from the"capped" end of the 
capsid. Viral RNA can be detected within 30 minutes of the virus being 
adsorbed into the insect cell. This indicates that movement of viral DNA 
to the nucleus and the initiation of viral transcription are rapid processes. 
Cytoskeletal rearrangements, cytoplasmic, and nuclear changes also occur 
during this phase which appears to be mediated by the components of the 
viral inoculum and the viral proteins expressed from early viral genes. 
The late phase of the infection (phase 2) starts around 6 hours post 
infection (p.i) and lasts up to 20-24 hours. This phase involves a period of 
intense viral DNA replication, late gene expression, and budded virus 
production. Progeny nucleocapsids leave the nucleus, possibly by a variety 
of routes and travel through the cytoplasm to the cytoplasmic membrane 
where they bud off individually. 
The very late phase (Phase 3), starts around 20-24 hours (p.i). Virus 
particles start to become embedded in a homogenous matrix of 
polyhedrin protein in the insect cell nucleus during this time. These 
viruses are called occluded virus particles (OV) and are released upon cell 
lysis during the late phase of the cycle. The polyhedrin protein is essential 
for the transmission of the virus, but expression of the protein is not 
necessary for virus survival under cell culture conditions. The OV bodies 
protect the virus from environmental inactivation (for example 
desiccation) prior to transmission to the insect larvae which become 
infected when they consume the OV during feeding. The virus is released 
under the alkaline conditions of the insect gut when ingested. 
The Baculogold system (Pharmingen) uses a baculovirus containing a 
lethal deletion which can be rescued when it recombines homologously 
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with a transfer vector containing the foreign gene when the virus and the 
transfer vector are present together inside the insect cell. Expression of the 
gene of interest is driven by a strong viral promoter [eg. the polyhedrin 
promoter, (polh)]. Inactivation of the polh gene by deletion or insertional 
activation of a foreign gene gives an occlusion body negative phenotype 
(occ-). This phenotype is readily distinguishible from the wild type occ 
baculovirus under the microscope and thus provides a marker with 
which to select recombinant baculoviruses. 
The polh promoter was used to drive expression of the PfTOP2 gene. It 
and was chosen not only because of the ease of selection for recombinant 
viruses, but also because it is expressed very late in the infection (16/18 
hours p.i.) when host cell gene expression has been shut down. In 
addition, this promoter has been reported in some instances to drive 
expression of foreign proteins to levels of up to 20-50% of total cell 
protein. 
5.2 Engineering the PfTOP2 gene for expression in baculovirus. 
The open reading frame of the PfTOP2 gene consists of five overlapping 
genomic clones (figure 1). In order to obtain one continous open reading 
frame that had unique 5' and 3' restriction sites compatible with the 
baculovirus transfer vector it was necessary to re-engineer the gene 
For some baculovirus genes, the context of the AUG translation initiation 
codon appears to be important for expression. For example, an A is often 
found in the -3 position and pyrimidines often appear at positions -1 and 
+5. Table 1 summerises this. Also the absence of a G in the seven 
nucleotides immediately preceding the AUG appears to be preferred. 
Although it is recognised that these rules may not be absolute, they do 
provide useful guidelines (O'Reilly 1992). 
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Figure 1. Diagrammatic representation of the PfTOP2 gene with selected 
restriction sites. 
Table 1. The AUG context of the baculovirus polh and p10 genes. 
Gene AUG context 
polh CCUAUAAAUAUGCCGG 
plO UUUACAAUCAUGUCAA 
Consensus A Y Y 
Position -3 -1 +5 
Taking these factors into account, the context of the AUG was changed to 
incorporate these features into the 5' oligonucleotide [Figure 3 (a and b)]. 
It was necessary to construct the PfTOP2 ORE using two different vectors 
(pUC19 and pUBS1) because two Pstl and BamHI sites are present in the 
gene. 
The ATG to Hin dill fragment of the PfTOP2 gene (figure 2) was 
constructed as follows. The 5' genomic clone pUC3/1 ([figure 1] Cheesman 
et al., 1994), was used as a template for a PCR using the oligonucleotides 
G6166/G6165. A PCR product of 1030 bp was isolated, purified and 
restricted with Kpnl and Pstl and ligated into pUC19 (Yanisch-Perron et 
al., 1985) containing the Pstl/ Hin dIll fragment of the gene. 
The remainder of the gene encompassing the Hin dill to TAA fragment 
(figure 2) was constructed by restricting the genomic clone pUBS 7 ([figure 
1] Cheesman et al., 1994) with Hindlil and BamHI and subcloning the 
fragment into vector pUBSi. The distal BamHI to TAA fragment was 
made using pUC 6 ([figure 1] Cheesman et al., 1994) as a PCR template to 
amplify this region using the oligonucleotides 445Y/G5626. A 1376 bp PCR 
fragment was isolated, purified and restricted with BarnHI and Sad, then 
cloned into pUBS containing the Hindlll/BarnHI fragment. 
The complete Kpnl/Sacl fragment (figure 2) was restricted with BglII 
which cuts just inside the Kpnl and Sacl sites to remove the entire ORF 
which was subcloned into the baculovirus transfer vector pVL1393 figures 
4 and 5). Recombinant plasmids were screened to ensure correct 




t I BamH I Hind III 
ATG 
G6165 G5626 
HindIl l BamHI :171iI Sac]   
-- 
PCR fragment genomic fragment PCR fragment 
- 
Figure 2. Strategy used to engineer the five genomic PfTOP2 clones into one continuous open reading 
frame for expression in baculovirus. Top diagram represents the PfTOP2 gene and shows the positions of 
the amplifying oligonucleotides G6166/G6165 and 445Y/G5626. Bottom diagram represents the modified 
PfTOP2 open reading frame in pUBS 1. 
The 5' Kpnl/Pstl fragment was made by PCR amplification using oligonucleotides G6166 and G6165. The 
3' BarnHI/Sacl fragment was made by PCR amplification of oligonucleotides 445Y and G5626. Both 
fragments were sequenced to ensure that no PCR introduced mutations had arisen. The 5' Kpnl/Pstl 
fragment was restricted and subcloned into pUBS 1 containing the Pstl/Hindlll genomic fragment. The 
3' BarnHI/Sacl fragment was restricted and subcloned into pUC19 containing the Hindlll/BamHI 
genomic fragment. The HindlIllSacl fragment was restricted and subcloned into pUBS 1 containing the 
Kpnl/Hindlll fragment. The complete gene cassette was excised as a BglII fragment and subcloned into 
the baculovirus transfer vector pVL1393 (figures 4 and 5) for expression. 
PfTOP2 sequence 
r 
5' ctcaaggtaccagatctataaacatggcgaaaaataaaact 3' 
Kpnl BglH - 3 -1 +5 
Figure 3 (a) Sequence of the 5' oligonucleotide G6166 that was used to amplify and 
introduce unique restriction sites into the 5' end of the gene. Sense PfTOP2 
nucleotides are shown in bold. The adenosine at position -3 and the cytosine at -1 
were incorporated to conform to the baculovirus polh and plO AUG consensus 
sequence. 
5' taatcttgaaccataaatttctagactcgagccatcg 3' 
B gill Sad 
Figure 3 (b) Sequence of the 3' oligonucleotide G5626 that was used to amplify and 
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Figure 4. Plasmid map of the baculovirus transfer vector pVL1393. The 
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Figure 5. Diagramatic representation of the baculovirus transfer vector pVL1393 polylinker. 
The pu//i ATG is mutated to ATT, and the polylinker is located at position +35. The plasmid was designed this way 
because it was thought that sequences downstream from the poih ATG might contribute to optimal promoter activity 
(O'Reilly 1992). 
A brief summary of the steps involved in making the PfTOP2 ORF is 
shown in figure 2. 
5.3 Identification of recombinant baculoviruses from co-transfection of 
insect cells. 
5.3.1 Selection of candidate recombinant baculoviruses. 
The recombinant baculovirus transfer vector pVL1393 harbouring the 
PfTOP2 gene was used in conjunction with linearised BaculoGoldTM 
DNA to co-transfect S. frugiperda (Sf9) cells (2.3.10.1). Wild type AcNPV 
was also used to infect a parallel batch of Sf9 cells to provide an occ 
phenotype positive control. Sf9 cells were also seeded without virus to 
provide a negative control which could be used for comparison. 
Following incubation at 27°C for four days, co-transfected Sf9 cells were 
examined for signs of infection. Microscopic analysis revealed that the 
cells were enlarged, exhibited the 0cc- phenotype and many were floating 
freely in the medium; these signs are characteristic of baculoviral 
infection. Wild type infected cells also appeared enlarged but showed the 
occ phenotype. Supernatants from the co-transfection and wild type 
infection were harvested and stored at 4°C. 
Pure viral stocks were made from both viral sources as outlined in section 
2.3.10.2. This involved infecting Sf9 cells with viruses diluted at 10-5 to 10-
8 in insect cell medium and overlaying the infected cells with an agarose 
plaquing solution. After four days incubation distinct plaques were visible 
following staining of the agarose with neutral red dye. Six individual, 
well isolated candidate recombinant PfTOP2 baculovirus plaques were 
picked and 4 were used for amplifying the virus to an acceptably high titre 
stock (2.3.10.3). Amplification of the viruses gave titres in the order of 
around 5 X 107 to 5 X 108 pfu/ml. 
5.3.2 Identification of recombinant baculoviruses by Southern blot 
analaysis. 
Total recombinant virus-infected insect cell DNA was prepared from 2 
viruses (1A and 2A) together with a AcNPV and uninfected Sf9 cell 
control. These were restricted with B gill, Southern blotted (2.3.4) and 
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hybridised to a PfTOP2 specific oligonucleotide to establish whether any of 
the candidate viruses were harbouring the PfTOP2 gene. The results of the 
Southern blot analysis are shown in figure 6 which demonstrates that 
only candidate recombinant baculovirus DNA hybridises to the probe. No 
cross-hybridisation of the probe to DNA derived from the unfected or 
AcNPV infected cells was observed. 
5.4 Primary characterisation of recombinant PfTOP2 baculovirus 
expression. 
In order to monitor expression of the PfTOP2 gene, Sf9 cells were infected 
for variable periods of time (0-72 hours p.i.) with recombinant 
baculoviruses 1A and 2A. Total protein synthesis was monitored by 
preparing whole cell extracts (2.5.4.3) that were analysed by SDS-PAGE 
fractionation and Coomassie blue staining. Using this method of 
detection, no evidence of gene expression was observed, however. 
Western blot analysis of whole cell extracts was performed to establish 
whether any recombinant PfTopoll was being produced. This was done in 
an attempt to increase the sensitivity and specificity of detection of the 
recombinant protein, in the event that it was being produced in very 
small quantities. Polyclonal antiserum raised against the N-terminal 
domain of PfTopoll as a GST fusion protein (Cheesman et al., 1994) was 
used for analysis of whole cell extracts size fractionated by SDS-PAGE and 
western blotted to nitrocellulose. This antiserum did not cross-react with 
proteins derived from recombinant or wild type virus infected cells, 
however. At this point the polyclonal antiserum raised against the 
carboxyterminal region of PfTopoll that was discussed in Chapter 3 had 
not been made. 
5.5 Northern blot analysis of recombinant baculoviruses. 
Northern analysis of recombinant baculoviruses was used as a means to 
establish whether the PfTOP2 gene was being transcribed by the polh 
promoter in vivo as there were no obvious signs of protein expression. 
20 tg of total RNA extracted from insect cells infected with wild type or 
recombinant PfTOP2 baculoviruses 1A and 2A for periods of 24 and 48 
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Figure 6. 
Southern blot of total DNA isolated from Sf9 insect cells. The DNA was 
restricted with Bgill, size fractionated on a 1% agarose gel, and blotted to 
Genescreen Plus membrane. The PfTOP2 positive control was derived 
from a restriction digest of the PfTOP2 gene in transfer vector pVL1393. 
The prehybridised membrane was probed using a PfTOP2 specific 
oligonucleotide (8565). 
Lane 1. Genomic DNA isolated from uninfected Sf9 insect cells. Lane 2. 
Total DNA isolated from wild type virus (AcNPV) infected Sf9 cells 
(negative control). Lane 3. PfTOP2 gene (positive control). Lane 4. Total 
DNA isolated from recombinant baculovirus 1A infected Sf9 cells. Lane 5. 
Total DNA isolated from recombinant baculovirus 2A infected Sf9 cells. 
The positions of the B gill fragments are indicated. 
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Figure 7. 
Northern blot analysis of total RNA extracted from insect cells harboring 
recombinant PfTOP2 or wild type baculovirus. 
Panel a. Ethidium bromide stained formaldehyde gel prior to northern 
blotting. Lane 1; wild type baculovirus at 24 hours post-infection (p.i.). 
Lane 2; recombinant PfTOP2 baculovirus 1A at 24 hours p.i. Lane 3; 
recombinant PfTOP2 baculovirus 2A at 24 hours p.i. Lane 4; recombinant 
PfTOP2 baculovirus 2A at 48 hours p.i. 
Panel b. Northern blot of the ethidium bromide stained formaldehyde gel 
shown in Panel a, probed with the 5' Kpnl/Pstl 1030 bp fragment of the 
PfTOP2 gene. The position of the 5 kb transcript is indicated. 
Panel c. The same northern blot as shown in Panel b, after stripping and 
reprobing with the 3' BaniHi/Saci 1376 bp fragment of the PfTOP2 gene. 
The position of the 5 kb transcript is indicated. 
The positions of the RNA size standards are indicted in kilobases. 
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hours as described in section 2.4.3 was size fractionated and blotted to a 
Genescreen Plus membrane. The northern blot was hybridised to the 32P 
random-labelled 1030 bp 5' Kpnl/Pstl fragment of the PfTOP2 gene (figure 
2), unbound probe was removed by washing and the membrane exposed 
to film. 
No hybridisation of this probe to the wild type baculovirus RNA was 
observed (figure 7 b-lane 1). However, a prominant band of approximately 
5 kb was detected by this probe in in all recombinant baculoviral RNA 
preparations (figure 7 b - lanes 2, 3 and 4). It is probable that the 5 kb signal 
represents the full length recombinant PfTOP2 mRNA as its size is 
consistent with that anticipated from the ORF of the gene (4191 bp). 
Several other highly abundant lower molecular weight polymorphic 
transcripts are also recognised by this probe but only in recombinant 
preparations. The same northern blot was stripped and exposed to film to 
ensure that all bound probe was removed. The blot was then reprobed 
with the 32P  random-labelled 3' end of the PfTOP2 gene (1376 bp 
BamHI/Sacl fragment- see figure 2) This probe also failed to hybridise to 
wild type baculovirus mRNA, but recognised the same 5 kb transcript in 
all of the recombinant RNA preparations. A similar pattern of lower 
molecular weight abundant polymorphic transcripts were also seen to 
hybridise to this 3' probe (figure 7 c). 
Figure 7 (a) shows the ethidium bromide stained formaldehyde gel prior 
to northern blotting. There is some evidence of DNA contamination in 
the samples, as testified by the presence of ethidium bromide staining 
material in the wells. Additionally there is also some "smearing" of the 
RNA samples, and the ratios of the 28S and 18S ribosomal RNA bands are 
unequal, suggesting that there may be some RNA degradation. In order to 
determine whether this "smearing" effect could be the result of DNA 
contamination of the samples, they were DNase I treated. DNase I 
treatment decreased the level of ethidium stained material observed in 
the wells (result not shown). UV spectrophotometry of the RNA samples 
showed that the quantity and quality of each of the samples were within 
normal limits. The 0D260/0D280 ratio were between 1.9 - 2.0 suggesting 
that the samples were not contaminated with residual phenol or protein. 
153 
In addition the 0D230, which is a measure of salt contamination was also 
within normal limits. 
5.6 Time course analysis of protein production from a recombinant 
PfTOP2 baculovirus. 
Western blot analysis (7% SDS polyacrylamide gel) of total protein from 
whole cell extracts (equal numbers of cells) infected with recombinant 
baculovirus 1A at time points of 18, 20, 22 and 24 hours was conducted 
(figure 8). This time, polyclonal antiserum directed against the species 
divergent carboxyterminal domain of PfTopoll was available and was 
used at a dilution of 1:1000. - 
A triplet of proteins of around 160/175 kDa was detected by this antiserum 
in recombinant cell extracts only. Additional lower molecular weight 
proteins were also recognised by this antiserum. Two of these proteins 
cross-reacted with the uninfected Sf9 control, and one with the wild type 
control. The low molecular weight proteins may be the products of in 
vivo proteolysis or may be the result of proteolysis occuring as the cells 
are lysed. The latter possibility seems less likely as the cells were lysed 
using SDS-.PAGE loading buffer. 
These results indicate that recombinant PfTopoll is being produced in 
baculovirus, albeit in very small quantities. 
5.7 Recombinant PfTopoll can be immunoprecipitated. 
1 X 106 insect cells were infected with recombinant baculovirus 1A for 
periods of 24 and 48 hours or a wild type baculovirus control for 48 hours 
A "mock infected" negative control also containing 1 X 106 uninfected 
insect cells was also set up. The cells were transferred to methionine-
deficient medium two hours before harvesting to deplete endogenous 
pools of the amino acid before pulse labelling. [35S] methionine was added 
one hour after being transferred to the methionine-deficient medium 
(2.5.8.1). 
Cell lysates were precleared using pre-immune rabbit serum before 
incubating with immune serum obtained from the same rabbit (directed 
against the species divergent carboxyterminal domain of PfTopoll) for 3 
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Figure 8. 
Western blot of total protein harvested from recombinant baculovirus 
infected Sf9 insect cells at 18, 20, 22 and 24 hours post infection (p.i.). 
The western blot was probed with a polyclonal antiserum directed against 
the C-terminal domain of PfTopoll at a dilution of 1:1000. Cross-reactive 
proteins were detected using anti-rabbit IgG-alkaline phosphatase 
conjugate at a dilution of 1:7500. 
Lane 1. Total protein isolated from uninfected Sf9 cells. Lanes 2, 3, 4 and 5. 
Total protein isolated from Sf9 cells infected with recombinant 
baculovirus 1A for 18, 20, 22 and 24 hours. Lane 6. Total protein isolated 
from wild type (AcNPV) baculovirus infected Sf9 cells at 24 hours p.i. 
The position of the protein size standards are indicated. The positions of 
the triplet of PfTopoll antibody cross-reactive proteins are marked. 
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Immunoprecipitation of recombinant PfTopoll from baculovirus infected 
Sf9 insect cells metabolically labelled with 35S methionine. 
Lanes 1 and 2. Recombinant baculovirus 1A at 24 and 48 hours post 
infection (p.i.). Lane 3 Wild type baculovirus at 48 hours p.1. Lane 4. 
Uninfected Sf9 insect cells. 
The position of the protein size standards are indicated. 




Lane 1 2 4 
hours to facilitate formation of the antibody-antigen complex. Immune 
complexes were precipitated using Protein A Sepharose (2.5.8.3) and size 
fractionated using SDS-PAGE with a 7% gel and the largest size gel plates 
available (250mm X 200mm), the gel dried and exposed to film. 
Figure 9 shows that a triplet of signals in the size range of 150-175 kDa are 
present in the recombinant PfTOP2 baculovirus sample; these are not 
present in the wild type control sample, nor are they present in the 
uninfected insect cell sample. Other lower molecular weight bands which 
may represent proteolytic fragments of the full length protein are also 
present. 
This result provides further evidence that recombinant PfTopoll is 
expressed in baculovirus. 
5.8 Re-engineering of the PfTOP2 gene to incorporate a 3' affinity tag to 
facilitate protein purification. 
Attempts were not made to purify recombinant PfTopoll due to the very 
low level of expression observed. Instead, it was decided to clone the gene 
into the baculovirus transfer vector pAcSG His, which encodes an N-
terminal hexahistidine tag which should make it possible to affinity 
purify the recombinant protein. This should simplify purification of the 
under-expressed recombinant protein from large scale cultures. 
It proved impossible to clone the PfTOP2 into this vector, however, so an 
alternative strategy was adopted to incorporate a 3' hexahistidine tag into 
the protein. This involved amplifying the 3' BamHI to TAA fragment of 
the gene as described previously (figure 2) using the sense oligonucleotide 
445Y, but this time using an antisense oligonucleotide encoding 6 
histidine residues immediately downstream of a thrombin cleavage site 
next to the last PfTOP2 codon. This was followed by a stop codon and B gill 
and SacI restriction sites. The PCR product was cloned following the same 
strategy as before (figure 2) into the baculovirus transfer vector pVL1393. 
Diagram 4.8 shows a plan of the modifications made to the gene to 
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Diagram 4.8. Plan of the PfTOP2 gene modified to 
express a C- terminal hexahistine tag downstream of 
a thrombin cleavage site. 
5.9 Identification of recombinant PfTOP2-His baculoviruses. 
Following successful co-transfection of Sf9 insect cells, clonal selection 
(2.3.10.2) and viral amplification (2.3.10.3), candidate recombinant 
baculoviruses were analysed for the presence of the PfTOP2 gene by 
restriction analysis and Southern blotting (results not shown). Two 
recombinant baculoviruses (3/1 and 4/1) yielded high titre viral stocks (1 
X 109 pfu/ml). Northern blot analysis and immunoprecipitation were not 
conducted this time. Recombinant baculovirus 4/1-His was found to 
express the same protein triplet as the untagged baculoviruses 1A and 2A 
(evaluated by western blotting and probing with anti-PfTopoll serum), 
and was subsequently used for all affinity purification work. 
5.10 Affinity purification of recombinant PfTopoll-His. 
5.10.1. Imidazole step purification of recombinant protein. 
Metal chelate affinity chromatography can be used as a means to purify 
hexahistidine tagged proteins. An immobilised gel matrix is charged with 
nickel ions to form a chelate. Proteins containing surface polyhistidine 
residues have a high affinity for the metal chelate and will bind strongly 
to the matrix. The adsorbed proteins can be removed by competitive 
elution using imidazole, or by lowering the pH of the elution buffer. 
Whole cells extracts, prepared from 250 ml of Sf9 cells (2.5 X 108 cells) 
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infected with recombinant baculovirus 4/1-His for a period of 48 hours 
were used for affinity purification (2.5.6) under non-denaturing 
conditions using a nickel column. In this case recombinant proteins were 
eluted in one step using 500mM imidazole. 
Figure 10 (a) shows the Coomassie blue stained gel following SDS-PAGE 
fractionation of the samples and also an identical SDS polyacrylamide gel 
following western blotting and probing with the C-terminal PfTopoll 
antiserum at a dilution of 1:1000 [figure 10 (b)]. 1 ml fractions were 
collected from the imidazole step elution and 40i.il samples of each were 
loaded onto each gel. Figure 10 (b), lane 2 shows that some proteins did 
not bind to the column and eluted in the flow through. Three distinct 
protein bands which co-migrate just below the 175 kDa size standard, 
along with some lower molecular weight bands can be observed. It is 
possible that these proteins did not bind to the column because the C-
terminal hexahistidine tag may have been conformationally hidden or 
degraded. 
Fractions 2 and 3 (Figure 10 b, lanes 5 and 6) from the imidazole eluant 
reveal two bands of approximately the size expected for recombinant 
PfTopoll (175/160 kDa). Several other bands of lower molecular weight 
also elute in fractions 2 and 3, the most striking of which are about 30 kDa 
in size. These proteins are most likely to be the products of N-terminal 
proteolysis of the recombinant protein because they are detected by the 
PfTopoll C-terminal antibody. 
This purification procedure was repeated at least twice and similar results 
were obtained each time (data not shown). In addition, fractions 2 and 3 
(lanes 5 and 6) were tested for evidence of recombinant PfTopoll enzyme 
activity using standard decatenation assay tests. Following dialysis against 
Topoll assay buffer to remove excess imidazole and salt, fraction 2 (lane 5) 
was found to contain a low level of activity (results not shown). 
5.10.2 Gradient purification of recombinant protein. 
An imidazole gradient elution purification was used in an attempt to 
obtain full length recombinant PfTopoll that is free of the hexahistidine 
tagged contaminating proteins of lower mobility (2.5.6). 
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Figure 10. 
Affinity purification of recombinant PfTopoll-His. 
Whole cell extracts from Sf9 insect cells infected with recombinant 
PfTOP2 baculovirus 4/1-His were loaded onto a nickel chelating column 
(Pharmacia) under non-denaturing conditions. Hexahistidine-tagged 
proteins were eluted in one 500mM imidazole step. 
Panel a. Coomassie blue stained SDS-polyacrylamide gel of affinity 
purified recombinant PfTopoll-His. 
Lane 1. Protein size standards. Lane 2. Unbound proteins. Lane 3. Column 
wash fraction 1. Lane 4. Column wash fraction 2. Lanes 5-12. 500mM 
imidazole eluted proteins (fractions 1-7). 
Panel b. Western blot of affinity purification shown in Panel a probed 
with anti-PfTopoll C- terminal serum. 
Lane 1. Protein size standards. Lane 2. Unbound proteins. Lane 3. Column 
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In this case, 1 litre (1 X 109) of infected cells Sf9 were used to prepare cell 
extracts. Proteins eluted from a gradient of 0-500mM imidazole were size 
fractionated using SDS-PAGE. One SDS-polyacrylamide gel was stained 
with coomassie blue and an identical gel was western blotted and probed 
with the same antisera used in section 5.10.1 at a dilution of 1:1000. 
Figure 11 shows the result of this experiment. Coomassie blue staining 
revealed the presence of some protein bands in fractions 2 and 3 and 4 
from the imidazole gradient (figure 11 a, lanes 5, 6 and 7). Western 
blotting shows that several proteins appear not to bind to the nickel 
column and elute in the flow through fraction (figure 11 b, lane 2). The 
pattern of these proteins is very similar to that obtained before (see figure 
10). The imidazole gradient elutes numerous PfTopoll C-terminal 
antibody cross-reacting proteins in lanes 5 and 6. This suggests that these 
proteins do not require a high concentration of imizazole to displace 
them from the nickel column. A doublet of proteins of approximately 160 
kDa are detected in fraction 2 of the imidazole gradient (Figure 11 b, lane 
5). Gradient purification was tried again several times to try to remove the 
lower molecular weight hexahistidine tagged proteins from full length 
recombinant PfTopoll but this was not possible. 
5.11 Analysis of enzyme activity. 
In order to establish whether the very small quantity of full length 
recombinant protein contained Topoll activity, fractions 1-6 (figure 11, 
lanes 4-9) from the imidazole gradient were tested (after removal of 
imidazole and salt by dialysis against Topoll assay buffer). 
200ng of KDNA was used for each decatenation assay, together with liii 
and 10il of each protein sample (2.9.3). As can be seen in Figure 12 (a), a 
low level of activity can be detected in almost all of the reactions 
containing 10.1 of protein from each fraction. 
This suggest that a co-purifying insect cell or viral encoded type II 
topoisomerase activity may be contaminating some or all of the fractions. 
In order to test for this possibility, a parallel experiment was conducted 
using an imidazole gradient to "mock" purify a non-histidine tagged 
recombinant baculovirus expressing P. falciparum DNA polymerase 
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Figure 11. 
Affinity purification of recombinant PfTopoll-His using an imidazole 
gradient. 
Whole cell extracts from Sf9 insect cells infected with recombinant 
PfTOP2 baculovirus 4/1-His were loaded onto a nickel chelating column 
(Pharmacia) under non-denaturing conditions. Hexahistidine tagged 
proteins were eluted using a gradient of 0-500mM imidazole. 
Panel a. Coomassie blue stained SDS-polyacrylamide gel of affinity 
purification. 
Lane 1. Protein size standards. Lane 2. Unbound proteins. Lane 3. Column 
wash fraction 1. Lanes 4-9. 0-500mM imidazole gradient (fractions 1-6). 
Panel b. Western blot of affinity purification shown in Panel a probed 
with anti-PfTopoll C-terminal serum. 
Lane 1. Protein size standards. Lane 2. Unbound proteins. Lane 3. Column 



















(PfPo18). Identical fractions were collected from the imidazole gradient, 
thus allowing a reasonably accurate comparison to be made between the 
hisidine-tagged PfTopoll fractions and the recombinant PfPo18. fractions. 
Figure 12 (b) shows the results of a decatenation assay conducted using 
"mock purified" recombinant PfPo18. The same amount of KDNA and 
protein were used as before, after imidazole and salt removal. As can be 
seen from a comparison of figure 12 (a) and (b), a similar profile of activity 
is apparent in each experiment. This strongly suggests that most, if not all, 
of the activity seen in recombinant PfTopoll preparations probably 
originates from the insect cell. 
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Figure 12. 
Panel a. Decatenation assay using recombinant PfTopoll-His 
Decatenation assay using 200ng of kinetoplast DNA (KDNA) and protein 
from fractions 1-6 of an imidazole gradient purification of recombinant 
PfTopoll-His. 1 and 10il of protein were drop dialysed to remove 
imidazole and salt contamination prior to conducting the assays. 
Lane 1. Assay conducted without protein. Lanes 2 and 3. Assays conducted 
on protein from fraction 1 of the gradient. Lanes 4 and 5. Assays 
conducted on protein from fraction 2 of the gradient. Lanes 6 and 7. 
Assays conducted on protein from fraction 3 of the gradient. Lanes 8 and 
9. Assays conducted on protein from fraction 4 of the gradient. Lanes 10 
and 11. Assays conducted on protein from fraction 5 of the gradient. Lanes 
12 and 13. Assays conducted on protein from fraction 6 of the gradient. 
Even numbered lanes contain assays conducted with 11.d of protein and 
odd numbered lanes contain assays conducted with 10il of protein. 
The positions of the open circular (OC) and covalently closed circular 
(CCC) DNA species are indicated. 
Panel b. Decatenation assay using recombinant PfPol 8 without a His tag. 
Decatenation assay using 200ng of kinetop last DNA (KDNA) and protein 
from fractions 1-6 of an imidazole gradient purification of recombinant 
PfPo1 o. 1 and 101 of protein were drop dialysed to remove imidazole and 
salt contamination prior to conducting the assays. 
The legend for this experiment is the same as shown in Panel a above. 
The positions of the open circular (OC) and covalently closed circular 
(CCC) DNA species are indicated. 
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5.12 Discussion. 
Heterologous expression of PfTopoll in baculovirus-infected Sf9 insect cell 
lines has been undertaken in an attempt to purify enough of the 
recombinant enzyme to facilitate biochemical analysis. 
Coomassie-stained SDS-polyacrylamide gels using whole cell lysates from 
insect cells infected with recombinant PfTOP2 baculoviruses did not 
reveal any novel proteins which were within the expected size range for 
recombinant PfTopoll. This indicated that (i) the protein was not being 
expressed, or (ii) the protein was expressed in very small quanitities, or 
(iii) the protein was undergoing rapid in vivo proteolysis. 
In order to investigate whether transcription of the PfTOP2 gene was 
occuring, total RNA was isolated and analysed by northern blotting. This 
technique revealed that a prominent transcript of around 5 kb was being 
made; a size that is consistent with the size of the PfTOP2 ORF of 4191 bp 
(if allowances are made for inclusion of a 5' leader and polyA tail). The 5 
kb transcript was identified by probing the same northern blot with the 5' 
and 3' ends of the PfTOP2 gene. These probes did not hybridise to mRNA 
derived from the wild type parent virus, confirming that the transcripts 
originate from the PfTOP2 gene. The presence of multiple abundant 
polymorphic transcripts derived from the recombinant PfTOP2 mRNA 
however, complicates the picture, but there may be an explanation for 
this. 
Late and very late baculoviral promoters (for example polh) have 
essential TAAG sequences from which mRNAs initiate. These TAAG 
sequences occur very infrequently in the AcNPV genome but some 
mapping of the sites has been done. For example, Garrity et al., (1997) 
have found five copies of the sequence in the upstream promoter region 
of the AcMNPV gp64 envelope fusion protein gene, although 
transcription is only detected from two of them. Vanstrien el al., (1996) 
have analysed the ubiquitin gene-cluster of the Spodeptera exigua 
nucleopolyhedrovirus (SeMNPV) and found that three major small 
transcripts were made late in the infection (400, 550 and 690 nt). Primer 
extension analysis showed that transcription started from two consensus 
late promoter elements (TAAG). Exactly what effect TAAG sequences 
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have on expression of foreign genes is difficult to predict, but their 
presence in either direction in the gene can reduce expression levels. For 
example, TAAG sequences in the sense direction may, depending upon 
their context, (which is presently unknown) cause transcription initiation 
within the gene. If on the other hand, CTTA sequences are present in the 
antisense direction, then formation of antisense transcripts might also 
occur. These could disrupt expression by causing the formation of a 
sense/antisense duplex transcript, thus leading to translational blocks 
(O'Reilly, 1992). 
The PfTOP2 gene has at least 19 TAAG motifs in the sense direction 
within the ORF. If any of these motifs are present in the appropriate 
context, then it is feasible that fortuitous transcription initiation could 
occur. It is also possible that PfTOP2 antisense transcripts may have been 
produced, but this possibility was not investigated. 
An alternative explanation is that RNA degradation is responsible for the 
presence of the highly abundant transcripts of less than 4 kb in size. 
Although we cannot completely eliminate this possibility, it seems 
unlikely for three reasons. Firstly the presence of the 5 kb transcript 
suggests that mRNA in this size range has not been degraded. Secondly, 
UV analysis indicates the the nucleic acid content appeared to be of high 
yield with no protein or salt contamination. Finally, discreet ribosomal 
RNA bands were present in the ethidium-stained gel following size 
fractionation. It is more difficult to understand why the 28S and 18S 
ribosomal bands are not present in equal amounts. At present it is not 
known whether baculovirus modifies the insect ribosomes during the 
course of its infection. 
Once the antiserum against the C-terminal portion of PfTopoll had 
become available it soon became apparent that recombinant PfTopoll was 
being produced as demonstrated by western blotting, and 
immunoprecipitation experiments. Both techniques showed that a 
characteristic triplet of proteins was produced of around 160/175 kDa, 
together with a somewhat larger protein. Similar protein triplets have 
been observed on western blots from parasites synchronised in ring, 
trophozoite and schizonts (chapter 4) using the same antiserum. 
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The fact that recombinant PfTopofl could not be detected by conventional 
protein staining techniques suggested that it was being made in very 
small quantities. Because of this, we decided to incorporate a 
hexahistidine affinity tag into the carboxy-terminus of PfTopoll to 
simplify protein purification and maximise yields. Nickel chelate 
chromatography purified a very small amount of full length PfTopoll. 
Fractions containing the recombinant protein were tested for their ability 
to decatenate kinetoplast DNA, which is a definitive test for a type II 
topoisomerase activity. Although enzyme activity was observed in some 
of the fractions recovered from the purification, it became clear that this 
was likely to be the result of a co-purifying insect cell activity after a 
parallel purification using a recombinant baculovirus expressing a 
different protein yielded similar results. 
It remains unclear why recombinant PfTopoll was produced in such a 
disappointingly low quantity but one possible explanation could be related 
to the TAAG motifs present in the gene, or another possibility is that the 
protein was toxic to the cell. PfPCNA, as mentioned previously, is a 
relatively small protein of some 30 kDa that has been successfully 
overexpressed in our laboratory using baculovirus. Analysis of the open 
reading frame in this case suggests that only two TAAG sequences are 
present in the sense direction. For small P.falciparum genes such as 
PfPCNA TAAG motifs may not occur frequently enough to cause 




Heterologous expression of P. falciparum topoisomerase II in S. 
cerevisiae. 
6.1 Introduction. 
The yeast S. cerevisiae is a very attractive system for the expression of 
foreign genes. Its genetics are more advanced than any other eukaryote 
with numerous temperature-sensitive mutants available that allow 
introduced sequences to be tested for their ability to complement the 
genetic defect. Other desirable features include its ease and safety of 
handling, together with the ability to grow rapidly on inexpensive 
medium. Most of the expression vectors in use today are based on the 2ji 
plasmid, and contain sequences that allow propagation in yeast and E. 
coli, as well as yeast promoter and terminator sequences. Although other 
yeasts are now routinely used for high level expression of foreign DNA 
sequences, (eg. the methyltroph Pichia pastoris), discussion of yeast in this 
chapter will be restricted to S. cerevisiae. 
Human Topoll a has been overexpressed in S. cerevisiae (Wasserman et 
al., 1993) and the 170 kDa recombinant enzyme is reported to be 
functionally indistinguishable from the authentic protein purified from 
HeLa cells. In addition, both a and 3 isoforms were able to complement 
yeast temperature sensitive t0p2 mutants which lack a functional 
topoisomerase II at the restrictive temperature (Wasserman et a!,, 1993 
and Meczes et al., 1997). Drug permeable, yeast t0p2 mutants were used to 
test known Topoll inhibitors against plasmid borne GALl inducible, 
Topoll a, Topoll 3 or yeast Topoll, thus providing a rapid method to 
analyse the differential drug sensitivity of each homologue (Meczes et al., 
1997). 
In view of the limited success we have experienced to date with 
heterologous expression of PfTopoll, we considered the possibility of 
adapting the yeast system used above as a feasible alternative to facilitate 
rapid screening of candidate PfTopoll inhibitors in vivo. We were 
initially concerned that there are few reported cases of successful 
overexpression of P. falciparum genes in S. cerevisiae, however, there are 
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a few examples where P. falciparuni sequences have been used 
successfully to complement S. cerevisicle temperature sensitive defects. 
For example, pyrimethamine and cycloguanil are compounds which have 
been used extensively to treat malaria, but rapid selection of populations 
of parasites which have developed resistance have compromised their 
effectiveness. Wooden et al., (1997) have used yeast temperature-
sensitive mutants that lack endogenous DHFR activity to investigate the 
frequency with which point mutations in the P. falciparum dihydrofolate 
reductase enzyme (PfDHFR) occur following exposure to the competitive 
inhibitors, pyrimethamine and cycloguanil. In this system, expression of 
the recombinant PfDHFR domain was controlled by the yeast dhfr 5' and 
3' regulatory regions, and the recombinant enzyme complemented the 
yeast defect. Yeast expressing recombinant PfDHFR are found to be 
sensitive to both of the drugs, at concentrations within the range that 
inhibit drug sensitive parasites in vivo. 
In a different study, yeast was used to develop a system for functional 
analysis of the pfindrl gene and its product, the Pghl protein, and to 
clarify its role as a transport molecule in drug resistance (Volkam et al., 
1995). Overexpression of the pfmdrl gene has been associated with the 
mefloquine-resistance and halofantrine-resistance phenotypes in P. 
falciparurn. The pfrndrl gene expressed in the yeast system was able to 
restore fertility to a sterile (ste6) mutant which lacked a functional 
exporter molecule for the a-factor pheromone. 
Both of these studies suggest that it is possible to express P.falciparum 
genes which are able to then rescue genetic defects in temperature-
sensitive yeast mutants. Encouraged by the success of these studies, we 
attempted heterologous expression of PfTopoll in S.cerevisiae strains 
engineered for overexpression, and in temperature-sensitive strains 
lacking a functional yeast Topoll at restrictive temperatures. 
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6.2 Construction of the PfTOP2 gene for expression in S. cerevisiae. 
To express the P. fcilciparuin TOP2 gene in yeast, the first four PfTOP2 
codons were replaced with the first five yeast TOP2 codons. This approach 
was based on earlier work of Wasserman et al., (1993) on the expression of 
human Topollcx in yeast. They demonstrated that by fusing the 29th codon 
of the human TOP2c gene, to the 5th codon of the yeast TOP2 gene, 
expression was improved. This improvement is probably related to the 
optimisation of the nucleotide sequences around the ATG codon. 
Several cloning steps were required to engineer the PfTOP2 gene for 
expression, including use of PCR to change the first four P. falciparum 
codons into the first five yeast Topoll codons. Figure 1 (a, b and c) outline 
the strategy that was used. The entire PfTOP2 cassette was excised as a 
SalI/Xhol fragment (figure ic) for subcloning into the yeast expression 
vector YEpWob6 (Figure 2, Wasserman et al., 1993). Numerous attempts 
to clone the coding sequence into YEpWob6 proved unsuccessful. The 
possibility that the gene is unstable in this particular vector led us to try to 
attempt to clone it into alternative vectors YCplac33 and YEplac195 [Figure 
3 (Geitz and Sugino, 1988)], but this approach also failed. 
At this stage we had no idea why the gene appeared to be unstable in all 
three of the vectors. We attempted to investigate this by ligating a Hindlil 
cassette containing a URA3 gene and 2 origin of replication (Gibbs et al., 
1993) into the vector pUBSi (pUBS/URA3). The GALl /PfTOP2 Sall/Xhol 
fragment from plasmid 218/PfTOP2 was subcloned into the Sa1I/Xhol site 
in pUBS/URA3. This procedure was conducted in pUBS because of the 
lack of suitable restriction sites in plasmid 218/PfTOP2. Very few 
transformants were recovered from these ligations, but in every case 
where the GALl /PfTOP2 insert was present, it was found that the URA3 
gene had been excised in vivo. This suggests that the PfTOP2 gene cannot 
co-exist on the same plasmid as the URA3 gene. 
Alternative selectable markers are available, and in an attempt to 
overcome this problem, the Sa1I/Xhol fragment containing the PfTOP2 
gene (218/PfTOP2, shown in figure 1 c) was subcloned into the Sail site of 












0 Wild type PfTOP2 sequence 899 
G6165 
Figure 1. 
Schematic of how the PfTOP2 gene was engineered for expression in S. 
cerevisiae. 
Sequence of the 5' oligonucleotide that was used to amplify the 5' 
end of the PfTOP2 gene. Unique Kpnl and BglII cloning sites are shown 
along with the 5 yeast codons that replace the first 4 PfTOP2 codons in 
the modified sequence. 
Sequence of the wild type PfTOP2 sequence that was used as a 
template for oligonucleotides H4535 and G6165. 
Figures 1 (a), (b) and (c). 
PfTOP2 gene fragments are highlighted in black in these diagrams. 
Schematic representation of the cloning steps involved in constructing 
the PfTOP2 gene into the penultimate cloning vector 218/PfTOP2. 
[shown in Fig.2 (c)]. Antibiotic resistance markers and plasmid orgin of 
replication are not shown. 
In figure 2 (a) the 5' end of the PfTOP2 gene following PCR was cloned 
as a Kpnl/Pstl fragment into plasmid 1 which already contained the 
Pstl/Hindffl fragment of the gene. 
In figure 2 (b) the Kpnl/Hindlll gene cassette was subcloned into 
Plasmid Cl making the entire PfTOP2 open reading frame. 
Figure 2 (c) The Bglll/Xhol fragment of the gene in plasmid C1/PfTOP2 
was subcloned into the BamHI/Xhol sites of Plasmid 218, to position 
the gene downstream of the GALl promoter. 
The pGAL1/PfTOP2 fragment (Sa1I/Xhol) in 218/PfTOP2 was excised 
ready to clone into the yeast expression vector YEpWOB6. 
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a) Construction of the 5' end of the PfTOP2 gene 
- 
Restrict the 5' PCR fragment with Kpnl/Pstl and clone into Plasmid 1. which 
already contains the Pstl/Hindffl fragment of the PfTOP2 gene 
Pstl 
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c) Fusion of the PfTOP2 gene to the GALl promoter in 
plasmid 218. 
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Physical map of the yeast/E.coli shuttle vector YEpWob6 that was used to 
express human Topoll a. In order to use this plasmid to express the 
PfTOP2 gene, the Sa1I/X7zol fragment containing the human Topoll a 
gene and GALl promoter was removed. 
Attempts to ligate the SalI/Xhol fragment containing the PfTOP2 gene 
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Physical maps of the yeast/E.coli shuttle vectors (Geitz and Sugino 1988) 
used for cloning of the PfTOP2 gene. 
The multiple cloning site (MCS) is based on pUC19 (Yanisch-Perron et al., 
1985) and contains the following restriction sites; HindllT, Sphl, Pstl, SalT, 
Xbal, BamHT, Smal, Kpnl, Sstl, and EcoRI. Each plasmid has a yeast 
origin of replication. YCp1ac33 is a centromeric plasmid containing a 
URA3 auxotrophic marker, YEp1ac195 and YEp1ac181 are episomal 
plasmids containing URA3 and LEU2 auxotrophic markers. 
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Sail and Xhol produce compatible sticky ends thus facilitating the cloning 
of the fragment into this vector which lacks an Xhol site. This approach 
was successful and the new construct was used for expression after 
sequencing of all the cloning borders and PCR amplified regions of the 
construct. 
6.3 Monitoring expression of the PfTOP2 gene. from a GALl promoter. 
6.3.1 Expression of PfTOP2 in JELl. 
The recombinant YEp1ac181/PfTOP2 expression plasmid was transformed 
into the protease-deficient yeast strain JELl (gift of Dr. Caroline Austin) 
for overexpression. The parental plasmid YEplac181, and YEpWob6 
containing the human Topoll a gene were also transformed into the same 
yeast strain to act as controls (2.3.6.4). 
Recombinant colonies were grown for 24 hours in yeast synthetic 
minimal medium with the appropriate amino acid supplements, 
including 2% glucose, 2% glycerol and 2% lactate as carbon sources. 5m1 of 
the culture was used to inoculate 9.5m1 of the same medium, but this 
time glucose was omitted to allow endogenous pools to be depleted before 
induction. After a further 24 hours when the 0D600 reached 0.59, the 
culture was induced with 2% galactose for a period of 4.5 hours (2.5.4.4). 
Initially, the choice of an appropriate 0D600 was based on the fact that the 
human Topoll a gene was only inducible in the range of 0.4-0.98. During 
the course of this work, a range of 0D600 between 0.2 and 1.0 were also 
tested. Yeast cultures were harvested and lysed in the presence of protease 
inhibitors and the lysates analysed by SDS-PAGE and Coomassie blue 
staining of the polyacrylamide gels. 
Figure 4 (a) shows the result of a typical experiment. A protein with 
apparent mobility of 170 kDa which is characteristic of expression of 
recombinant human Topoll a can be seen in lane 5. The expected size of 
recombinant PfTopoll is around 160 kDa, but no evidence of expression of 
a protein of this size was observed (figure 4, lane 3). A duplicate 
polyacrylamide gel was western blotted and probed with the PfTopoll C-
terminal antiserum. Figure 4 (b) shows that although there appears to be a 
band of approximately the right size for recombinant PfTopoll (-160 kDa), 
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Figure 4. (a). 
Total protein isolated from S. cerevisiae cultures was size fractionated 
using SDS-PAGE. The polyacrylamide gel was stained with Coomassie 
blue to visualise the protein bands. 
Lane 1 contains protein derived from a culture containing the parent 
vector YEplac181 without the PfTOP2 gene. Lane 2 contains protein 
derived from a non-induced culture containing the GAL1/PfTOP2 
construct in YEplac181 (Yeplacl8l/PfTOP2). Lane 3 contains protein 
derived from induced cultures containing the Yep1ac181/PfTOP2 
construct. Lane 4 contains protein derived from non-induced cultures 
containing the human Topoll a gene in YEpWOB6. Lane 5 contains 
protein derived from induced cultures containing the human Topoll a 
gene in YEpWOB6. 
The positions of the protein size standards are shown on the left of the 
figure (in kilodaltons). 
Figure 4 (b). 
Figure 4 (b) shows a duplicate gel of the one described in figure 4 (a). The 
gel was western blotted to a nitrocellulose membrane and probed with 
antiserum raised against the C-terminal region of PfTopoll. 
The contents of the lanes are as described in figure 4 (a). Protein size 
standards are indicated on the left of the figure. 
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the band is present in all of the samples, as are two other smaller bands of 
around 80 and 60 kDa. In order to ensure that the apparent lack of 
expression of plasmid YEplac181/PfTOP2 could not be attributed to loss of 
the plasmid from the cells (JELl), yeast cultures were lysed, the 
recombinant plasmid recovered, and transformed into DH5a (2.3.1.3). The 
recombinant plasmid was isolated on each occasion that this procedure 
was performed. 
6.3.2 Expression of PfTOP2 in temperature-sensitive yeast strains. 
The recombinant YEp1ac181/PfTOP2 plasmid and YEplac181 parental 
plasmid and YEpWob6 were transformed into four temperature sensitive 
S. cerevisiae strains JCW 26 (top 2-4), SD117 (top 2-1), JCW28 (topl, top2-4) 
and SD119 (topl-1, top2-1). JCW 26/SD117 strains have inactive 
topoisomerase II, and JCW 28/SD119 have inactive topoisomerases I and 
II enzymes at restrictive temperatures (34°C). 
Complementation tests were conducted as such; cultures containing 
either the recombinant plasmid or parent plasmid, were grown overnight 
in minimal medium (with appropriate amino acid supplements) and 2% 
glycerol/2% lactate. Cell numbers were counted before washing in 
minimal medium without a carbon source. 3 X 105 cells were spotted onto 
selective medium containing 2% glucose, or 2% glycerol/2% lactate 
supplemented with 2% galactose. 3 X 105 cells were also spotted onto 
duplicate plates for each strain, and were incubated at the permissive 
temperature (23°C) to ensure that the cells could grow normally, while 
the duplicate plate, was incubated at the restrictive temperature (34°C). 
Plates were incubated for up to ten days (2.5.9). 
All of the strains grew normally at permissive temperatures. Strains 
grown at restrictive temperatures with YEp1ac181/PfTOP2 or YEplac181 
plasmids showed no signs of growth ten days after plating. Strains grown 
at the restrictive temperature with YEpWob6 containing the human 
Topoll a gene were viable, however. In order to test the possibility that 
recombinant PfTopofl may have been expressed at a high enough level to 
be toxic to the cells, we decided to test a range of galactose concentrations 
in case the level of inducer being used was too high. Complementation 
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tests were set up as above, except that cells were spotted at 1 X 105 and the 
glycerol/ lactate plates were in this case supplemented with galactose at 
final concentrations of 0.05%, 0.5%, 1% and 2% per plate. 
Duplicate plates were set up so that individual replicates could be 
incubated at permissive or restrictive temperatures. After ten days, cells 
grown at permissive temperatures showed normal signs of growth, but 
cells grown at restrictive temperatures showed no growth. We conclude 
either that (i) recombinant PfTopoll has not been functionally expressed 
in these t.s. strains, or (ii) the recombinant enzyme was expressed but was 
unable to replace the function of the defective yeast Topoll. The fact that 
expression of recombinant PfTopoll in the expression strain JELl was not 
observed, may indicate that the former of these two possibilities is the 
more likely. 
In an attempt to ascertain why expression of the recombinant protein was 
not observed, we decided to investigate whether the GALl promoter was 
actively transcribing the gene upon induction with galactose. 
6.4. Truncated PfTOP2 transcripts are expressed from the GALl promoter 
in yeast. 
Total RNA was prepared (2.4.2) from 200m1 cultures of JELl containing 
YEp1ac181/PfTOP2 or before and after galactose induction (5 hours). In 
addition, JELl harbouring the parent plasmid YEplac181 alone was used 
with induction. 18tg of each sample of total RNA was size fractionated on 
a 1% agarose gel containing formaldehyde, and northern blotted to a 
Genescreen Plus membrane (DuPont). This was probed with a 5' 1.8 kb (1-
1795 nt) fragment of the PfTOP2 gene. Figure 5 (a) shows the ethidium 
bromide-stained formaldehyde gel prior to northern blotting. Figure 5 (b) 
shows a northern blot of the same gel after probing with the PfTOP2 gene 
specific probe. Lane 2 of figure 5 (b) shows a transcript of approximately 
350 nucleotides which hybridises to this probe. The transcript is only 
present in RNA derived from an induced culture containing the PfTOP2 
recombinant plasmid. Lanes 3 and 4, which contain RNA derived from 
an uninduced culture containing YEp/ac181/PfTOP2, and a culture 
containing the parental plasmid alone, do not hybridise to this probe. 
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Figure 5. 
Northern blot analysis of total RNA derived from yeast cultures. 
Figure 5 (a) shows the ethidium bromide-stained formaldehyde-treated 
agarose gel prior to northern blotting. 
Lane 1 shows the 0.24-9.5 kb RNA ladder (Gibco BRL). Lane 2 shows total 
RNA from a galactose-induced culture containing the GAL1/PfTOP2 
construct in the shuttle vector YEplac181 (YEplac181/PfTOP2). Lane 3 
shows total RNA from a non-induced culture containing the 
YEplcic181/PfTOP2 construct. Lane 4 shows total RNA from a galactose-
induced culture containing the parent vector YEplac181 without the 
GALl /PfTOP2 construct. 
Figure 5 (b) shows the same formaldehyde gel blotted to Genescreen Plus 
membrane, and probed with a 5' 1.8 kb fragment of the PfTOP2 gene. The 
signal derived from the 350 nt transcript is arrowed. 









In order to map the 3' end(s) of the transcript(s) we decided to reverse 
transcribe the mRNA using a Notl-d(T)18 oligonucleotide which would be 
able to prime synthesis of the first strand cDNA provided that the PfTOP2 
transcript(s) had been polyadenylated. 
6.5. Reverse transcription of the PfTOP2 mRNA identifies sequence 
motifs that may cause premature transcriptional termination. 
Total RNA derived from the induced PfTOP2 sample that had previously 
been used for northern blotting, was used for this experiment. SDS was 
removed from the samples by phenol/ chloroform extraction and the 
RNA was recovered with ethanol precipitation. lOjig of RNA was treated 
with DNase I to remove any contaminating DNA from the sample. To 
ensure that the DNasel was active, 0.8.tg of plasmid DNA was treated and 
the reaction products monitored on an ethidium stained 1% agarose gel to 
confirm that the DNA had been completely degraded. DNase I was 
removed from the RNA samples by phenol/ chloroform extraction, 
followed by ethanol precipitation of the RNA. 
First-strand cDNA synthesis was achieved using the Pharmacia First-
Strand cDNA synthesis Kit (described in section 2.4.4). This uses moloney 
murine leukemia virus (M-MuLV) reverse transcriptase to catalyse cDNA 
synthesis from a Notl-d(T)is primer, in the presence of dNTPs. Following 
synthesis of the cDNA, the resulting double-stranded DNA/RNA 
duplexes were amplified by PCR. This involved using the same Notl-
d(T)18 primer that was used to prime reverse transcription, and a PfTOP2-
specific gene primer (719S). In a control reaction, the same primers were 
also used for PCR with a sample of the same RNA that had not been 
reverse transcribed. This was done to ensure that no DNA was present in 
the samples following DNase I treatment. A positive control was also 
used to ensure that the Taq polymerase and PCR parameters were 
functioning correctly. The template for this PCR was the PfTOP2 gene 
with PfTOP2 specific primers 719S and 288S which should give a PCR 
product of around 350 bp in size. 
The products of the reverse transcriptase-PCR (RT-PCR) were Southern 
blotted, and a 5' [P 321  labelled PfTOP2 specific oligonucleotide (460S) which 
Figure 6. (a) 
Analysis of the products of reverse-transcribed RNA, (RT-PCR) using the 
PfTOP2 specific oligonucleotide 719(S) and the Notl-d(T)18 primer that was 
originally used to prime synthesis of the cDNA. The PCR products were 
run out on a 1% agarose gel and stained with ethidium bromide. The gel 
was Southern blotted to Genescreen Plus membrane and probed with a 5' 
[32P] labelled oligonucleotide 460(5) which spans nucleotides 319-340 of 
the PfTOP2 gene. 
Lane 1 contains a PCR product derived from PCR amplification of the first 
strand cDNA. Lane 2 represents a PCR control, where total RNA isolated 
from galactose-induced cultures that was not reverse-transcribed was used 
as a template for a PCR. Lane 3 contains a 350 bp PCR product derived 
from amplifiction of the PfTOP2 gene. 
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spans nucleotides 319-340 of the gene was used to probe the blot. The 
results of this experiment are shown in figure 6. A major band of 
approximately 360 bp, along with a less abundant band of around 700 bp 
was detected by this probe; these were present only in the sample derived 
from the recombinant plasmid following galactose induction. 
The PCR product was ligated into the TA pCRTMII cloning vector (figure 
7), transformed into INVaF' cells, and white colonies were picked and 
screened for the presence of recombinant plasmids. Although several 
attempts were made to isolate the 700 bp product, only the smaller, more 
abundant 360 bp product could be isolated from the transformation. Three 
clones from the transformation were analysed and their sequences are 
shown in figure 8. Polyadenylation sites were found to map to 370 (two 
clones, numbers 1 and 72) and 376 nt (1 clone, number 30) from the AUG. 
In addition, the poly (A) tails of the transcripts contained 15-18 adenine 
residues. 
6.6. Replacement of putative transcription termination signals in the 
PfTOP2 gene. 
An analysis of the region upstream of polyadenylation sites has revealed 
the presence of sequence motifs that have been demonstrated to act 
together to cause 3' end formation of yeast mRNA (Guo and Sherman, 
1995). The 3' regions of seven genes in which major polyadenylation sites 
have been precisely mapped by sequencing are shown in Figure 9. Three 
interdependent, cis acting elements have been identified in S. cerevisiae; 
they are (I) the efficiency element, (ii) the positioning element and (iii) the 
actual poly (A) site. The efficiency element acts to enhance the function of 
the second element, the positioning element, sited downstream, which 
determines the actual site of polyadenylation. Polyadenylation often falls 
16-27 nucleotides downstream of the positioning element and occurs 
preferentially after a pyrimidine base (figure 10). 
An examination of the first 400 nt of the PfTOP2 gene reveals that several 
candidate efficiency and positioning elements occur within this region 
(shown in figure 8). In order to verify that these sequence motifs may be 
the cause of the premature transcription termination occurring at these 
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Map of the pCRTMll TA Cloning vector. 
M13 Reverse Primer So6 Promoter 
CAG GAA ACA G ATG C ATG ATT ACG CCA AGC ii AT TTA G3T GAG ACT ATA GM 
GM CTT ICr CGA TAC T G TAC TAA IGO i TCG A TA AAT CCA CIG TGA TAT CTT 
Nsil Htndlll kpnl Sad Barni-( I Spe 
TAC TCA AGO TAT GOA TCA AGO TTG GTA CCG AGO TCG GAT CCA CIA GTA ACG WC 
ATG AGT TCG ATA CCT AGT TCG MC CAT GOC TCG AGC CIA GGT GAT CAT TGC CGG  
BstXI EcoRl EcoRl EcoRV 
GOC GM TTC IGO AGA TAT WC AGI GIG CIG GM 
_____________TI Ct33 C77 MG ACG TCT ATA CGG TCA CAC GAC CT-1 MG CCG 
Avat 
PaeP7I 
8stXl Nod XIrol NsiI Xbal Apal  
CCA TCA CAC TGG CGG CCG CIC GAG CAT GOA TCT AGA Gr33 CCC MT TCG I= TAT 
T ACT GIG ACC GCC GOC GAG CIC GrA cGr AGA TCT CCC GM ITA AGO IGGO ATA 
77 Promoter M13 (-20) Forward Primer M13(-40) Forward Primer 
ACT GAG TCG TAT T C MT TCA CIG GOC crc GIT TTA CM CT CG',- GAG TG3 GM MC 







Figure 7. Map of the pCRTMll TA Cloning vector. 
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gtc tac gtc gac atc cac 
agt cjta tat at gat ggg gaa ggt att cct dta gat JTTcjat 4aa gaa 
S V Y N D G E G I P V D I H K E 
aacatc 
atg at ata talt gta cca cat atg att ttt gga gaa tta 
M N I Y V P H N I F G E L 
Figure 8. 
Nucleotide sequence of the PfTOP2 gene showing the major polyadenylation 
sites that map at 370 and 376 nt from the AUG (shown as arrows). Also shown 
are the putative efficiency elements (boxed sequences) and the putative 
positioning element (italicised sequence). Sequences that were changed in an 
attempt to abolish premature transcription termination in the gene are shown 




ACTI .......  TAA. .. .20. . . TGTTTATGTATGTACCTCTCTCTCTATTTCTATTTTTAAACCACCCTCTCAATAAAATAA 
V 
AAATAATAAAGATTTTTAAGG 




CYC1 ....... TAA. . .120. . . CCTATTTATTTTTTTATAGTTATGTTAGTATTAACAACGTTATTTATATTTCAAATT 
GAL 7 .......  TAA. . .100. . . AGTGACAATATATATATATATATATAATAATGACATCATTATCTGTAAAT 
(0 
01 
GCN4 ....... TGA.. . .12. . . TTTATTTTATATTTTTTATTTCATTCTCGTGTATAACGAMTAGATACATPCAC 
'V 
TTAGATAAGAATTAATCTTTTTATGCCAATTT 




RHO1 .......TAG.. . 154. - - TCTTCTCTACATATAAGTGTATTGCTCAGTAAGTATTATCATCTATTAAAG 
Figure 9. Putative efficiency (-) and positioning (-) elements for 3' end formation of some yeast mRNAs. 
Arrows denote major poly (A) sites. Figure adapted from Guo and Sherman, 1995. 
Enhances downstream Promotes poly (A) sites 16-27 nt 
elements downstream, preferably after 
cytidine residues 
Efficiency element Positioning P oly(A) site 
element  
(1) (2) (3) 
Distance between 1 and 2 is 
variable but sensitive to 
spacing. 
7 7 




TATATA AAGAA C or  
TAGTATGTA AAAAAA followed 
'ITTFTATA AATAAA by 1 or 
more A's 
Figure 10. Schematic representation of the elements involved in 3' end 
formation of yeast mRNA. (1) the efficiency element, (2) the positioning 
element and (3) the actual poly (A) site. Figure adapted from Sherman and 
Guo, 1995. 
points in the PfTOP2 gene, we decided to change specific nucleotides 
within this sequence using PCR mutagenesis. The positions of the sites 
that were changed and their relationship with respect to the gene are 
shown in figure 11. 
6.7. Northern analysis of the modified PfTOP2 sequence expressed from a 
GALl promoter in yeast. 
Total RNA derived from induced cultures of the unmodified and 
modified PfTOP2 constructs were size fractionated and probed with the 
same PfTOP2 gene fragment (5' 1.8 kb, 1-1795 nt) that was used before to 
probe the original northern blot. Figure 12 shows the results of this 
experiment. Lane 1 contains RNA derived from the unmodified gene 
construct. A major transcript of around 360 nt can be seen; this transcript 
corresponds to the 370/376 nt transcripts identified by RT-PCR. Over-
exposure of the membrane also reveals a minor transcript of around 
650/700 nt in size. This signal could be interpreted to be derived from a 
transcript which may be the product of transcriptional read-through the 
major transcriptional block observed at 376 nt. In lane 2 (figure 12) a 
major transcript of around 600/700 nt can be seen, along with three very 
faint signals, the largest of which is about 2400 nt in length. 
This result shows that the major transcriptional block in the unmodified 
PfTOP2 gene, was abolished by changing the putative efficiency elements 
as such: (i) tatata to tctaca, (ii) tagata to tcgaca, (iii) tacata to tccaca and (iv) 
tatata to catcta. 
6.8 Identification of additional elements that may be responsible for 
premature transcriptional termination. 
Total RNA from the same sample used for northern blotting (section 6.7) 
was used for this experiment after SDS from the storage buffer was 
removed by phenol/ chloroform extraction, and ethanol precipitation. 
10g of RNA was treated with DNase I to remove any contaminating 
DNA from the sample. The activity of the enzyme was checked as 
described in section 6.5. of this chapter. DNase I was removed from the 
samples by phenol/ chloroform extraction and ethanol precipitation. 
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Figure 11. 
Replacement of putative transcription termination signals in the PfTOP2 
gene. 
In an attempt to abolish the premature transcription termination 
observed when the PfTOP2 gene is expressed from a GALl promoter in 
yeast, putative efficiency elements that occur within the gene sequence 
were mutationally replaced. 
Figure 11 (a) shows the oligonucleotides (V7276 and V7277) that were 
used to introduce specified point mutations into the gene. 
shows the sequence of the PfTOP2 gene in the region where 
transcription termination has been demonstrated to occur, and the 
relationship of oligonucleotides V7276 and V7277 with respect to this 
sequence. 
shows a diagrammatic representation of the positions of all of the 
oligonucleotides that were used to amplify this region of the gene. As can 
be seen in Figure 1 (a), flanking oligonucleotides H4535 and G6165 made it 
possible to restrict the PCR product with Kpnl and Pstl so that the 
fragment could be cloned into YEplac181 in the steps described in Figure 1 
(a) to (c). 
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Figure 11. Replacement of putative transcription termination signals in the PfTOP2 gene. 
Sequence of the oligonucleotides that were used to modify the wild type PfTOP2 sequence in an attempt to abolish premature 
transcription termination. Bold type denotes the base changes in the sequence. 
5' CCTGTCGACATCCACAMGA7JTGAACATCTATGTAC 3' 
Sense strand sequence modifying oligonucleotide V7276. 
3 'CAGATGTTACTACCCCTTCCATAAGGACAGCTGTAGGTGTTTCTTTACTTG 5' 
Antisense strand sequence modifying oligonucleotide V7277. 
The sequence of the PfTOP2 gene in the region where transcription has been demonstrated to terminate. Underlining denotes the sequence 
of the oligonucelotides that were used to incorporate silent point mutations that change the third base in a particular codon which is marked 
with a star. The boxed region denotes the region of homology between oligonucleotides V7276 and V7277. 
0 
gte tac aat gat ggg gaa ggt att atc tat gta cca cat atg att ttt gga 
tag ata cat ggt gta tac taa aaa cct 
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Positions of amplifying 
oligonucleotides with respect to the 
template that was used for PCR 
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Wild type PfTOP2 gene I 
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Figure 12. 
Northern blot analysis of total RNA derived from yeast cultures 
containing the unmutated version of the PfTOP2 gene, or a version of the 
gene where putative transcription termination sequences have been 
altered by PCR mutagenesis. The formaldehyde gel was blotted to 
Genescreen Plus membrane and probed with an 1.8 kb 5' fragment of the 
PfTOP2 gene. 
Lane 1 shows total RNA from a galactose induced culture containing the 
unmutated PfTOP2 gene construct (YEplac18l/PfTOP2). Lane 2 shows total 
RNA from a galactose induced culture containing the mutated version of 
the GAL1/PfTOP2 contruct in YEplac181. The positions of the transcripts 
are arrowed, and the positions of the RNA size markers are shown on the 
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First-strand cDNA sythesis was conducted using the same method as 
described in section 6.5 using the Pharmacia First-Strand cDNA synthesis 
Kit. The same NotI-d(T)18 primer was used to prime synthesis of the first 
strand cDNA. RT-PCR was conducted as described previously (section 6.5) 
using the same Notl-d(T)is primer and sense PfTOP2 specific primer 
(719S). These primers were also used for RT-PCR using the same RNA 
which had not been reverse transcribed. This was done to ensure that no 
DNA was present in the samples following DNase I treatment. A positive 
control was also used as described in section 6.5. 
The products of the reverse transcriptase-PCR (RT-PCR) were Southern 
blotted, and a 5' [32P]  labelled PfTOP2 specific oligonucleotide (460S) was 
used to probe the blot. This probe did not detect any of the bands that were 
present following agarose gel electrophoresis, which included a major 
band of approximately 700 bp, along with less abundant bands of around 
500 and 300 bp (shown in figure 13) We cannot account for the failure of 
this probe to hybridise to any of the bands derived from the RT-PCR, but it 
is possible that the DNA did not transfer to the membrane efficiently. The 
PCR products were ligated into the TA pCRTMII cloning vector 
(Invitrogen), transformed in INVcF' cells, and white colonies were picked 
and screened for the presence of recombinant plasmids. Several clones 
were obtained from the transformation but only two contained inserts. 
These were sequenced to map their 3' ends. 
The nucleotide sequence of clone numbers 1 and 2 are shown in figure 14. 
Both clones terminate 617 bp from the ATG. An analysis of the sequence 
reveals several candidate efficiency and positioning elements. 
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Figure 13. 
Agarose gel electrophoresis of PCR products. These were amplified from 
cDNA derived from reverse transcription of total RNA isolated from 
induced cultures containing the PfTOP2 gene in which the putative 
transcription termination sites had been altered. 
Lane 1 shows the positions of the 7. DNA cut with HindIII size standards 
(Gibco BRL) that were used. Their sizes are, from the top of the gel to the 
bottom; 23.15, 9.42, 6.56, 438, 2.32 2.02 and 0.56. 
Lane 2 contains a 350 bp PCR product derived from amplifiction of the 
PfTOP2 gene. Lane 3 contains a PCR product derived from PCR 
amplification of the first strand cDNA. Lane 4 represents a PCR control, 
where total RNA isolated from galactose induced cultures that had not 
been reverse transcribed was used as a template for a PCR 
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Figure 14 
Nucleotide sequence of the clones obtained from RT-PCR of transcripts derived from expression of the 
PfTOP2 gene that was previously modified to abolish the putative efficiency elements which were 
believed to cause premature transcription termination. 
The position of polyadenylation is denoted by an arrow. Candidate efficiency elements are double 




Heterologous expression of PfTopoll with an N-terminal modification 
which replaced the first four P. fa1cipirum codons with the first five yeast 
codons has been undertaken. This was done in the expectation that this 
modification would increase the likelihood of expression of the gene in 
yeast, in much the same way that a similar approach was successful for 
expression of human Topoll a (Wasserman et al., 1993). 
The N-terminal modified sequence was fused to a GALl promoter which 
could be regulated with galactose or glucose carbon sources. Originally, the 
intention was to subclone the GAL1/PfTOP2 cassette into the expression 
plasmid YEpWob6, but the construct was not maintained in any plasmid 
which contains a URA3 auxotrophic marker. This problem was 
circumvented by cloning the cassette into YEp1ac181 which contains a 
LEU2 auxotrophic marker instead. Initially, expression of the recombinant 
protein was monitored in two ways (i) induced cultures were lysed and 
size fractionated using SDS-PAGE. Polyacrylamide gels were stained with 
Coomassie blue and analysed for the presence of a novel band of around 
160 kDa, the expected size of the recombinant protein. (ii) the same 
construct was transformed into t.s. yeast mutants lacking a functional 
Topoll, or Topol and Topoll at restrictive temperatures, to determine 
whether expression of recombinant PfTopoll could rescue the defect(s). 
Protein gels stained with Coomassie blue showed no evidence of 
expression of recombinant PfTopoll. However, induction of the human 
Topoll a positive control was observed, indicating that the conditions 
being used for expression were favourable. In addition to the absence of 
detectable protein, no evidence that expression of recombinant PfTopoll is 
able to rescue t.s. yeast strains that are defective in Topoll, or Topol and 
Topoll function was observed; varying the amount of inducer used was 
also found to have no effect on cell growth at restrictive temperatures. 
In order to investigate the lack of evidence of expression, we decided to 
look at steady state mRNA levels before and after induction of the 
protein. This would provide information on whether the GALl promoter 
was transcribing the gene. Northern analysis of total RNA showed that 
truncated PfTOP2 transcripts were produced. A major transcript of around 
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around 360 nt was observed. Prolonged exposure of the membrane also 
revealed a larger but less abundant transcript of approximately 700 nt in 
length. RT-PCR was used to map the 3' ends of these transcripts, but only 
the smaller cDNAs (370 bp and 376 bp) could be isolated. 
The P. falciparum PfTOP2 gene, in line with many other genes of P. 
falciparum has an AT-content of over 74%, and although S. cerevisiae 
genes have, on average, 60% AT-content, we were concerned that this 
fundamental difference in gene structure could be detrimental to gene 
expression. Indeed, fortuitous transcription termination has been 
reported in other species with DNA of unusually high AT-content. For 
example, Romanos et al., (1991) expressed the 1.5 kb Tetanus toxin 
fragment C (71%, AT-content) in S. cerevisiae and found that truncated 
transcripts were produced. Full length transcripts were only produced 
after resynthesising the entire gene to increase the G+C content from 29% 
to 47%. Romanos et al., (1992) also report that the P. falciparum gene 
encoding p195 (0.88 kb) gives rise to multiple short mRNAs when 
expressed in S. cerevisiae. 
Yeast mRNAs are processed at their 3' ends by endonucleolytic cleavage 
and polyadenylation to produce transcripts that end with a poly (a) tail of 
about 70 adenosine residues. Russo et a!,, (1991) were the first to propose 
that specific cis acting motifs could be responsible for 3'-end formation of 
yeast mRNA. The efficiency element TATATA and related sequences, 
function to enhance the efficiency of a second element, the positioning 
element (AAGAA and related sequences) which in turn acts to position 
the actual site of polyadenylation. The fact that both of these elements are 
A+T rich increases the likelihood that these motifs may be present in the 
PfTOP2 gene, due to its high AT-content. The sequence of the PfTOP2 
gene upstream of the site where premature transcription termination 
occurred was analysed to determine whether any candidate efficiency or 
positioning elements were present. Four candidate efficiency elements, 
and one positioning element were revealed in the sequence. The 
candidate positioning element falls within 16-27 nt of the 370 nt poly (A) 
site that is reported to be functionally relevant in the model proposed by 
Guo and Sherman (1995). 
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PCR mutagenesis of the putative efficiency elements within the PfTOP2 
gene was used in an attempt to eliminate these elements and thus bypass 
the transcriptional block in the gene. Northern analysis of the mRNA 
produced from the modified gene revealed that an abundant longer 
transcript of approximately 600/700 nt was produced, along with other 
larger transcripts that could only be detected on overexposed blots. RT-
PCR of this mRNA mapped the polyadenylation site to 617 nt from the 
AUG. Analysis of the sequence upstream of the Poly (A) site also reveals 
the presence of candidate transcription termination signals. These differ 
in sequence from the efficiency and positioning elements identified in the 
unmodified gene sequence, however, which illustrates the difficulties 
faced in removing such sequences from the coding sequence. It is clear 
that hitherto unidentified sequences are able to promote cleavage and 
polyadenylation. However, sorting them out, even by this method is 
likely to be time consuming and expensive. 
It was mentioned in the introduction to this chapter that the DHFR and 
Pgh 1 proteins of P. falciparum have been used to complement t.s. 
mutations in the yeast DHFR gene and the ste6 gene of S. cerevisiae. 
PfDHFR is a small gene (684 bp) encoding the 228 amino acid DHFR 
domain of the DHFR-TS enzyme. Analysis of the sequence reveals the 
presence of several candidate efficiency elements, such as one TATATA, 
and at least seven TATG motifs, in addition to at least 10 positioning 
elements (for example, a minimum of seven AAAAA and two AATAA 
motifs can be identified in the sequence). Recombinant PfDHFR has not 
been purified from yeast, and although expression levels have not been 
determined, it seems likely that the enzyme may not be expressed at high 
levels (Dr. Carol Sibley, pers comm.). The fact that transcript production 
has also not been measured, means that we do not know whether the 
presence of these sequences could act to reduce the overall level of protein 
production. 
Ruetz et al., (1996) have tried to purify recombinant PfPghl protein from 
S.cerevisiae t.s. mutants, but although they were able to demonstrate the 
presence of the protein by immunofluorescence staining of yeast 
transformants, they were unable to detect the protein on western blots. 
I; 
Their interpretation of these findings are that the protein must have a 
very short half-life in vivo. PfPghl is a relatively large gene (4256 bp) 
which has an overall A+T content of 75% making it probable that 
candidate transcriptional termination sequences will be present. It would 
be interesting to know whether some degree of gratuitous transcription 
termination may be responsible for poor expression of PfPghl, as is the 






The potential value of topoisomerase II as a target for antimalarial drugs, 
coupled with the difficulty of purifying the active protein from the 
parasite itself, made it desirable to isolate the coding sequence for the 
protein and attempt to express it in a more amenable cell system. We 
chose to use expression systems that are routinely employed for 
expression of foreign proteins, such as Escherichia coli, the 
baculovirus/insect cell system and Saccharornyces cerevisiae, in the hope 
that with one or more of them a sufficiently high level of active protein 
might be produced to permit biochemical studies and drug tests to be 
performed. 
7.2 Heterologous expression in E. coli. 
Extensive knowledge of the genetics of E. coli have made it a valuable tool 
for the expression of foreign DNA sequences. However, not every 
sequence can be expressed in this system. Numerous factors influence 
whether a foreign DNA sequence will be expressed. Some of the reasons 
why a particular recombinant protein is not produced in high yield are, 
for example, (a) subtle differences between the structural features of the 
foreign gene and the genes of the bacterium, (b) the mRNA may be 
unstable, (c) there may be differences in codon usage between E. coli and 
the organism from which the foreign DNA is derived, (d) the 
recombinant protein may be expressed, but may not fold correctly 
resulting in proteolysis, and (e) the recombinant protein may be toxic to 
the cell. One of the major obstacles to functional heterologous expression 
in E. coil relates to the inability of the system to perform the post-
translational modifications characteristic of many eukaryotic proteins. 
Although it did not prove possible to purify full length recombinant 
PfTopoll from E. coli, there is evidence to suggest that the protein, or part 
of it, may have been expressed. Western blots derived from induced 
cultures containing the PfTOP2 ORF as a fusion to GST, displayed 
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numerous GST-cross reactive proteins that were less than 100 kDa in size. 
Our failure to detect full length recombinant protein could indicate that 
the protein is toxic to the cells, however, if that is the case, then it is clear 
that toxicity is not dependent on the functionality of the protein. 
Reasonable levels of expression of the N-terminal (599 amino acid) and C-
terminal (404 amino acid) regions of PfTopoll were observed, suggesting 
that the failure of expression of full length PfTopoll was not caused by the 
structural peculiarities of the gene, or differences in codon usage at least. 
7.3 Heterologous expression using baculovirus. 
As an expression system, baculovirus has gained considerable recognition 
during the 1990s. This is particularly so for the expression of eukaryotic 
proteins where biological activity is the primary consideration. Insect cells 
are believed to execute many of the post-translational modifications that 
are believed to be important for full biological activity, such as 
phosphorylation, glycosylation, and signal peptide cleavage. Furthermore, 
disulphide bond formation and protein folding are also reported to be 
performed more readily in this system. 
There are several factors that may adversely affect heterologous 
expression of a foreign gene in baculovirus, including, (i) the presence of 
introns, (ii) the context of the AUG, (iii) the presence of 5' and 3' 
untranslated regions in the gene, and (iv) the presence of TAAG and 
CTTA sequence motifs in the foreign gene. 
Immunologically detectable quantities of recombinant PfTopoll were 
produced in baculovirus, but the yields were poor. The reasons for this 
were not immediately obvious. There are no introns, or 5' and 3' 
untranslated regions present in the PfTopoll construct. Moreover, the 
context of the AUG in the wild type PfTOP2 gene was modified to 
conform to a consensus sequence that appears to be preferred for 
expression by those bacuidvirus genes for which information is available. 
However, analysis of the PfTOP2 mRNA transcribed by baculovirus 
revealed numerous truncated transcripts which suggests that TAAG and 
CTTA signals may be influencing the level of full length transcription. 
Inspection of the PfTOP2 gene sequence revealed at least 19 TAAG 
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sequence motifs on the sense strand. TAAG and CTTA sequence motifs 
are known to specify late and very late transcript initiation sites in 
baculoviral genes, in the sense and antisense directions, respectively. The 
PfTOP2 gene was expressed from the late polh promoter, and this may 
have increased the possibility that the TAAG/CTTA motifs within the 
gene were "seen" more readily as transcription initiation sites. This 
unfortunate but interesting possibility has been remarked on by Dr. R.D. 
Possee (Institute of Virology and Environmental Microbiology - Oxford) 
as being the most likely cause of low level expression of the PfTOP2 gene 
(pers comm.). It would certainly be interesting to see whether the removal 
of these sequence motifs improves the expression levels of the gene. 
An additional problem encountered with the system was revealed when 
attempts to purify the recombinant protein were made. Although 
immunologically detectable amounts of the full length protein were 
purified using a nickel affinity column, a co-purifying host cell Topoll 
activity was present. It may have been possible to remove this 
contaminating activity if larger quantities of PfTopoll has been made. 
Rossi et al., (1996) have purified recombinant human Topol from 
baculovirus using a similar approach. Although the recombinant enzyme 
was expressed at high levels (4 mg from 10 infected cells) and purified by 
nickel column chromatography, Rossi et al., report that trace amounts of a 
co-purifying insect cell Topol are likely to be present. 
7.4 Heterologous expression in S. cerevisiae. 
Yeast is an attractive system for expression of foreign genes. It combines 
well defined genetics, ease of handling and availability of temperature 
sensitive mutants, with inexpensive conditions for growth. But not all 
foreign sequences express well in yeast. Many of the factors that influence 
the level of expression of a foreign gene in E. coli are also common to 
yeast (discussed above in a to e). Differences in codon usage, for example, 
may affect expression of foreign proteins, but other P. falciparum genes, 
such as DHFR have been successfully expressed in S. cerevisiae indicating 
that this may not be a problem. 
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Although human Topoll a and p have been expressed in yeast, expression 
of recombinant PfTopoll was not observed. However, we have been able 
to determine at least one reason, possibly the main one, why this is the 
case. Because of the relatively high (74%) A+T content of the PfTOP2 
sequence, it contains within it gratuitous AT-rich elements that are 
known to direct 3' end formation of yeast mRNA. These elements, which 
are known as the efficiency and positioning elements were suspected of 
causing premature transcription termination in the PfTOP2 gene. The fact 
that the transcriptional blocks could be abolished by mutagenesis directed 
at specific sites within the sequence confirms this. Other potential 
transcription termination signals are clearly present downstream of the 
second transcriptional block in the PfTOP2 sequence, and although only 
some of these may be present in the right context to cause transcription 
termination, their frequent occurrence, and the fact that we may not be 
able to identify all of them, precludes the possibility of changing all of the 
sequences involved individually by site directed mutagenesis. 
An alternative approach, chemical synthesis of the entire gene, to remove 
all candidate transcription termination elements and to increase the G+C 
content, may be the way forward to achieving full length expression of the 
PfTOP2 gene in yeast. 
7.5 Expression of PfTopoll throughout the blood stages of parasite growth. 
An analysis of the stage-specific expression of PfTopoll was also conducted 
using parasites that had been synchronised in ring, trophozoite or 
schizont stages. PfTOP2 transcripts were found to accumulate principally 
in the trophozoite stage parasite, although nuclear run-on analysis 
(conducted by Paul Horrocks) revealed that the promoter was active at all 
developmental stages. 
Topoii protein accumulated predominately in trophozoites and schizonts, 
and at similar levels, whilst enzyme activity, as measured by decatenation 
of KDNA, reached a peak at schizogony. 
These findings provide the basis for future work to examine in greater 
detail how expression of PfTopoll is regulated, and the ability of Topoll 
poisons to act selectively against the parasite enzyme, thus providing new 
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7.6 Future work. Heterologous expression in S. cerevisiae. 
Reconstruction of the gene for PfTopoll would involve designing 100-
mer oligonucleotides, which, whilst preserving the unique amino acid 
sequence of the wild type gene, will introduce specific changes into the 
DNA sequence to increase the G+C content and eliminate the mRNA 
cleavage and polyadenylation sites. Alignment of the wild type PfTOP2 
DNA sequence with the proposed synthetic sequence shows that 
considerable stretches of identity remain. This makes it possible to use the 
antisense strand of the wild type gene (isolated from M13) as a scaffold 
with which to align each 100-mer oligonucleotide by hybridisation. This 
process could be conducted using five 100-mer oligonucleotides which can 
be ligated together to make a 500 nt segment of gene which can be 
amplified by PCR. Eight segments, each of around 500 nt, will be PCR 
amplified in this way to make up the entire synthetic gene. Each segment 
will contain unique restriction sites to facilitate cloning, and, after 
sequencing to ensure that the synthetic sequence is correct, the final 
product can be expressed in yeast. 
Unfortunately, shortage of time precluded this plan from being fully 
implemented, but it will be pursued in future in the hope that expression 
and complementation of the top2 defect in yeast will be achieved. 
Use of alternative expression systems, such as the slime mold 
Dictyostelium discoideurn may also be worth consideration in the future. 
The DNA of this organism is highly A+T biased and as such may be 
useful for expression of the A+T rich PfTOP2 gene. Fasel et al., (1992) have 
expressed the circumsporozoite protein of P. falciparum in D. discoideu,n 
and found that the natural characteristics of the protein (as judged by size 
and epitope recogition) were retained. 
Another approach would involve the use of established methods 
which are able detect cleavable complex formation in vivo following 
treatment of the parasite with topoisomerase II poisons which are known 
to act via this mechanism. This approach would bypass purification of the 
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